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By the end of the Lebanese civil war in 1992, the healthcare system in Lebanon was at its worst. 
Since then, the Lebanese government has adopted a “public rehabilitation strategy” for the health 
sector, entailing the double objective of supporting the Ministry of Public Health in planning for 
health resources and services, as well as reducing health expenditures [1]. This reform has attained 
recognized accomplishments in terms of improving the equity and efficiency of the national 
healthcare system [2]. Nevertheless, the system is still striving to reconcile the two competing values 
of quality improvement and cost containment [3,4]. As ensuring “better health for all Lebanese” while 
reducing health expenditures is at the top of the national health agenda [1,3,4], there have been 
numerous calls for incorporating health technology assessment (HTA) to support decision making in 
national health care [4–6]. HTA is “a form of policy research that systematically examines short- and 
long-term consequences, in terms of health and resource use, of the application of a health 
technology” [7]. HTA aims to provide input to decision making in policy and practice [7], and 
employs economic evaluations as a core component of this process [8].  
This dissertation aims to explore the HTA of hyperphosphatemia management among hemodialysis 
patients, with a focus on the Lebanese setting. We open this First Chapter with an overview of the 
burden of hyperphosphatemia among hemodialysis patients. We then display current knowledge 
related to the economic considerations of phosphorus-lowering interventions. We present, thereafter, 
the current situation in Lebanon in terms of managing hemodialysis patients, HTA and economic 
evaluations. We conclude with the objectives and outline of the dissertation. 
 
HYPERPHOSPHATEMIA: A HEAVY CLINICAL AND ECONOMIC BURDEN 
Chronic Kidney Disease (CKD) is a general term for heterogeneous disorders affecting the structure 
and function of the kidney, leading to sustained kidney damage and/or a decreased level of kidney 
function [9,10]. As the disease progresses, kidney failure develops, and associated complications 
become increasing risks for morbidity and mortality. This is when treatment by renal replacement 
therapy (RRT) becomes essential for survival [11]. RRT modalities include in-center hemodialysis, 
home hemodialysis, peritoneal dialysis, and kidney transplantation. Despite the increasing use of 
kidney transplantation (especially in Nordic countries, numerous other European countries, some 
Arab Gulf countries, and Canada, etc.) and home hemodialysis (especially in Australia and New 
Zealand) [12], in-center hemodialysis remains the main RRT worldwide [12–15]. Hemodialysis is a 
method for clearing waste products and removing excess fluids from the body [16]. Using an artificial 
kidney, the blood from the patient circulates through a dialyzer, where waste products are removed 
by diffusion and fluids by ultrafiltration. Cleared blood is then returned to the patient with the 
assistance of a pump and tubing [17].  RRT is unable to reverse kidney damage, and renal failure is 
often coupled with a loss of the excretory, regulatory and endocrine functions of the kidney, leading 
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to complications in almost every organ system [18]. Specifically, the progression of renal disease is 
accompanied by a disturbance of the normal homeostasis of phosphorus, mainly due to the imbalance 
of the bone metabolic axis and the inability of the damaged kidneys to excrete phosphorus load. These 
changes lead to a positive phosphorus balance and subsequently elevated serum phosphorus level, i.e. 
hyperphosphatemia [19]. The latter is a well-established risk factor for morbidity and mortality [20–
25], and is labeled “the silent killer of hemodialysis patients” [26]. Hyperphosphatemia is also linked 
to increased all-cause, cardiovascular, and fracture-related hospitalizations [27,28]. Moreover, it is 
associated with higher odds of pruritus, poor sleep quality [23], bone pain and deformities, muscle 
pain and weakness [29,30], calciphylaxis [31], decreased physical functioning [32], as well as greater 
prescription of medication and a higher pill burden [33,34], resulting in significant cost implications 
for healthcare systems [27,33,35,36], and a lower quality of life (QOL) for affected patients [34,37]. 
Accordingly, adequate serum phosphorus control is a key aim of treatment approaches for possibly 
reducing health-related complications [9,10], and improving patients’ QOL and longevity [37]. The 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) [9] 
guidelines recommend maintaining serum phosphorus between 3.5 and 5.5 mg/dL, whereas the more 
recent Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [10] suggest lowering 
phosphorus levels towards the “normal” range of 2.5-4.5 mg/dL. The efficacy of these 
recommendations has yet to be demonstrated, as to date we lack conclusive evidence that decreasing 
serum phosphorus to a certain target level is associated with beneficial patient outcomes [38]. 
 
HYPERPHOSPHATEMIA MANAGEMENT: THE EVERLASTING CHALLENGE 
More than a decade after the first international clinical practice guideline addressing the CKD-mineral 
bone disorder was issued [9], a gap still exists between the recommended and measured serum 
phosphorus levels of hemodialysis patients in clinical practice [39]. Hyperphosphatemia remains the 
most common mineral abnormality among this patient population in developed and developing 
countries [40,41]. With nearly 1 in 2 hemodialysis patients being hyperphosphatemic [42,43], 
hyperphosphatemia management is one of the most important challenges facing contemporary 
nephrology [44].  
Hyperphosphatemia is essentially managed by a combination of three strategies: (1) hemodialysis, 
(2) phosphate binding medications, and (3) a low-phosphorus diet. As mentioned above, hemodialysis 
removes phosphorus from the blood through dialytic techniques. However, this treatment is unable 
to maintain a net zero balance of phosphorus [29], and typically needs to be coupled with other 
measures. Phosphate binders are medications that bind with phosphorus and reduce its net intestinal 
absorption. They are often categorized either as calcium-based, calcium-free or combination 
preparation agents [45]. The former two types have been studied widely. Their prescription is 
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governed by many factors, including the side effects of the pill itself, pill burden, patient compliance, 
and the phosphorus content of meals/snacks, in addition to cost considerations, all of which are 
essential in considering the prescription of these medications [39,45]. Non-adherence to phosphate 
binders prevails among hemodialysis patients, ranging between 22 and 74% (mean: 51%), and is 
mainly driven by higher pill burden, among other factors [46,47]. Finally, dietary phosphorus 
restriction is the basis for achieving optimal phosphorus management, and a low-phosphorus diet has 
been described as the most effective means in this regard [48,49]. Nevertheless, adherence to a low-
phosphorus diet is thought to be the least prevalent and the “most complicated” among all dietary 
restrictions required from hemodialysis patients [50]. Non-adherence rates remain exceedingly high, 
ranging between 19 and 57% [40,51]. Education in nutrition is an effective intervention for enhancing 
adherence and facilitating dietary changes among chronic patients [52]. Specifically, through 
systematic reviews of the literature, Matteson & Russell [53], Caldeira et al. [54] and Karavetian et 
al. [55] concluded that highly intense, long-term, individualized nutrition education, provided by 
renal dietitians and using cognitive/behavioral strategies, is effective in managing hyperphosphatemia 
among hemodialysis patients, without compromising their nutritional status. Patients exhibit 
improved adherence when dietitians provide nutritional care tailored to their medical (e.g. residual 
kidney function, co-morbid conditions, medications including binder therapy, serum values), dietary 
(e.g. food preferences and intake) and personal characteristics (e.g. culture, socioeconomic status, 
religious status and beliefs) [52,56–58]. This highlights the important role of a competent renal 
dietitian as an integral part of the multidisciplinary nephrology team. Renal dietitians are uniquely 
qualified to provide intensive patient education and carefully plan a well-balanced diet to maintain 
an optimal nutritional status and prevent the rise of serum phosphorus [10,59,60]. 
 
Hemodialysis, phosphate binders and a low-phosphorus diet have proven to be clinically effective 
interventions in managing hyperphosphatemia. Yet, given continually rising healthcare costs and the 
reality of limited budgets, cost considerations are gaining more and more attention in decision 
making, with regard to the adoption of health technologies [61].  
 
HTA is the multidisciplinary field of policy analysis that encompasses the medical, social, ethical and 
economic implications of development, diffusion, and use of a health technology [62]. It addresses 
both the direct and intended consequences of a health technology, as well as its indirect and 
unintended outcomes, in a systematic, transparent, unbiased, and robust manner [62,63]. HTA is used 
to determine the relative “value for money” provided by a health technology. By acting as a bridge 
between the world of research and decision making, HTA aims to guide policy makers regarding the 
appropriate use of technology and the efficient allocation of resources [62–64]. Economic evaluations 
are frequently used in HTA, as an insightful tool for achieving efficiency in health care [61]. 
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Economic evaluations compare the costs and consequences of at least two interventions (the one 
under study and a natural comparator). They cover a wide range of studies, including cost-
effectiveness analyses (CEA), which are used if the effects are expressed in natural units, and cost-
utility analyses (CUA) which are used if the intervention affects both length and quality of life. In 
CUA, the quality-adjusted life-year (QALY) is used as outcome [61]; this is considered as the 
preferred outcome in economic evaluations [65]. The role of HTA varies significantly between 
countries [62], and although several countries have developed systems to identify health technologies 
that provide the best value for money, formal HTA appears to be non-existent or limited in low- and 
middle-income countries, where there is evidence only of some informal HTA [66,67]. 
 
HYPERPHOSPHATEMIA MANAGEMENT: ECONOMIC CONSIDERATIONS 
As mentioned above, hyperphosphatemia management among hemodialysis patients relies on 
adequate dialysis, phosphate binders, and a low-phosphorus diet. Hemodialysis is the most costly 
RRT [68,69], posing a significant financial burden on national health systems. For instance, in the 
US in 2014, more than $26 billion were spent on hemodialysis patients ($87,638 per patient per year, 
in comparison with $73,612 for peritoneal dialysis and $32,586 for renal transplantation) [70]. 
Coverage and reimbursement for hemodialysis treatment differ significantly between countries [71]. 
In numerous low-income countries, renal failure patients have no access to health insurance, which 
makes treatment by hemodialysis unaffordable. For example, the cost of one session of hemodialysis 
amounts to $100 in Nigeria, which represents twice the minimum monthly wage paid to federal 
government workers [72]. In contrast, treatment by dialysis is covered in most high-income countries, 
despite its high cost and high cost per QALY gained ($129,090) [73–75]. This is partly due to the 
fact that without dialysis, patients face certain death, and as a “rule of rescue,” societies tend to adopt 
therapies that avert certain death and direct resources towards them [75,76].  
Phosphate-binding agents are the most frequently prescribed medications in dialysis patients, 
averaging 7 to 10 pills per day (the median daily pill count is 9) [34,36,39,77]. They are first as well 
in terms of spending [36]; for instance, their market value exceeds $1.5 billion in the US alone [38]. 
Phosphate binders could cost some patients close to $1,000 monthly [51]. Yet these medications 
constitute a heterogeneous group in terms of cost. Although calcium-based binders are inexpensive, 
their efficacy and cost-effectiveness have been outweighed by concern about their elemental calcium 
load and its safety over the long term [48]. On the other hand, non-calcium-based binders are highly 
expensive. They are associated with increased public costs, creating a significant cost barrier to their 
use in many patients [38,78]. The cost of implementing guidelines for hyperphosphatemia 
management using these binders would be debilitating to health systems [35]. Accordingly, the 
number of published economic evaluations assessing phosphate binders has markedly increased in 
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recent years, in an attempt to explore whether the use of these agents would provide more value for 
money in comparison with traditional calcium-based binders [79–87]. However, evidence regarding 
the comparative cost-effectiveness of these agents remains scarce, and the quality of published 
economic evaluations of phosphate binders is understudied. Taken the widespread use of these 
medications and the high cost of novel calcium-free agents, reviewing and critically appraising 
evidence about their cost-effectiveness is essential for identifying research gaps in this field and 
generating valid, reliable and transparent conclusions for policymakers and researchers.  
Finally, the implementation of evidence-based guidelines for renal practice, including the adequate 
staffing of dietitians, is associated with decreased hemodialysis patient hospitalization and mortality 
[88,89]. Moreover, interventions promoting the effective control of dietary phosphorus were 
suggested to increase in parallel the efficacy of phosphate binders and improve the quality of care 
among hemodialysis patients [90]. This would imply tremendous cost savings if shown to be true 
[77]. Nutrition education for hyperphosphatemia management was thus suggested as a promising 
cost-effective intervention. Yet, to date, no rigorous economic evaluation of this intervention is 
available. Accordingly, given the high-quality supportive clinical evidence, the cost-effectiveness of 
nutrition education for hyperphosphatemia management, as provided by renal dietitians, is worthy of 
investigation. 
 
MANAGEMENT OF HEMODIALYSIS PATIENTS IN LEBANON 
As in many countries, renal failure is a growing public health problem in Lebanon. According to the 
Lebanese National Kidney Registry (NKR) [91], the prevalence of hemodialysis grew by 33% 
between 2007 and 2012 (from 570 patients per million people in 2007 to 700 per million in 2012), in 
comparison with an increase of 5% in the Lebanese population during the same period. The Lebanese 
Ministry of Public Health covers the cost of therapy for 55.8% of hemodialysis patients, which is 
reported to account for approximately 8% of its budget [91]. The rest of the patients are mainly 
covered by the National Social Security Fund (25%), followed by the army, the general security and 
the internal security forces, the employee’s mutuality, and private insurance for very few patients 
[91]. Detailed information regarding the financial impact of hemodialysis on Lebanese society and 
its main drivers is still scarce. 
Since hemodialysis units in Lebanon are exclusively hospital-based, hospital dietitians are in charge 
of the dietetic management of hemodialysis patients, and until now limited healthcare resources have 
inadvertently forced the decision to not have a dedicated renal dietitian for hemodialysis patients. The 
role of the hospital dietitian in the hemodialysis unit is neither described nor regulated by the 
Lebanese Healthcare Organizations Accreditation Law. Accordingly, dietetic care for hemodialysis 
patients is often overlooked by hospital dietitians, who are overloaded with their other administrative, 
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food service and clinical duties. Most hospital dietitians allocate one yearly routine consultation per 
hemodialysis patient, in addition to brief consultations following nephrologists’ consult requests [92]. 
This time allocation falls far below the recommended 30 minutes per patient per week (26 hours) 
[93]. Furthermore, Lebanese hospital dietitians exhibit poor knowledge regarding and low conformity 
with the implementation of international evidence-based practice guidelines [92]. Dietetic care for 
hemodialysis patients in Lebanon suffers from the absence of regulating policies, the lack of 
continuous education or certification programs in renal dietetics, the lack of integrating dietitians into 
the medical team, the unavailability of culturally-specific educational tools, and limited time for 
providing evidence-based practice nutritional care [94,95]. In parallel, Lebanese hemodialysis 
patients exhibit poor nutrition-related outcomes and might be at risk of malnutrition [91,96]. 
Specifically, hyperphosphatemia is a common finding. Despite the fact that 88% of patients use 
phosphate binders [91], around 41% of Lebanese hemodialysis patients are hyperphosphatemic [96]. 
 
The Nutrition Education for Management of Osteodystrophy (NEMO) [96] is a randomized controlled 
trial conducted in 12 hospital-based hemodialysis units. Its design is displayed in Figure 1. NEMO 
proposed a novel model of care for hyperphosphatemia management in Lebanon, where dietitians are 
provided with sufficient skills, tools and time to provide nutrition education for hemodialysis patients. 
In more detail, NEMO assessed the effect of a 2-hour per month stage-based nutritional education 
program provided by dedicated dietitians on serum phosphorus control. NEMO compared this model 
of care (Dedicated Dietitian: DD, where two key factors of the nutrition education are ensured: (1) 
dietitian education, and (2) recommended dietitian-to-patient time following international guidelines) 
with the existing practice (Existing Practice: EP) in Lebanon, lacking both dietitian education and 
dietitian-to-patient time factors, and to a proposed alternative (Trained Hospital Dietitian: THD), 
where dietitian education is ensured through an intensive training similar to one applied in the DD 
group, yet contact time with hemodialysis patients is not established. NEMO reported significantly 
improved serum phosphorus management, increased adherence to a low-phosphorus diet, increased 
knowledge related to the low-phosphorus diet, slower deterioration in some components of QOL and 
in the nutritional status of the general hemodialysis population [94,97]. However, the effect of this 
intervention specifically on patients with hyperphosphatemia (in terms of serum phosphorus and 
nutritional status outcomes) was not explored. Assessing the impact of the nutrition education among 
this sub-population is of utmost importance, since these patients exhibit unique demographic and 
clinical characteristics, are at increased morbimortality risk due to their elevated serum phosphorus 
level and for whom the intervention aiming to decrease serum phosphorus is appropriately targeted. 
In addition to the positive clinical effect of this intervention, it would be important for decision makers 
to know its value for money spent. Accordingly, an economic evaluation should be performed.  
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Figure 1. Design of the NEMO Trial [96]. 
 
HEALTH TECHNOLOGY ASSESSMENT AND ECONOMIC EVALUATIONS IN LEBANON 
Over a decade ago, the promotion of the creation of a national HTA agency was suggested as a core 
component of the strategy for national health care reform in Lebanon [5]. This agency would be 
responsible for initiating a systematic approach for value-based care in the country and informing 
public health decision making, through research, collection of information, analysis and reporting on 
the cost-effectiveness of health technologies [5]. Yet, to date, no concrete steps in this regard have 
been undertaken, save for a few exceptions in oncology management and immunotherapy, where 
decisions have recently been taken with a focus on budget impact [6]. Implementing a national 
program for HTA was mainly deferred due to the shortage of local expertise and multi-disciplinary 
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specialists in the public sector, the lack of epidemiological and clinical data, the absence of clearly 
defined health priorities and health outcomes needs, and improper communication and collaboration 
between stakeholders in health care [5,6]. Similarly, the performance and dissemination of economic 
evaluations in Lebanon is uncommon. For instance, a search conducted on February 20, 2017 of 
Pubmed employing the terms of ("Technology Assessment, Biomedical"[Mesh] OR "Cost-Benefit 
Analysis"[Mesh]) AND "Lebanon"[Mesh] results in only 11 records. Another search of the 
University of York’s Centre for Reviews and Dissemination (CRD) on the NHS Economic Evaluation 
Database (NHS EED) and HTA database using the "Lebanon"[Mesh] results in only 1 record. 
 
OBJECTIVES AND OUTLINE OF THE THESIS 
The aim of this dissertation is to provide insights into the HTA of hyperphosphatemia management 
among hemodialysis patients in Lebanon and explore economic considerations in this regard.  
The objectives are to provide an overview of the cost-effectiveness of interventions for 
hyperphosphatemia management among hemodialysis patients; to explore the financial burden of 
hemodialysis and hyperphosphatemia management in Lebanon and to evaluate the clinical and 
economic value of intensive nutrition education as a phosphorus-lowering intervention. 
More specifically, in Chapter 2, we systematically review and critically appraise the available 
evidence regarding the cost-effectiveness of interventions for managing hyperphosphatemia among 
hemodialysis patients. In fact, although an increasing number of economic evaluations of phosphorus-
lowering interventions are being published, the evidence behind the comparative cost-effectiveness 
of these agents is still scarce, and their quality is understudied. In Chapter 3, in light of the scarcity 
of economic information on hemodialysis in Lebanon, we provide detailed estimates on the societal 
cost-of-illness of this RRT and its main drivers, using data from the NEMO trial. We also gain insights 
into the financial burden of hyperphosphatemia management in this patient population in Lebanon. 
The remaining 2 chapters explore the clinical and economic value of a novel model of dietetic care 
for hyperphosphatemia management among hemodialysis patients in Lebanon. Chapter 4 explores 
the impact of intensive nutrition education provided by dedicated dietitians on serum phosphorus 
management among hemodialysis patients with hyperphosphatemia and compares this intervention 
with existing practices in Lebanon and with a proposed alternative. Finally, Chapter 5 explores the 
societal cost-effectiveness and cost-utility of this intervention, and informs decision makers about its 
value for money spent. The objectives of this dissertation are summarized in Figure 2.  
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Figure 2. Outline of the dissertation. 
 
Chapter 6 reviews the major findings of the dissertation and discusses its methodological challenges, 
strengths and limitations, as well as its clinical, economic, societal, public health and research 
implications.  
  
Chapter 1: General Introduction
Chapter 2: Review and critically appraise published economic evaluations of phosphorus-
lowering interventions among hemodialysis patients
Chapter 3: Explore the cost-of-illness of hemodialysis and its drivers in Lebanon
Chapter 4: Assess the clinical effectiveness of intensive nutrition education among 
hyperphosphatemic hemodialysis patients in Lebanon
Chapter 5: Evaluate the cost-effectiveness and cost-utility of intensive nutrition education 
among hemodialysis patients in Lebanon
Chapter 6: General Discussion
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ABSTRACT 
Managing hyperphosphataemia in haemodialysis patients is resource-intensive. A search for 
cost-effective interventions in this field is needed to inform decisions on the allocation of 
healthcare resources. NHSEED, MEDLINE, EMBASE and CINAHL were searched for full 
economic evaluations of hyperphosphataemia-managing interventions in adult haemodialysis 
patients, published between 2004 and 2014, in English, French, Dutch or German. Incremental 
cost-effectiveness ratios of the interventions were up-rated to 2013US$ using Purchasing 
Power Parity conversion rates and Consumer Price Indices. The quality of included studies was 
assessed using the Extended Consensus on Health Economic Criteria List. Twelve out of the 
1681 retrieved records fulfilled the inclusion criteria. They reported only on one aspect of 
hyperphosphataemia management, which is the use of phosphate binders (calcium-based and 
calcium-free, in first-line and sequential use). No economic evaluations of other phosphorus-
lowering interventions were found. The included articles derived from five countries and most 
of them were funded by pharmaceutical companies. The incremental cost-effectiveness ratios 
of phosphate binders ranged between US$11,461 and US$157,760 per quality-adjusted life-
year gained. Calcium-based binders (especially calcium acetate) appear to be the optimal cost-
effective first- and second-line therapy in prevalent patients, while the calcium-free binder, 
lanthanum carbonate, might provide good value for money, as second-line therapy, in incident 
patients. The studies' overall quality was suboptimal. Drawing firm conclusions was not 
possible due to the quality heterogeneity and inconsistent results. Future high-quality economic 
evaluations are needed to confirm the findings of this review and to address other interventions 
to manage hyperphosphataemia in this population. 
 
KEYWORDS 
Cost-benefit analysis; hyperphosphatemia; kidney failure, chronic; renal dialysis. 
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INTRODUCTION 
Renal failure is a growing public health problem [1], with haemodialysis (HD) being its 
primary treatment modality. Elevated serum phosphorus- hyperphosphataemia- is one 
particular complication of renal failure. It is consistently and independently associated with 
several adverse outcomes such as the chronic kidney disease- mineral bone disorder (CKD-
MBD) and increased risk of morbidity and mortality [2,3]. Normalizing serum phosphorous is 
suggested as essential for achieving adequate mineral-bone metabolism and improving survival 
[4,5]. Serum phosphorus management relies on dietary restriction, removal from the blood 
through dialysis and the use of phosphate-binding medications to reduce intestinal absorption 
[4,5]. Currently used binders are calcium-based: calcium acetate (CA), calcium carbonate 
(CC)... or calcium-free: sevelamer, lanthanum carbonate (LC) [6]… Finally, novel iron-based 
agents may be soon available for the treatment of hyperphosphatemia [6]. 
Hyperphosphataemia and its management pose a high financial burden on the patients and 
healthcare systems [7,8], and given the scarcity of resources, integrating health-economic 
evaluations while formulating evidence-based practice guidelines is highly recommended [9]. 
Economic evaluations of healthcare interventions provide evidence for value of money spent 
[9] and are now increasingly used to assist policymakers in resource allocation [10]. 
Several reviews in this field were previously conducted [11-13]. Komaba et al. [11] and Goto 
et al. [12] suggested LC as a cost-effective second-line therapy, especially in patients with 
moderate to severe hyperphosphataemia. In these reviews, however, the cost-effectiveness of 
first-line sevelamer and that of LC versus (vs.) sevelamer were not established [11,12]. CA 
combined with magnesium carbonate was suggested by Plagemann et al. [13] as a cost-
effective first-line therapy. However, this review [13] did not include any full economic 
evaluation of this combination and was funded by the pharmaceutical industry. None of these 
reviews adopted a systematic methodology nor critically appraised the quality of included 
studies. Moreover, they focused only on the cost-effectiveness of phosphate binders (PB). We 
could not identify any systematic review exploring the cost-effectiveness of different types of 
hyperphosphataemia-managing interventions in adults undergoing HD. 
Therefore, we aim to systematically review the evidence on the economic evaluations of 
different phosphorus-lowering interventions, whether related to dialysis, pharmacotherapy or 
diet. We also aim to assess the quality of included studies and identify research gaps in this 
field in order to generate valid, reliable and transparent conclusions to policymakers and 
researchers. 
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METHODS 
Standard methods for conducting and reporting systematic reviews (PRISMA) [14] were used. 
The protocol of this review was registered in the International Prospective Register of 
Systematic Reviews (PROSPERO) (CRD42014014631). 
 
LITERATURE SEARCH STRATEGY 
A search for published economic evaluations was performed on NHSEED, MEDLINE, 
EMBASE and CINAHL. An exhaustive search strategy employing the most sensitive search 
filters [15,16] to retrieve economic evaluations was elaborated. For the other terms, HD and 
hyperphosphataemia, the search included free-text words and controlled vocabulary. The 
search strategy was validated by an information specialist and is available in Supporting 
Information Appendix S1. The references of eligible studies were searched to identify papers 
missed by database searches. Finally, searches were rerun before the final analyses (01-01-
2015). 
 
INCLUSION AND EXCLUSION CRITERIA 
Preset inclusion criteria consisted of: original article; intervention for hyperphosphataemia 
management in adults undergoing maintenance HD; full economic evaluation comparing the 
costs and consequences of two or more interventions [17], namely cost-benefit, effectiveness 
and utility analyses; article in English, French, Dutch or German; and published between 01-
01-2004 (after the release of K/DOQI Guidelines for Bone Metabolism and Disease [5]) and 
31-12-2014.  
 
SELECTION OF STUDIES 
Two reviewers screened retrieved titles and abstracts to identify potentially eligible studies. At 
least two reviewers independently assessed the full texts of these studies against inclusion 
criteria. Disagreements were resolved by discussion. 
 
DATA EXTRACTION, DATA ANALYSIS AND QUALITY ASSESSMENT 
At least two reviewers independently performed evidence synthesis and critical appraisal, using 
standardized forms. Disagreements were resolved by discussion or with a third author, where 
necessary. A descriptive synthesis of the characteristics of the included studies was done. The 
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primary source of effectiveness used for conducting the analysis, the population, the 
comparator and the results of the base-case analysis (incremental cost-effectiveness ratios 
(ICER) reported as cost per life-year (LY) or quality-adjusted life-year (QALY) gained) were 
reported. Results of subgroup and sensitivity analyses were reported, when available. To enable 
comparability across studies, all incremental ratios were converted to US$, using Purchasing 
Power Parity (PPP) conversion rates [18], and up-rated to 2013US$ using Consumer Price 
Indices (Index, 2010=100) [19]. A cost-effectiveness threshold of US$50,000/QALY was 
applied [20]. For quality assessment, reviewers used the Extended Consensus on Health 
Economic Criteria (CHEC) List [21], in which the CHEC List [22] was extended with one 
question on modelling assumptions and validation. Twenty items were scored using: Yes (1), 
Suboptimal (0.5), No (0) and Not Applicable. The maximum score was 19 for trial-based 
economic evaluations and 20 for models. 
 
STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS, version 21. Independent-samples t-test and 
Fisher’s exact test were employed to investigate the associations between the studies' 
characteristics and quality. Statistical significance was accepted at P<0.05.  
 
RESULTS 
The search retrieved 1681 records of which 12 articles were included in the analysis (Figure 
1). 
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Figure 1. Flow chart of the inclusion process of search results.  
EE, economic evaluation; HD, haemodialysis. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA 
Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 
2009; 6: e1000097. doi: 10.1371journal.pmed1000097. 
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All included articles reported on the cost-effectiveness of only one type of intervention, which 
is the use of PB. As reported in Table 1, included studies were mostly conducted in the United 
Kingdom (n=5) [23,26,28,41,43]. Half of the articles were published in pharmacoeconomic 
journals [23,26,32,34,37,43] and eight studies were funded by pharmaceutical companies 
[23,26,32,34,37,41,43,44]. All articles adopted a payer perspective and all except Ruggeri et 
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al. [39] used model-based analysis, especially markov models (n=6) [23,35,37,41,43,44]. 
QALY were outcome measures in four studies [26,28,31,35], and QALY and LY in five studies 
[23,37,41,43,44]. Incident [39,41,43,44] and prevalent [23,26,28,31,32,34,37] patients were 
studied; with the majority being hyperphosphataemic. The studied binders were calcium-based, 
mainly CC and CA and calcium-free, mainly sevelamer hydrochloride (SH) and LC. Five 
studies [26,28,31,43,44] compared the cost-effectiveness of PB as second-line therapy. Details 
on populations, comparators, results and sensitivity analyses are found in Supporting 
Information Appendix S2. 
 
RESULTS OF INCLUDED STUDIES 
Figures 2, 3 and 4 present the comparators and main results of the articles. When compared 
with calcium-based binders, CBB: CC and/or CA, the cost-effectiveness of calcium-free 
binders in prevalent patients was inconsistent between studies. The most studied one was 
sevelamer [23,28,32,34,35,37,39,41]. Its ICER ranged from greatly above US$100,000 [28,35] 
to US$36,803/QALY gained [23]. First-line calcium-free binders in prevalent patients were 
compared only in Park et al. [37], where LC had an ICER of US$26,835/QALY gained. SH 
was the only studied calcium-free binder vs. CBB in incident patients, with an ICER of 
US$47,153/QALY gained [45]. For first-line use, CA appear to be the most cost-effective 
therapy with an ICER of US$11,818/QALY gained [28]. The results of the cost-effectiveness 
of second-line PB in prevalent patients derived mainly from Dasgupta et al. [28] (we reviewed 
the methods and results of this study, which are available in the Appendix F of the NICE 
clinical guideline 15735). The continuous use of CA was the most cost-effective intervention 
with an ICER of US$11,818/QALY gained. Switching from CA to SH was slightly above the 
cost-effectiveness threshold, leading to an ICER of (US$54,898/QALY gained, compared with 
CC. All other treatment strategies were dominated (less effective and more costly) or 
extendedly dominated (producing additional gains in effectiveness at incremental costs higher 
than those of the next most effective strategy). Brennan et al. [26] reported that LC was cost-
effective when compared with CC (US$48,787/QALY gained). The ICER of LC further 
decreased when compared with a treatment including SH and CBB and reached 
US$33,396/QALY gained [31]. In incident patients, second-line LC vs. CBB offered good 
value for money [43,44], with ICERs ranging between US$11,461 and US$11,525/QALY 
gained. 
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Figure 2. Incremental cost-effectiveness ratios of phosphate binders in first-line use. Incremental 
cost-effectiveness ratios (ICER) are up-rated to 2013US$; ICER are reported as US$/quality-adjusted life-years 
(QALY) gained. Different colours represent different set of comparators. ‡Incident patients. CA, calcium acetate; 
CBB, calcium-based binders; CC, calcium carbonate; LC, lanthanum carbonate; SC, sevelamer carbonate; SH, 
selevamer hydrochloride. 
 
Figure 3. Incremental cost-
effectiveness ratios of 
phosphate binders in first-
line use.  
Incremental cost-effectiveness 
ratios (ICER) are up-rated to 
2013US$; ICER are reported as 
US$/life-years (LY) gained. 
Different colours represent 
different set of comparators. 
‡Incident patients. CA, calcium 
acetate; CBB, calcium-based 
binders; CC, calcium carbonate; 
SH, selevamer hydrochloride. 
 
 
Figure 4. Incremental cost-effectiveness ratios of phosphate binders in second-line use. 
Incremental cost-effectiveness ratios (ICER) are up-rated to 2013US$; ICER are reported as US$/ quality-adjusted 
life-years (QALY) gained. Different colours represent different set of comparators. ‡Incident patients. CA, 
calcium acetate; CBB, calcium-based binder; CC, calcium carbonate; CL, calcium lactate; LC, lanthanum 
carbonate; NS, no switch; SH, selevamer hydrochloride.  
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In subgroup analyses, the ICER of first-line calcium-free binders slightly decreased when older 
patients (≥65 years) were included in Bernard et al. [46]; the opposite was found by Manns et 
al. [35], Taylor et al. [41] and Dasgupta et al. [28]. The sequential use of calcium-free binders 
in severely hyperphosphataemic patients resulted in better cost-effectiveness [26], where the 
ICER of LC vs. CC dropped from US$241,334/QALY gained in patients with serum 
phosphorus of 5.6-6.5 mg/dL to US$17,413/QALY gained in patients with serum phosphorus 
above 7.9 mg/dL.  
In sensitivity analyses, results were robust to changes in various model parameters in the 
majority of the studies. The most common influential factors were efficacy, drug costs, time 
horizon (i.e. shorter horizons resulted in higher ICERs; especially for calcium-free binders in 
sequential use), utility of renal failure and inclusion of future unrelated costs. In fact, whenever 
included, dialysis costs resulted in much higher ICERs. Finally, studies funded by 
pharmaceutical companies were more likely to report ICERs favouring their sponsors 
(P=0.018). 
 
RESULTS OF THE QUALITY ASSESSMENT 
Quality assessment results are displayed in Table 2. The only included trial-based economic 
evaluation [39] scored 10/19. Mean quality scores for models was 14.77±2.19 (11.50-19.00). 
The economic study design was appropriate in all articles. However, description of the study 
population [23,26,35,37,41,43,44] and conduct of deterministic and probabilistic sensitivity 
analyses [23,26,28,31,35,39,41,43] were suboptimal in more than half of the studies. Reporting 
structural assumption and validation of the model was suboptimal in seven studies 
[23,26,32,34,41,43,44]. Costs and outcomes were not appropriately discounted in four studies 
[31,34,37,39]. Studies that were not funded by pharmaceutical companies [28,35] had 
significantly higher scores (18.00 vs. 13.55; P=0.01). The majority of high-quality studies 
favoured first- and second-line use of CBB over calcium-free binders in prevalent patients 
[28,35]. Only one high-quality study [44], funded by the industry, reported better cost-
effectiveness of second-line LC over CBB, in incident patients. 
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DISCUSSION 
Our results confirm what was suggested by Komaba et al. [11] and Goto et al. [12] on the lack 
of conclusive evidence advocating the systematic use of sevelamer in real clinical settings. 
While both reviews suggested LC as a cost-effective sequential therapy, our results support 
this use only in incident patients. The use of calcium-free binders in HD patients was promoted 
because of their association with lower rates of treatment-related hypercalcaemia, which may 
reduce vascular calcification [33,47]. However, recent high-quality evidence did not establish 
their superiority over CBB in terms of serum phosphorus management [46]. Regarding HD 
patient mortality, two recent meta-analyses studied the impact of calcium-free binders vs. CBB 
and reported inconsistent results [46,48]. Plagemann et al. [13] proposed the novel preparation 
of CA and magnesium carbonate as a cost-effective first-line therapy; our extensive search did 
not result in any economic evaluation of this combination. 
The included studies differed in several areas, such as patient populations: prevalent vs. 
incident, study design: markov model, patient-level simulation, trial-based..., primary source 
of efficacy: phosphorus control vs. survival, costs included: dialysis, transplantation... and their 
sources, health utilities... and were conducted in five different countries. All these factors affect 
the validity of the direct comparison of the findings of these studies [49] and hinder our ability 
to make clear recommendations on the relative cost-effectiveness of PB. This was also 
indicated in systematic reviews in other areas of healthcare [45]. For these reasons, and taking 
into consideration the descriptive nature of this review, the validity of the results of the included 
studies and subsequently this review should be interpreted with caution. 
Our secondary aim was to assess the quality of included articles. On average, scores were 
suboptimal and this was mainly due to the numerous methodological shortcomings and poorly 
justified modelling assumptions. Suboptimal quality of economic evaluations was also reported 
by previous systematic reviews [45,50,51]. 
 
STRENGTHS AND LIMITATIONS OF THIS SYSTEMATIC REVIEW 
Although this systematic review provides valuable information for researchers and 
policymakers, the overall evidence behind its findings was suboptimal. While previous reviews 
focused on the cost-effectiveness of PB only, this review pioneered in systematically searching 
for economic evaluations of all phosphorus-lowering interventions. We followed standard 
methods for conducting and reporting systematic reviews and exhaustively searched multiple 
databases. However, we did not search the grey literature and were limited to articles published 
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after the release of K/DOQI guidelines [5], the first guidelines to assist decision-making in the 
field of hyperphosphataemia management in HD patients.  
We followed recommended steps [52] for converting ICERs to the same currency for the same 
year, to enable comparison between the studies and generate potentially applicable conclusions 
to different countries. Another limitation of this review is the adopted cost-effectiveness 
threshold of US$50,000- a conveniently cited value in the USA [20]. Cost-effectiveness 
thresholds are influenced by healthcare resources, reimbursement mechanisms, cultural and 
social factors, and thus differ between countries [53]; however, due to the heterogeneity in 
results, changing the threshold would not have affected our conclusion. 
We also appraised the quality of included studies; a first in the field of economic evaluations 
of PB. Despite using a validated checklist, differences in quality judgment might be due to the 
contribution of all reviewers in this process. The mean quality of included studies was 
suboptimal in nature and most of them were funded by pharmaceutical companies. Lexchin et 
al. [54] reported that pharmacoeconomic studies sponsored by the industry tended to favour 
the sponsor's product; we found similar results. Finally, for some comparators or situations, 
only one study/model was found. All these factors affect the quality of our findings and limit 
our ability to draw firm conclusions. 
 
IMPLICATIONS FOR RESEARCHERS 
Several research gaps were identified. We did not find any publication on the cost-effectiveness 
of other interventions for hyperphosphatemia management despite their increasing use in 
clinical practice, such as dietary interventions, exercise during dialysis and non-dialysis times, 
dialysis prescription (long vs. standard hour and frequent vs. standard dialysis), and adherence-
promoting interventions. Economic evaluations of these interventions are needed, especially in 
the fields of dialysis prescription and adherence promotion, as they were effective in terms of 
decreased serum phosphorus [55-57] and phosphate binders dose [57], an resulted sin better 
survival [56], improved quality-of-life [58], and cost savings [59], among others. Several 
drawbacks were mentioned in the included articles, primarily pertaining to the lack of data in 
the following areas: long-term effects of PB on survival and other health outcomes; cost impact 
and utility of hypercalcaemic events; utility of different PB and their side effects, adherence 
rates with different binders and their effects on outcomes and costs… Also, we could not 
identify any head-to-head comparison between calcium-free binders. Goto et al. [31] assessed 
second-line LC vs. a treatment comprising SH, CC and calcium lactate, and found that the 
former was cost-effective. In contrast, Vegter et al. [44] performed a cost-minimization 
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analysis between second-line LC and SH, and reported that the former was 23% less expensive; 
full economic evaluations of these agents are needed. Economic evaluations between LC and 
sevelamer are also needed in patients with hypercalcaemia and who do not tolerate CBB. 
Finally, further research is needed to better understand the cost-effectiveness of PB in certain 
populations, especially elderly, severely hyperphosphataemic, hypercalcaemic...  
 
IMPLICATIONS FOR PUBLIC-HEALTH POLICYMAKERS 
Although hyperphosphataemia and its management pose clinical and financial burdens in HD 
patients worldwide, included articles derived from five high-income countries only. This 
highlights the lack of country-specific economic evaluations, particularly in low- and middle-
income countries. Until further country-specific research is available, the results of this 
systematic review might be used by decision makers who are constantly faced by healthcare 
resource constraints. More evidence is needed to inform policy-makers whether the cost of 
high-cost binders is warranted, especially that up-till-now, no controlled randomized trial had 
supported the benefits of lowering serum phosphorus to suggested targets, on patient-level end 
points [4,5]. 
 
CONCLUSION 
In conclusion, we found limited high-quality evidence on the cost-effectiveness of PB in adult 
HD patients. Their ICER ranged between US$11,461 and US$157,760/QALY gained. In view 
of the quality heterogeneity and inconsistent results of included studies, it was not possible to 
draw firm conclusions. CBB- especially CA, appear to be the most cost-effective therapy, in 
first-line and sequential use, in prevalent patients. LC might provide good value for money, as 
second-line therapy, in incident patients. We were not able to identify any study on other 
interventions to manage hyperphosphataemia in this population. Future high-quality economic 
evaluations are needed. 
 
Acknowledgements 
We would like to thank Ms. Aida Farha, medical information specialist, for her assistance in 
developing the search strategy. 
  
CHAPTER 2 
41 
REFERENCES  
1. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: Global dimension and 
perspectives. Lancet 2013; 382: 260–72. 
2. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral 
metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study 
(DOPPS). Am. J. Kidney Dis. 2004; 44 (Suppl 2): 34–8. 
3. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different 
levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns 
Study (DOPPS). Am. J. Kidney Dis. 2008; 52: 519–30. 
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. 
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009; 76 (Suppl 
113): 1–130. 
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism 
and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42 (Suppl 3): 1–202. 
6. Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment 
of hyperphosphatemia in chronic kidney disease patients on dialysis: A comparison of safety 
profiles. Expert Opin. Drug Saf. 2014; 13: 551–61. 
7. White A, Odedina F, Xiao H, Campbell E, Segal R. The economic burden of end-stage 
renal disease with hyperphosphatemia: A study of Florida Medicaid. Dis. Manag. Health 
Outcomes 2006; 14: 99–106. 
8. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone 
metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007; 71: 
312–7.  
9. Haller MC, Vanholder R, Oberbauer R, Zoccali C, Van Biesen W. Health economics and 
European Renal Best Practice – Is it time to bring health economics into evidence-based 
guideline production in Europe? Nephrol. Dial. Transplant. 2014; 29: 1994–7.  
10. Brousselle A, Lessard C. Economic evaluation to inform health care decision-making: 
Promise, pitfalls and a proposal for an alternative path. Soc. Sci. Med. 2011; 72: 832–9. 
11. Komaba H, Moriwaki K, Kamae I, Fukagawa M. Towards cost-effective strategies for 
treatment of chronic kidney disease-mineral and bone disorder in Japan. Ther. Apher. Dial. 
2009; 13 (Suppl 1): 28–35. 
12. Goto S, Komaba H, Fukagawa M, Nishi S. Optimizing the cost-effectiveness of treatment 
for chronic kidney disease-mineral and bone disorder. Kidney Int. Suppl. 2013; 3: 457–61. 
COST-EFFECTIVE P-LOWERING INTERVENTIONS 
 
42 
13. Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost 
effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ. Rev. 2011; 1: 
1–9. 
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 
reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010; 8: 336–41. 
15. Glanville J, Kaunelis D, Mensinkai S. How well do search filters perform in identifying 
economic evaluations in MEDLINE and EMBASE. Int. J. Technol. Assess. Health Care 2009; 
25: 522–9. 
16. Glanville J, Fleetwood K, Yellowlees A, Kaunelis D, Mensinkai S. Development and 
testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa: 
Canadian Agency for Drugs and Technologies in Health, 2009. 
17. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. 
Med. Care 2005; 43 (Suppl): 5–14.  
18. Organisation for Economic Co-operation and Development (OECD). PPPs and exchange 
rates. 2014. [Updated Jul 2015; cited 7 Dec 2014.] Available from URL: 
http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4 
19. Organisation for Economic Co-operation and Development (OECD). Monthly 
comparative price levels. 2014. [Updated Jul 2015; cited 8 Dec 2014.] Available from URL: 
http://stats.oecd.org/Index.aspx?DataSetCode=CPL#  
20. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – The curious 
resilience of the $50,000-per-QALY threshold. N. Engl. J. Med. 2014; 371: 796–7. 
21. Odnoletkova I, Goderis G, Pil L et al. Cost-effectiveness of therapeutic education to 
prevent the development and progression of type 2 diabetes: Systematic review. J. Diabetes 
Metab. 2014; 5: 1000438. 
22. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of 
methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int. 
J. Technol. Assess. Health Care 2005; 21: 240–45. 
23. Bernard L, Mendelssohn D, Dunn E, Hutchison C, Grima DT. A modeled economic 
evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney 
disease among patients on dialysis in the United Kingdom. J. Med. Econ. 2013; 16: 1–9. 
24. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based 
phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130–7. 
25. Suki WN. Effects of sevelamer and calcium-based phosphate binders on mortality in 
hemodialysis patients: Results of a randomized clinical trial. J. Ren. Nutr. 2008; 18: 91–8. 
CHAPTER 2 
43 
26. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V. The cost-effectiveness of 
Lanthanum Carbonate in the treatment of hyperphosphatemia in patients with end-stage renal 
disease. Value Health 2007; 10: 32–41. 
27. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of 
lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus 
calcium carbonate. Nephron. Clin. Pract. 2005; 100: c8–c19. 
28. Dasgupta I, Shroff R, Bennett-Jones D, McVeigh G. Management of 
hyperphosphataemia in chronic kidney disease: Summary of National Institute for Health and 
Clinical Excellence (NICE) guideline. Nephron Clin. Pract. 2013; 124: 1–9. 
29. National Institute for Health and Care Excellence. Hyperphosphataemia in chronic 
kidney disease (CG157). 2014. [Updated Dec 2015; cited 1 Jan 2015.] Available from URL: 
http://guidance.nice.org.uk/CG157 
30. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate 
binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin. 
Nephrol. 2004; 2: 104–15. 
31. Goto S, Komaba H, Moriwaki K et al. Clinical efficacy and cost-effectiveness of 
lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin. J. Am. 
Soc. Nephrol. 2011; 6: 1375–84. 
32. Huybrechts KF, Caro JJ, Wilson DA, O’Brien JA. Health and economic consequences of 
sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005; 8: 549–
61.  
33. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and 
aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245–52. 
34. Huybrechts KF, Caro JJ, O’Brien JA. Prevention and management of hyperphosphatemia 
with sevelamer in Canada: Health and economic consequences. Value Health 2009; 12: 16–9. 
35. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation 
of sevelamer in patients with end-stage renal disease. Nephrol. Dial. Transplant. 2007; 22: 
2867–78. 
36. Suki W, Zabaneh R, Cangiano J et al. A prospective, randomized trial assessing the 
impact on outcomes of sevelamer in dialysis patients – The DCOR trial. Am. Soc. Nephrol., 
Pennsylvania, Philadelphia: 2005. 
37. Park H, Rascati KL, Keith MS et al. Cost-effectiveness of lanthanum carbonate versus 
sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage 
renal disease: A US payer perspective. Value Health 2011; 14: 1002–9. 
COST-EFFECTIVE P-LOWERING INTERVENTIONS 
 
44 
38. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. 
sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A 
crossover study. Clin. Nephrol. 2009; 4: 252–8. 
39. Ruggeri M, Bellasi A, Cipriani F et al. Sevelamer is cost effective versus calcium 
carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: A 
patient-level economic evaluation of the INDEPENDENT-HD study. J. Nephrol. 2014; 27: 1–
10. 
40. Di Iorio B, Molony D, Bell C et al. Sevelamer versus calcium carbonate in incident 
hemodialysis patients: Results of an open-label 24-month randomized clinical trial. Am. J. 
Kidney Dis. 2013; 62: 771–8. 
41. Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. An economic evaluation 
of sevelamer in patients new to dialysis. Curr. Med. Res. Opin. 2008; 24: 601–8. 
42. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary 
calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 
71: 438–41.  
43. Vegter S, Tolley K, Keith MS, Postma MJ. Cost-effectiveness of lanthanum carbonate in 
the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value 
Health 2011; 14: 852–8. 
44. Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR. Cost-effectiveness of 
lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: A Canadian 
payer perspective. Clin. Ther. 2012; 34: 1531–43. 
45. Hiligsmann M, Evers SM, Sedrine WB et al. A systematic review of cost-effectiveness 
analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 2014; 33: 205–24. 
46. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Phosphate 
binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane 
Database Syst. Rev. 2011; (2): CD006023. 
47. Toussaint N, Lau K, Polkinghorne K, Kerr P. Attenuation of aortic calcification with 
lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot 
randomized controlled trial. Nephrology 2011; 16: 290–98. 
48. Jamal S, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based 
phosphate binders on mortality in patients with chronic kidney disease: An updated systematic 
review and meta-analysis. Lancet 2013; 382: 1268–77. 
49. Elliott RA, Putman K, Davies J, Annemans L. A review of the methodological challenges 
in assessing the cost effectiveness of pharmacist interventions. Pharmacoeconomics 2014; 32: 
1185–99. 
CHAPTER 2 
45 
50. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation 
literature in Thailand. Pharmacoeconomics 2007; 25: 467–79. 
51. Alaqeel SA. State of health economic evaluation research in Saudi Arabia: A review. 
Clinicoecon. Outcomes Res. 2012; 4: 177–84. 
52. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 
Chichester: Wiley-Blackwell, 2008.  
53. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for cost-effectiveness 
in health care. Brussels: Belgian Health Care Knowledge Centre, 2008. 
54. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and 
research outcome and quality: Systematic review. BMJ 2003; 326: 1167–70. 
55. Karavetian M, de Vries N, Rizk R, Elzein H. Dietary educational interventions for 
management of hyperphosphatemia in hemodialysis patients: A systematic review and meta-
analysis. Nutr. Rev. 2014; 72: 471–82. 
56. Tentori T, Zhang J, Li Y et al. Longer dialysis session length is associated with better 
intermediate outcomes and survival among patients on in-center three times per week 
hemodialysis: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). 
Nephrol. Dial. Transplant. 2012; 27: 4180–88. 
57. Kerr PG, Agar JW, Hawley CM. Alternate night nocturnal hemodialysis: The Australian 
experience. Semin. Dial. 2011; 24: 664–7. 
58. Karavetian M, Elzein H, Rizk R, Bechwaty F, de Vries N. Effect of behavioral stage-
based nutrition education on management of osteodystrophy among hemodialysis patients, 
Lebanon. Patient Educ. Couns. 2015; 98: 1116–22. 
59. Ramakrishnan K, Braunhofer P, Newsome B et al. The economic impact of improving 
phosphate binder therapy adherence and attainment of guideline phosphorus goals in 
hemodialysis patients: A Medicare cost-offset model. Adv. Ther. 2014; 31: 1272–86. 
  
COST-EFFECTIVE P-LOWERING INTERVENTIONS 
 
46 
Supporting Information Appendix S1: Search strategy 
 
1) NHSEED via CRD 
((MeSH DESCRIPTOR Phosphorus EXPLODE ALL TREES) OR (MeSH DESCRIPTOR 
Phosphates EXPLODE ALL TREES) OR (phosphorus or phosphat* or hyperphosphat* or 
hyper-phosphat*)) AND ((MeSH DESCRIPTOR Kidney Failure, Chronic EXPLODE ALL 
TREES) OR (MeSH DESCRIPTOR Renal Dialysis EXPLODE ALL TREES) OR (MeSH 
DESCRIPTOR Renal Insufficiency) OR (MeSH DESCRIPTOR Renal Replacement 
Therapy) OR (MeSH DESCRIPTOR Kidney Diseases OR MeSH DESCRIPTOR Uremia) 
OR (((renal OR kidney) NEAR3 (replacement* OR insufficien* OR impaire* OR failure OR 
disease*)) OR (dialys* OR hemodialys* OR haemodialys*) OR ((endstage* OR end-stage*) 
NEAR3 (renal OR kidney)) OR (uremi* OR azotemi* OR uraemi*) OR (chronic NEAR3 
(renal OR kidney) NEAR3 injur*) OR (ESKD OR ESKF OR ESRD OR ESRF OR HD OR 
MHD))) IN NHSEED FROM 2004 TO 2014 
 
2) MEDLINE using OVID 
1. exp Economics/ 
2. quality of life/ 
3. value of life/ 
4. Quality-adjusted life years/ 
5. models, economic/ 
6. markov chains/ 
7. monte carlo method/ 
8. decision tree/ 
9. ec.fs. 
10. economic$.tw. 
11. (cost? or costing? or costly or costed).tw. 
12. (price? or pricing?).tw. 
13. (pharmacoeconomic? or (pharmaco adj economic?)).tw. 
14. budget$.tw. 
15. expenditure$.tw. 
16. (value adj1 (money or monetary)).tw. 
17. (fee or fees).tw. 
18. "quality of life".tw. 
19. qol$.tw. 
20. hrqol$.tw. 
21. "Quality adjusted life year$".tw. 
22. qaly$.tw. 
23. cba.tw. 
24. cea.tw. 
25. cua.tw. 
26. utilit$.tw. 
27. markov$.tw. 
28. monte carlo.tw. 
29. (decision adj2 (tree$ or analys$ or model$)).tw. 
30. ((clinical or critical or patient) adj (path? or pathway?)).tw. 
31. (managed adj2 (care or network?)).tw. 
32. or/1-31 
33. Letter.pt. 
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34. Editorial.pt. 
35. Historical article.pt. 
36. Animals/ not humans/ 
37. OR/33-36 
38. 32 not 37 
39. exp Hyperphosphatemia/ 
40. exp Phosphorus/ 
41. *Phosphates/ 
42. (phosphorus or phosphat* or hyperphosphat* or hyper-phosphat*).ti,ab,sh. 
43. OR/39-42 
44. exp Kidney Failure, Chronic/ 
45. exp Renal Dialysis/ 
46. exp Renal Insufficiency, Chronic/ 
47. Renal Replacement Therapy/ 
48. Renal Insufficiency/ 
49. *Kidney Diseases/ 
50. *Uremia/ 
51. ((renal or kidney) adj3 (replacement* or insufficien* or impaire* or failure or 
disease*)).ti,ab,sh. 
52. (dialys* or hemodialys* or haemodialys*).ti,ab,sh. 
53. ((endstage* or end-stage*) adj3 (renal or kidney)).ti,ab,sh. 
54. (uremi* or azotemi* or uraemi*).ti,ab,sh. 
55. (chronic adj3 (renal or kidney) adj3 injur*).ti,ab,sh. 
56. (ESKD or ESKF or ESRD or ESRF or HD or MHD).ti,ab. 
57. OR/44-56 
58. 38 AND 43 AND 57 
59. limit 58 to (yr="2004 -Current" and (dutch or english or french or german)) 
 
3) EMBASE using OVID 
1. exp health economics/ 
2. exp health care cost/ 
3. exp quality of life/ 
4. economic$.tw. 
5. (cost? or costing? or costly or costed).tw. 
6. (price? or pricing?).tw. 
7. (pharmacoeconomic? or (pharmaco adj economic?)).tw. 
8. budget$.tw. 
9. expenditure$.tw. 
10. (value adj1 (money or monetary)).tw. 
11. (fee or fees).tw. 
12. "quality of life".tw. 
13. qol$.tw. 
14. hrqol$.tw. 
15. "quality adjusted life year$".tw. 
16. qaly$.tw. 
17. cba.tw. 
18. cea.tw. 
19. cua.tw. 
20. utilit$.tw. 
21. markov$.tw. 
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22. monte carlo.tw. 
23. (decision adj2 (tree$ or analys$ or model$)).tw. 
24. ((clinical or critical or patient) adj (path? or pathway?)).tw. 
25. (managed adj2 (care or network?)).tw. 
26. OR/1-25 
27. exp Hyperphosphatemia/ 
28. exp Phosphorus/ 
29. *Phosphate/ 
30. (phosphorus or phosphat* or hyperphosphat* or hyper-phosphat*).ti,ab,sh. 
31. OR/27-30 
32. exp Chronic Kidney Failure/ 
33. exp Hemodialysis/ 
34. exp Kidney Failure/ 
35. Renal Replacement Therapy/ 
36. *Kidney Disease/ 
37. *Uremia/ 
38. ((renal or kidney) adj3 (replacement* or insufficien* or impaire* or failure or 
disease*)).ti,ab,sh. 
39. (dialys* or hemodialys* or haemodialys*).ti,ab,sh. 
40. ((endstage* or end-stage*) adj3 (renal or kidney)).ti,ab,sh. 
41. (uremi* or azotemi* or uraemi*).ti,ab,sh. 
42. (chronic adj3 (renal or kidney) adj3 injur*).ti,ab,sh. 
43. (ESKD or ESKF or ESRD or ESRF or HD or MHD).ti,ab. 
44. OR/32-43 
45. 26 AND 31 AND 44 
46. Limit 46 to ((dutch or english or french or german) and yr="2004 -Current") 
 
4) CINAHL using EBSCO 
S1. MH "Economics+" 
S2. MH "Financial Management+" 
S3. MH "Financial Support+" 
S4. MH "Financing, Organized+" 
S5. MH "Business+" 
S6. S2 OR S3 OR S4 OR S5 
S7. S1 NOT S6 
S8. MH "Health Resource Allocation" 
S9. MH "Health Resource Utilization" 
S10. S8 OR S9 
S11. S7 OR S10 
S12. TI (cost or costs or economic* or pharmacoeconomic* or price* or pricing*) OR AB 
(cost or costs or economic* or pharmacoeconomic* or price* or pricing*) 
S13. S11 OR S12 
S14. PT editorial 
S15. PT letter 
S16. PT commentary 
S17. S14 or S15 or S16 
S18. S13 NOT S17 
S19. MH "Animal Studies" 
S20. (ZT "doctoral dissertation") or (ZT "masters thesis") 
S21. S18 NOT (S19 OR S20) 
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S22. MH "Hyperphosphatemia" 
S23. MH "Phosphorus" 
S24. MM "Phosphates" 
S25. TI (phosphorus or phosphat* or hyperphosphat* or hyper-phosphat*) OR AB 
(phosphorus or phosphat* or hyperphosphat* or hyper-phosphat*) 
S26. S22 OR S23 OR S24 OR S25  
S27. MH "Kidney Failure, Chronic+" 
S28. MH "Hemodialysis+" 
S29. MH "Renal Insufficiency, Chronic+" 
S30. MH "Renal Insufficiency" 
S31. MM "Kidney Diseases" 
S32. MM "Uremia" 
S33. TI ((renal or kidney) N3 (replacement* or insufficien* or impaire* or failure or 
disease*)) OR AB ((renal or kidney) N3 (replacement* or insufficien* or impaire* or failure 
or disease*)) 
S34. TI (dialys* or hemodialys* or haemodialys*) OR AB (dialys* or hemodialys* or 
haemodialys*) 
S35. TI ((endstage* or end-stage*) N3 (renal or kidney)) OR AB ((endstage* or end-stage*) 
N3 (renal or kidney)) 10. TI (uremi* or azotemi* or uraemi*) OR AB (uremi* or azotemi* or 
uraemi*) 
S36. TI (chronic N3 (renal or kidney) N3 injur*) OR AB (chronic N3 (renal or kidney) N3 
injur*) 
S37. TI (ESKD or ESKF or ESRD or ESRF or HD or MHD) OR AB (ESKD or ESKF or 
ESRD or ESRF or HD or MHD) 
S38 S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR 
S37 
S39 S21 AND S26 AND S38 
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6
/Q
A
L
Y
 g
ai
n
ed
 
L
C
: 
ex
te
n
d
ed
ly
 d
o
m
in
at
ed
 
 S
ec
o
n
d
-l
in
e 
th
er
ap
y
: 
 
C
C
 (
n
o
 s
w
it
ch
):
 r
ef
er
en
ce
 
C
A
 (
n
o
 s
w
it
ch
):
 £
8
,1
9
7
/Q
A
L
Y
 g
ai
n
ed
 
C
A
->
S
H
: 
£
3
8
,0
7
8
/Q
A
L
Y
 g
ai
n
ed
 
C
C
->
L
C
; 
C
C
->
S
H
; 
L
C
 (
n
o
 s
w
it
ch
);
 S
H
 
(n
o
 s
w
it
ch
):
 d
o
m
in
at
ed
 
C
A
->
L
C
: 
ex
te
n
d
ed
ly
 d
o
m
in
at
ed
 
 IC
E
R
 i
n
 S
u
b
g
ro
u
p
 a
n
al
y
si
s 
in
 s
ec
o
n
d
-l
in
e 
th
er
ap
y
: 
 
≥
6
5
 y
ea
rs
: 
C
C
 (
n
o
 s
w
it
ch
):
 r
ef
er
en
ce
 
C
A
 (
n
o
 s
w
it
ch
):
 £
6
,4
4
1
/Q
A
L
Y
 g
ai
n
ed
 
C
A
->
L
C
: 
£
4
3
,7
7
8
/Q
A
L
Y
 g
ai
n
ed
 
C
A
->
S
H
: 
£
5
4
,1
9
3
/Q
A
L
Y
 g
ai
n
ed
 
S
H
 (
n
o
 s
w
it
ch
):
 £
3
,2
3
9
,0
7
6
/Q
A
L
Y
 
g
ai
n
ed
 
C
C
->
L
C
; 
C
C
->
S
H
; 
L
C
 (
n
o
 s
w
it
ch
):
 
d
o
m
in
at
ed
 
F
ir
st
-l
in
e 
th
er
ap
y
:‡
  
C
A
: 
$
1
1
,8
1
7
.7
4
/Q
A
L
Y
 g
ai
n
ed
 
S
H
: 
$
1
2
6
,7
4
9
.8
/Q
A
L
Y
 g
ai
n
ed
 
L
C
: 
ex
te
n
d
ed
ly
 d
o
m
in
at
ed
 
 S
ec
o
n
d
-l
in
e 
th
er
ap
y
: 
 
C
C
 (
n
o
 s
w
it
ch
):
 r
ef
er
en
ce
 
C
A
 (
n
o
 s
w
it
ch
):
 $
1
1
,8
1
7
.7
4
/Q
A
L
Y
 
g
ai
n
ed
 
C
A
->
S
H
: 
$
5
4
,8
9
7
.6
2
/Q
A
L
Y
 g
ai
n
ed
 
C
C
->
L
C
; 
C
C
->
S
H
; 
L
C
 (
n
o
 s
w
it
ch
);
 S
H
 
(n
o
 s
w
it
ch
):
 d
o
m
in
at
ed
 
C
A
->
L
C
: 
ex
te
n
d
ed
ly
 d
o
m
in
at
ed
 
 IC
E
R
 i
n
 S
u
b
g
ro
u
p
 a
n
al
y
si
s 
in
 s
ec
o
n
d
-
li
n
e 
th
er
ap
y
: 
 
≥
6
5
 y
ea
rs
: 
C
C
 (
n
o
 s
w
it
ch
):
 r
ef
er
en
ce
 
C
A
 (
n
o
 s
w
it
ch
):
 $
9
,2
8
6
.0
8
6
/Q
A
L
Y
 
g
ai
n
ed
 
C
A
->
L
C
: 
$
6
3
,1
1
5
.3
9
/Q
A
L
Y
 g
ai
n
ed
 
C
A
->
S
H
: 
$
7
8
,1
3
0
.8
5
/Q
A
L
Y
 g
ai
n
ed
 
S
H
 (
n
o
 s
w
it
ch
):
 $
4
,6
6
9
,8
2
4
/Q
A
L
Y
 
g
ai
n
ed
 
C
C
->
L
C
; 
C
C
->
S
H
; 
L
C
 (
n
o
 s
w
it
ch
):
 
d
o
m
in
at
ed
 
O
n
e-
w
ay
 s
en
si
ti
v
it
y
 a
n
al
y
si
s:
 
R
es
u
lt
s 
w
er
e 
n
o
t 
se
n
si
ti
v
e 
w
h
en
 m
o
st
 o
f 
th
e 
u
n
ce
rt
ai
n
 m
o
d
el
 p
ar
am
et
er
 v
al
u
es
 a
re
 
ch
an
g
ed
. 
 P
ro
b
ab
il
is
ti
c 
se
n
si
ti
v
it
y
 a
n
al
y
si
s:
 N
R
 
G
o
to
, 
2
0
1
1
 
[3
1
] 
P
re
v
al
en
t 
h
y
p
er
p
h
o
sp
h
at
em
ic
 
p
at
ie
n
ts
 
A
d
d
it
iv
e 
L
C
 v
s.
 
co
n
v
en
ti
o
n
al
 
tr
ea
tm
en
t 
(S
H
, 
C
C
 
an
d
 C
a 
la
ct
at
e)
, 
as
 
se
co
n
d
-l
in
e 
th
er
ap
y
  
F
o
r 
L
C
 v
s.
 C
o
n
v
en
ti
o
n
al
 t
re
at
m
en
t:
 
$
3
4
,8
9
6
/Q
A
L
Y
 g
ai
n
ed
 
F
o
r 
L
C
 v
s.
 C
o
n
v
en
ti
o
n
al
 
tr
ea
tm
en
t:
$
3
3
,3
9
6
.8
7
/Q
A
L
Y
^
 
O
n
e-
w
ay
 s
en
si
ti
v
it
y
 a
n
al
y
si
s:
  
R
es
u
lt
s 
w
er
e 
n
o
t 
se
n
si
ti
v
e 
to
 c
h
an
g
es
 i
n
 
v
ar
io
u
s 
k
ey
 p
ar
am
et
er
s 
 
R
es
u
lt
s 
w
er
e 
se
n
si
ti
v
e 
to
: 
↓
ef
fe
ct
 o
f 
L
C
 
o
n
 C
V
D
 i
n
ci
d
en
ce
 a
n
d
 m
o
rt
al
it
y
 b
y
 4
0
%
, 
6
0
%
 a
n
d
 8
0
%
; 
In
cl
u
d
in
g
 d
ia
ly
si
s 
co
st
 
 P
ro
b
ab
il
is
ti
c 
se
n
si
ti
v
it
y
 a
n
al
y
si
s:
  
B
as
ed
 o
n
 a
 W
T
P
 o
f 
$
5
0
,0
0
0
/Q
A
L
Y
 
g
ai
n
ed
, 
ad
d
it
iv
e 
L
C
 s
h
o
w
ed
 a
 9
7
.4
%
 
p
ro
b
ab
il
it
y
 o
f 
b
ei
n
g
 c
o
st
-e
ff
ec
ti
v
e 
co
m
p
ar
ed
 w
it
h
 c
o
n
v
en
ti
o
n
al
 t
re
at
m
en
t 
  
A
u
th
o
rs
 &
 
Y
ea
r 
P
o
p
u
la
ti
o
n
 
C
o
m
p
a
ra
to
r 
M
a
in
 R
es
u
lt
s 
(I
C
E
R
) 
 
A
d
ju
st
ed
 I
C
E
R
 i
n
 $
 f
o
r 
2
0
1
3
  
(I
n
d
ex
, 
2
0
1
0
=
1
0
0
) 
S
en
si
ti
v
it
y
 A
n
a
ly
si
s 
H
u
y
b
re
ch
ts
, 
2
0
0
5
 [
3
2
] 
P
re
v
al
en
t 
h
y
p
er
p
h
o
sp
h
at
em
ic
 
p
at
ie
n
ts
 
S
H
 v
s.
 C
A
, 
as
 f
ir
st
-
li
n
e 
th
er
ap
y
 f
o
r 
1
 
y
ea
r 
F
o
r 
S
H
 v
s.
 C
A
: 
$
1
,6
4
1
/L
Y
 g
ai
n
ed
 
($
2
2
1
9
/d
is
co
u
n
te
d
 L
Y
 g
ai
n
ed
) 
an
d
 
$
4
4
4
8
/C
V
 e
v
en
t 
p
re
v
en
te
d
 
F
o
r 
S
H
 v
s.
 C
A
: 
$
2
,8
7
2
.5
9
6
/d
is
co
u
n
te
d
 
L
Y
 g
ai
n
ed
 a
n
d
 $
5
7
5
8
.1
3
/C
V
 e
v
en
t 
p
re
v
en
te
d
 
O
n
e 
w
ay
 s
en
si
ti
v
it
y
 a
n
al
y
si
s:
 
R
es
u
lt
s 
w
er
e 
 n
o
t 
se
n
si
ti
v
e 
to
 c
h
an
g
es
 i
n
 
v
ar
io
u
s 
p
ar
am
et
er
s.
 
R
es
u
lt
s 
w
er
e 
se
n
si
ti
v
e 
to
: 
ti
m
e 
h
o
ri
zo
n
 (
2
, 
3
, 
4
  
an
d
 1
2
 y
ea
rs
 o
n
w
ar
d
);
 i
n
cl
u
d
in
g
 
fu
tu
re
 c
o
st
s;
 i
m
p
ac
t 
o
f 
tr
ea
tm
en
t 
o
n
 
ca
rd
ia
c 
ca
lc
if
ic
at
io
n
; 
in
it
ia
ti
n
g
 t
re
at
m
en
t 
w
h
en
 L
D
L
-c
h
o
le
st
er
o
l 
>
1
0
0
 m
g
/d
L
 
 P
ro
b
ab
il
is
ti
c 
se
n
si
ti
v
it
y
 a
n
al
y
si
s:
  
T
h
e 
li
k
el
ih
o
o
d
 o
f 
S
H
 b
ei
n
g
 c
o
st
-e
ff
ec
ti
v
e 
is
 5
1
%
 a
n
d
 9
5
%
 f
o
r 
C
E
R
 c
ei
li
n
g
 o
f 
$
2
5
0
0
 a
n
d
 $
1
0
,0
0
0
/d
is
co
u
n
te
d
 L
Y
 
g
ai
n
ed
, 
re
sp
ec
ti
v
el
y
 
H
u
y
b
re
ch
ts
, 
2
0
0
9
 [
3
4
] 
P
re
v
al
en
t 
h
y
p
er
p
h
o
sp
h
at
em
ic
 
p
at
ie
n
ts
 
S
H
 v
s.
 C
C
 a
s 
fi
rs
t-
li
n
e 
th
er
ap
y
 f
o
r 
1
 
y
ea
r 
F
o
r 
S
H
 v
s.
 C
C
: 
C
A
D
$
1
2
,3
8
4
/d
is
co
u
n
te
d
 
L
Y
 g
ai
n
ed
 
F
o
r 
S
H
 v
s.
 C
C
: 
$
1
2
,1
6
2
.7
8
/d
is
co
u
n
te
d
 
L
Y
 g
ai
n
ed
 
O
n
e 
w
ay
 s
en
si
ti
v
it
y
 a
n
al
y
si
s:
 
R
es
u
lt
s 
w
er
e 
n
o
t 
se
n
si
ti
v
e 
to
 c
h
an
g
es
 i
n
 
v
ar
io
u
s 
p
ar
am
et
er
s.
 
R
es
u
lt
s 
w
er
e 
se
n
si
ti
v
e 
to
: 
ti
m
e 
h
o
ri
zo
n
 
(≤
5
 y
ea
rs
);
 e
ff
ic
ac
y
 o
f 
S
H
 
 P
ro
b
ab
il
is
ti
c 
se
n
si
ti
v
it
y
 a
n
al
y
si
s:
  
T
h
e 
li
k
el
ih
o
o
d
 o
f 
S
H
 b
ei
n
g
 c
o
st
-e
ff
ec
ti
v
e 
is
 A
R
O
U
N
D
 5
0
%
 a
n
d
 9
5
%
 f
o
r 
C
E
R
 
ce
il
in
g
 o
f 
C
A
N
$
7
5
0
0
 a
n
d
 
C
A
N
$
1
5
,0
0
0
/d
is
co
u
n
te
d
 L
Y
 g
ai
n
ed
, 
re
sp
ec
ti
v
el
y
 (
D
A
T
A
 F
R
O
M
 T
H
E
 
G
R
A
P
H
) 
 
 
A
u
th
o
rs
 &
 
Y
ea
r 
P
o
p
u
la
ti
o
n
 
C
o
m
p
a
ra
to
r 
M
a
in
 R
es
u
lt
s 
(I
C
E
R
) 
 
A
d
ju
st
ed
 I
C
E
R
 i
n
 $
 f
o
r 
2
0
1
3
  
(I
n
d
ex
, 
2
0
1
0
=
1
0
0
) 
S
en
si
ti
v
it
y
 A
n
a
ly
si
s 
M
an
n
s,
 
2
0
0
7
 [
3
5
] 
P
at
ie
n
ts
 
re
p
re
se
n
ta
ti
v
e 
o
f 
ty
p
ic
al
 
C
an
ad
ia
n
 
d
ia
ly
si
s 
p
at
ie
n
ts
 
S
H
 v
s.
 C
C
, 
as
 f
ir
st
-
li
n
e 
th
er
ap
y
 
F
o
r 
S
H
 v
s.
 C
C
: 
M
o
d
el
 1
 (
p
ri
m
ar
y
):
 C
A
N
$
1
5
7
,5
0
0
/Q
A
L
Y
 
g
ai
n
ed
 
M
o
d
el
 2
 (
C
M
A
):
 S
 d
o
m
in
at
ed
 
M
o
d
el
 3
 (
m
o
rt
al
it
y
 o
v
er
 t
im
e:
 f
ir
st
 2
 y
ea
rs
 
v
s.
 ≥
3
 y
ea
rs
):
 C
A
N
$
1
2
7
,0
0
0
/Q
A
L
Y
 
g
ai
n
ed
  
M
o
d
el
 4
 (
m
o
rt
al
it
y
/a
g
e:
 <
6
5
 v
s.
 ≥
6
5
 
y
ea
rs
):
 C
A
N
$
2
7
8
,1
0
0
/Q
A
L
Y
 g
ai
n
ed
 
 S
u
b
g
ro
u
p
 a
n
al
y
si
s:
  
≥
6
5
 y
ea
rs
: 
C
A
N
$
1
0
5
,5
0
0
/Q
A
L
Y
 g
ai
n
ed
 
≥
5
5
 y
ea
rs
: 
C
A
N
$
1
0
2
,7
0
0
/Q
A
L
Y
 g
ai
n
ed
 
≥
4
5
 y
ea
rs
: 
C
A
N
$
9
7
,0
0
0
/Q
A
L
Y
 g
ai
n
ed
  
F
o
r 
S
H
 v
s.
 C
C
: 
M
o
d
el
 1
: 
$
1
5
7
,7
6
0
.2
/Q
A
L
Y
 g
ai
n
ed
 
M
o
d
el
 3
: 
$
1
2
7
,2
0
9
.9
/Q
A
L
Y
 g
ai
n
ed
 
M
o
d
el
 4
: 
$
2
7
8
,5
5
9
.6
/Q
A
L
Y
 g
ai
n
ed
 
 S
u
b
g
ro
u
p
 a
n
al
y
si
s:
  
≥
6
5
 y
ea
rs
: 
$
1
0
5
,6
7
4
.3
/Q
A
L
Y
 g
ai
n
ed
 
≥
5
5
 y
ea
rs
: 
$
1
0
2
,8
6
9
.7
/Q
A
L
Y
 g
ai
n
ed
 
≥
4
5
 y
ea
rs
: 
$
9
7
,1
6
0
.2
8
/Q
A
L
Y
 g
ai
n
ed
 
S
ce
n
ar
io
 a
n
al
y
se
s:
  
E
x
cl
u
si
o
n
 o
f 
d
ia
ly
si
s 
an
d
 t
ra
n
sp
la
n
ta
ti
o
n
- 
re
la
te
d
 h
ea
lt
h
 c
ar
e 
co
st
s:
 C
A
N
$
4
3
,8
0
0
-
$
1
8
6
8
,0
0
/Q
A
L
Y
 g
ai
n
ed
 (
M
o
d
el
s 
1
, 
2
, 
3
).
  
E
x
cl
u
d
in
g
 t
h
e 
co
st
s 
o
f 
d
ia
ly
si
s 
an
d
 
tr
an
sp
la
n
ta
ti
o
n
 a
n
d
 i
n
cl
u
d
in
g
 o
n
ly
 
p
at
ie
n
ts
 ≥
6
5
 (
M
o
d
el
 4
):
 $
2
3
,3
0
0
/Q
A
L
Y
 
g
ai
n
ed
 (
u
n
re
al
is
ti
ca
ll
y
 o
p
ti
m
is
ti
c 
es
ti
m
at
e 
o
f 
th
e 
co
st
-e
ff
ec
ti
v
en
es
s 
o
f 
S
H
).
 
U
S
 s
ce
n
ar
io
: 
 
S
H
 v
s.
 C
C
: 
$
1
5
6
,7
0
0
/Q
A
L
Y
 g
ai
n
ed
; 
 
S
H
 v
s.
 C
A
: 
$
1
7
5
,0
0
0
/Q
A
L
Y
 g
ai
n
ed
 
D
C
O
R
-s
p
ec
if
ic
 s
ce
n
ar
io
: 
 
S
H
 v
s.
 C
C
: 
$
1
7
9
,2
0
0
/Q
A
L
Y
 g
ai
n
ed
; 
 
S
H
 v
s.
 C
A
: 
$
2
0
5
,0
0
0
/Q
A
L
Y
 g
ai
n
ed
 
 O
n
e-
w
ay
 s
en
si
ti
v
it
y
 a
n
al
y
si
s:
  
R
es
u
lt
s 
w
er
e 
ro
b
u
st
 t
o
 c
li
n
ic
al
ly
 p
la
u
si
b
le
 
ch
an
g
es
 i
n
 a
ll
 u
n
ce
rt
ai
n
 v
ar
ia
b
le
s 
 P
ro
b
ab
il
is
ti
c 
se
n
si
ti
v
it
y
 a
n
al
y
si
s 
S
ig
n
if
ic
an
t 
u
n
ce
rt
ai
n
ty
 i
n
 t
h
e 
tr
u
e 
co
st
-
ef
fe
ct
iv
en
es
s 
o
f 
S
H
: 
th
e 
li
k
el
ih
o
o
d
 t
h
at
 
th
e 
u
se
 o
f 
S
H
 w
o
u
ld
 b
e 
co
st
-e
ff
ec
ti
v
e 
is
 
1
5
 a
n
d
 3
2
%
 f
o
r 
a 
W
T
P
 o
f 
C
A
N
$
5
0
,0
0
0
 
o
r 
$
1
0
0
,0
0
0
/Q
A
L
Y
 g
ai
n
ed
 (
M
o
d
el
 1
).
 
F
o
r 
th
e 
su
b
g
ro
u
p
 o
f 
p
at
ie
n
ts
 ≥
6
5
 y
ea
rs
, 
th
e 
p
ro
b
ab
il
it
y
 t
h
at
 t
h
e 
u
se
 o
f 
S
H
 w
o
u
ld
 
b
e 
co
st
-e
ff
ec
ti
v
e 
is
 2
1
 a
n
d
 4
4
%
 f
o
r 
a 
W
T
P
 o
f 
C
A
N
$
5
0
,0
0
0
 o
r 
$
1
0
0
,0
0
0
/Q
A
L
Y
 g
ai
n
ed
, 
re
sp
ec
ti
v
el
y
. 
 
 
 A
u
th
o
rs
 &
 
Y
ea
r 
P
o
p
u
la
ti
o
n
 
C
o
m
p
a
ra
to
r 
M
a
in
 R
es
u
lt
s 
(I
C
E
R
) 
 
A
d
ju
st
ed
 I
C
E
R
 i
n
 $
 f
o
r 
2
0
1
3
  
(I
n
d
ex
, 
2
0
1
0
=
1
0
0
) 
S
en
si
ti
v
it
y
 A
n
a
ly
si
s 
P
ar
k
, 
2
0
1
1
 
[3
7
] 
P
re
v
al
en
t 
h
y
p
er
p
h
o
sp
h
at
em
ic
 
p
at
ie
n
ts
 
L
C
 v
s.
 S
H
, 
as
 f
ir
st
-
li
n
e 
th
er
ap
y
 (
af
te
r 
p
re
v
io
u
s 
tr
ea
tm
en
t 
w
it
h
 C
B
B
) 
F
o
r 
L
C
 v
s.
 S
H
: 
 
IT
T
 p
o
p
u
la
ti
o
n
: 
IC
E
R
: 
$
2
4
,7
2
4
/Q
A
L
Y
 g
ai
n
ed
 a
n
d
 
$
1
5
,0
5
3
/L
Y
 g
ai
n
ed
 (
li
fe
 e
x
p
ec
ta
n
cy
 a
lo
n
e 
co
n
si
d
er
ed
) 
 C
o
m
p
le
te
r 
p
o
p
u
la
ti
o
n
: 
IC
E
R
: 
$
1
5
,2
8
5
/Q
A
L
Y
 g
ai
n
ed
 a
n
d
 
$
9
,3
3
7
/L
Y
 g
ai
n
ed
 
F
o
r 
L
C
 v
s.
 S
H
: 
 
IT
T
 p
o
p
u
la
ti
o
n
: 
IC
E
R
: 
$
2
6
,8
3
4
.5
9
/Q
A
L
Y
 g
ai
n
ed
 a
n
d
 
$
1
6
,3
3
8
.0
1
/L
Y
 g
ai
n
ed
 
  C
o
m
p
le
te
r 
p
o
p
u
la
ti
o
n
: 
IC
E
R
: 
$
1
6
,5
8
9
.8
2
/Q
A
L
Y
 g
ai
n
ed
 a
n
d
 
$
1
0
,1
3
4
.0
6
/L
Y
 g
ai
n
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ABSTRACT  
Aim: Renal failure is a growing public health problem, and is mainly treated by hemodialysis. 
This study aims to estimate the societal costs of hemodialysis in Lebanon. 
Methods: This was a quantitative, cross-sectional cost-of-illness study conducted alongside the 
Nutrition Education for Management of Osteodystrophy trial. Costs were assessed with a 
prevalence-based, bottom-up approach, for the period of June-December 2011. The data of 114 
patients recruited from 6 hospital-based units were collected through a questionnaire measuring 
health care costs, costs to patients and family, and costs in other sectors. Recall data were used 
for the base-case analysis. Sensitivity analyses employing various sources of resources use and 
costs were performed. Costs were uprated to 2015US$. Multiple linear regression was 
conducted to explore the predictors of societal costs. 
Results: The mean 6-month societal costs were estimated at $9258.39. The larger part was 
attributable to heathcare costs (91.7%), while costs to patient and family and costs in other 
sectors poorly contributed to the total costs (4.2% and 4.1%, respectively). In general, results 
were robust to sensitivity analyses. Using the maximum value for hospitalization resulted in the 
biggest difference (+15.5% of the base-case result). Female gender, being widowed/divorced, 
having hypertension comorbidity, and higher weekly time on dialysis were significantly 
associated with greater societal costs. 
Limitations: Information regarding resource consumption and cost were not readily available. 
Rather, they were obtained from a variety of sources, with each having its own strengths and 
limitations.  
Conclusion: Hemodialysis represents a high societal burden in Lebanon. Using extrapolation, 
its total annual cost for the Lebanese society is estimated at $61,105,374 and the mean total 
annual cost ($18,516.7) is 43.70% higher than the gross domestic product per capita forecast 
for 2015. Measures to reduce the economic burden of hemodialysis should be taken, by 
promoting chronic kidney disease's prevention and encouraging transplantation. 
 
KEYWORDS 
Costs and cost analysis; cost of illness; hemodialysis; Lebanon. 
INTRODUCTION 
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Renal failure is an emerging global public health problem [1–4], and hemodialysis (HD) is its 
main treatment modality [3,4]. As the prevalence of renal failure continues to escalate, the need 
for HD is also increasing in both developed and developing countries [5,6]. 
Although a life-saving therapy, HD poses a heavy burden on the patients [7,8]. It requires 
attending a 3-5-hour treatment session 3-times a week, adhering to a wide range of dietary 
restrictions and complex medications regimens. HD patients are at increased risks of mortality 
[9], morbidity, and hospitalization [10,11]. They have lower quality-of-life compared with the 
general population [12] and with patients treated with other renal replacement therapies (RRT) 
[13]. HD also results in an increased long-term mental, emotional, and physical burden on HD 
patients' caregivers, and adversely affects their quality-of-life [14].  
HD is the leading resource-consuming RRT [15–17], and its medical expenditures pose a 
significant burden on national health systems [17–19]. In 2003, in Jordan, the overall 
expenditure on HD was ≈ US$30 million, approaching 4% of the total health expenditures, 
which is disproportionately greater than the 0.03% prevalence of this patient population [20]. 
HD is also costly in terms of patient and family costs. Although productivity losses for HD 
patients, their families or caretakers have been rarely assessed and incorporated into economic 
evaluations, recent literature highlights this component as a cost driver for HD. In India, 24.4% 
of total HD costs was attributed to productivity losses due to entering the dialysis procedure 
[21]. Similar figures were reported from Chile, where patients’ loss of productivity and 
unemployment contributed to 28.5% of total HD costs [22]. HD is also costly in terms of costs 
in other sectors. In England in 2010, an annual cost of £26,835 has been estimated for each 
patient’s journeys to HD centers [17]. 
Knowing its increasing prevalence and high cost, HD needs to be addressed by specific 
healthcare policies. Estimating the financial burden of HD and exploring its dimensions and 
drivers are first required in order to assist public health policy-makers in making informed 
planning and budgeting decisions. Cost-of-illness (COI) studies assess the economic burden of 
a particular health problem over a defined period of time. These studies intend to draw the 
public’s attention to particular health problems while providing useful information to foster 
policy debate. COI studies inform planning of healthcare services, evaluation of policy options 
and prioritization of research [23].  
Just et al. [15] and Mushi et al. [18] systematically reviewed published cost of dialysis 
(peritoneal dialysis and HD) studies. These reviews highlighted the methodological flaws and 
differences across studies and pinpointed the scarcity of studies adopting a societal perspective. 
They concluded that the cost drivers and costs of HD vary widely among countries and between 
authors in the same country and recommended additional research, particularly in developing 
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countries. Between-country differences were also highlighted by Ranasinghe et al. [24], where 
the reported annual expenses per HD patient varied from US$3,423 in India to US$77,506 in 
the US. No studies conducted in Lebanon were identified in these reviews. 
In Lebanon, in 2015, 3300 patients were receiving HD in 64 hospital-based units. According to 
the National Kidney Registry (NKR) of Lebanon, the prevalence of HD has grown by 33% 
between 2007 and 2012 (570 to 700 patients per million people, respectively), compared to an 
increase of 5% in the Lebanese population during the same period. This was mainly due to 
improved diagnosis and providing renal replacement therapy to older patients [25]. Up to-now, 
no previous studies have addressed the financial impact of HD on the Lebanese society or 
explored the main cost drivers in this patient population. This study aims, therefore, to estimate, 
in a representative sample of Lebanese adult patients, the 6-month costs of HD, from a societal 
perspective. 
 
METHODS 
The current study is a multi-center, retrospective, bottom-up (referring to patient recall/records), 
prevalence-based COI estimate. It was conducted alongside the Nutrition Education for 
Management of Osteodystrophy (NEMO) trial, the protocol of which is detailed in Karavetian 
et al. [26]. In brief, NEMO is a multi-center randomized controlled trial in Lebanese hospital-
based HD units. NEMO explored the effectiveness of intensive nutritional education on the 
management of the Chronic Kidney Disease- Mineral Bone Disorder (CKD-MBD) among 
Lebanese adult HD patients. Twelve hospital-based HD unites were randomly recruited to the 
NEMO trial from the official list of hospital-based HD units in Lebanon. These units were 
randomly assigned to two clusters: (1) cluster A (6 units) and (2) cluster B (6 units). Cluster A 
patients were then randomly assigned according to their HD shifts into two protocols: (1) 
Dedicated Dietitian (intervention group) and (2) Existing Practice (control group). Cluster B 
patients were assigned to the Trained Hospital Dietitian protocol (partial intervention group). 
The COI analysis was carried out in the units randomly recruited to the control group. These 
six units were receiving care following existing practice (control group). NEMO was conducted 
according to the guidelines of the Declaration of Helsinki and all procedures involving human 
subjects were approved by the institutional review board of each participating institution [26]. 
 
SUBJECTS AND PROCEDURE 
Eligible patients were those being treated in HD units recruited to the study. They had to be 
Lebanese, adults (≥18 years), stable (free of the following diseases: cancer, infection with the 
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Human Immunodeficiency Virus and hepatitis), and on HD for ≥6 months. Eligible patients 
had also to be capable to communicate either verbally or through writing. They had to be willing 
to participate and sign the consent form. Eligible subjects were approached for participating in 
the study. Those who did not meet the inclusion criteria listed above were excluded.  
Data collection was through face-to-face interviews with HD patients, during HD sessions. Data 
were collected retrospectively for the period between June and December 2011, at one time-
point (January 2012: end of intervention phase). Recall data were used for the base-case 
analysis. 
 
COST PERSPECTIVE 
The study adopted a societal perspective; accordingly, all costs that burden society were 
accounted for, whenever possible. The societal perspective incorporates all costs regardless 
who incurs them [27]. The COI followed 3 steps: identification, measurement and valuation. 
Step I: Identification of costs 
Included costs were those related to HD, its consequences and treatment and were categorized 
as (1) health care sector costs: costs of maintenance HD and pertaining services, such as 
nephrologist consultation (provided each session), nursing services, laboratory procedures, 
basic solutions to provide dialysis, administrative materials, costs of equipment, and expenses 
for the dialysis room..., emergency HD, hospitalization, medications, specialist physician- other 
than nephrologist, i.e. cardiologist, neurologist, gastroenterologist…, dietitian and psychologist 
consultations, and integrated home care provided by physicians or nurses; (2) costs to patient 
and family, such as caregiver costs and productivity losses; and (3) costs in other sectors: travel 
costs [28]. 
Step II: Measurement of costs 
A resource utilization questionnaire was developed in English for measuring cost items. The 
questionnaire included questions on sociodemographic characteristics, health services and other 
services’ utilization. It was designed by the research team to meet the condition of Lebanese 
HD patients. This was done because different disease areas, health care systems and cultural 
specificities affect health care and other resources use. Finally, the questionnaire was translated 
to Arabic and pilot-tested on 20 adult Lebanese HD patients. The feedback from the pilot was 
taken into consideration in the final version of the questionnaire (Appendix 1).  
Step III: Valuation of costs (Table 1) 
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The costs were gathered and calculated in Lebanese pounds (L.L.), converted to US$ (1 
US$=1507.5 L.L.; year of reference: 2011) [29] and uprated to 2015US$ using Consumer Price 
Indices (Index, 2010=100) [30]. A macro-costing valuation was applied, whereby composite 
intermediate resources (e.g. inpatient day, HD session...) were identified and measured. For the 
base-case and sensitivity analyses, the mean reported costs incurred by patients were used to 
value costs of the following resources: HD and emergency HD, consultations with health care 
professional, hospitalizations and professional care. The cost of drugs were derived from the 
Lebanese National Drug Index for the year 2011 [31]. Valuation of informal care was based on 
the proxy good method [32] and the valuation of productivity losses were based on the human 
capital approach [33]. The mean quantity/frequency of use of each service was multiplied by 
its respective mean unit cost to obtain the total costs. The total costs for all patients were divided 
by the number of included patients in order to estimate the mean cost per patient for the 6-
month period.  
 
SENSITIVITY ANALYSES 
In order to test the robustness of our results, three sensitivity analyses were conducted. The first 
analysis used the minimum and maximum costs reported by the patients for the main cost 
drivers. We calculated first the total costs for each modified cost, i.e. minimum and maximum 
costs for each item separately, and then for all modified costs combined, thus allowing us to 
obtain the lowest and highest estimates. In the second analysis, we used information collected 
from the questionnaire for resources use but estimated resources costs using information 
collected from key informants from the Lebanese Ministry of Public Health, the Lebanese 
Ministry of Labor, the Lebanese Society for Nephrology and Hypertension, the Syndicate of 
Hospitals and third party payers in Lebanon. For the third analysis, we used information 
collected from the patients’ medical charts regarding use of health care resources and costs 
collected from key informants for resources costs valuation. Resources costs pertaining to the 
base-case and sensitivity analyses are available in Appendix 2. 
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Table 1. Cost measurement and valuation (2015 US$) 
 Unit Cost 
 Base-case analysis Sensitivity analysis 
 Minimum Maximum 
Health care sector costs 
HD 
HD  Session 97.90 94.32 103.05 
Emergency HD Session 97.90 94.32 103.05 
Health care professionals 
Specialist physician Contact 52.80 20.96 153.70 
Dietitian Contact NA NA 
Psychologist Contact 34.92 NA 
Medications Various Various NA 
Hospitalization Day 189.25 22.70 702.19 
Professional home care Hour 24.45 10.13 52.66 
Costs to patient and family 
Informal care Hour 1.67 NA 2.18 
Productivity losses Day Various NA 
Costs in other sectors 
Travel Trip 2.79 NA 
HD: hemodialysis 
 
STATISTICAL ANALYSIS 
Descriptive analysis of the patients’ characteristics, consumption of different resources and 
different costs were performed using SPSS, version 21. For the sensitivity analysis, the mean 
difference with the base-case analysis results was calculated. Missing data for resources use 
(volume) were replaced by the mean value reported by the patients of the same HD unit. This 
was done because the nephrologists usually adopt common practice guidelines and treatment 
protocols for patients treated in the same unit.  
Forward multiple linear regression analysis was performed to determine predictors of societal 
costs. We used a set of predictors capturing socio-demographic (age, gender, work status, social 
status) and clinical characteristics (vintage, HD time per week, malnutrition inflammation score 
(MIS), diabetes comorbidity, hypertension comorbidity and cardiovascular disease 
comorbidity). As a first step, we assessed through a bivariate analysis, the association between 
societal costs and each of the above-mentioned variables. Independent t-test, one-way ANOVA 
and Pearson correlation were used. Variables with statistical significance <0.2 were included in 
the forward multiple linear regression analysis (age, gender, social status, HD time per week, 
MIS, hypertension comorbidity). Adjusted R2 was calculated to provide information about the 
variance in societal costs explained by the complete model. The results were presented as 
standardized (β) coefficients. p<0.05 was considered statistically significant. 
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RESULTS 
PARTICIPANTS’ CHARACTERISTICS 
Of 133 participants (already enrolled in the NEMO trial) that were approached to participate in 
the COI analysis, 119 agreed to participate (89%). A total of 114 provided complete responses 
to the questionnaire and were included in our analysis. The final sample consisted of 63 males 
and 51 females, with a mean age of 60.25 years. 47.4% of the sample were older than 64 years 
(complete). Only 17.5% of the sample were employed at the time of the analysis. The others 
were either unemployed (38.6%) or retired (43.9%). On average, patients were on dialysis for 
47.82 months and had 9.51 hours of dialysis per week. Their mean MIS was normal (7.90). 
Patients’ characteristics are further displayed in Table 2. 
Table 2. Patients characteristics (n=114) 
Socio-demographic characteristics N (%) 
Gender, Male 63 (55.3) 
Social status  
Single 14 (12.3) 
Married 93 (81.6) 
Widowed 7 (6.1) 
Educational level  
Illiterate 25 (21.9) 
Read and write 19 (16.7) 
Elementary 30 (26.3) 
High school 22 (19.3) 
University 18 (15.8) 
Employment status, Employed 20 (17.5) 
 Mean (SD) 
Age (years) 60.2 (14.3) 
Clinical characteristics N (%) 
Primary cause of HD initiation  
Diabetes 20 (17.5) 
CVD, HTN 17 (14.9) 
Renal diseases 43 (37.7) 
Other 34 (29.8) 
Co-morbidities  
Diabetes 41 (36.0) 
HTN 76 (66.7) 
CVD 24 (21.1) 
 Mean (SD) 
HD vintage (months) 47.82 (49.38) 
HD time/week (hours) 9.50 (2.71) 
MIS 7.90 (3.53) 
SD: standard deviation, HD: hemodialysis, CVD: cardiovascular disease, HTN: 
hypertension, MIS: malnutrition inflammation score 
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RESOURCES USE 
On average, patients underwent 67.76 sessions of HD during the assessed 6 months. During 
this period, few patients reported contacts with health care professionals, with the exception of 
specialist physician (23.7%). Nevertheless, specialist physician-patient contact was low, with 
less than 1 contact on average in the past 6 months. Use of professional home care was also 
minimal (1.8%). Most commonly used drugs were calcium carbonate (78.9%), intravenous (IV) 
iron (70.2%), erythropoietin (EPO) (64.9%) and vitamin B complex (53.5%). 35.1% of patients 
were hospitalized during the past 6 months, with a mean length of stay of 2.82 days. Almost 
half (47.4%) of the patients reported receiving care from their family or friends (informal care), 
with an average of 117.01 hours being dedicated to care for them in the past 6 months. During 
the same period, 47.4% of the patients reported being unable to perform daily activities (paid 
and unpaid labor) due to HD, with a mean of 94.75 lost labor hours. Resources use during the 
6- month period is detailed in Table 3. 
 
SOCIETAL COSTS 
The societal costs for each patient were estimated at US$9258.39 over a period of 6 months, 
with health care costs accounting for 91.73% of this cost. The biggest part of the total costs was 
attributed to regular HD, at US$6632.68 per patient per 6 months (71.64% of societal costs). 
Medications accounted for the second biggest cost (13.67%), with US$1264.31 per patient per 
6 months. EPO, IV Iron and Sevelamer were the most costly medications (US$870.24, 
US$134.20 and US$109.26 per patient per 6 months, respectively). The third biggest cost was 
attributed to hospitalization, with a mean of US$532.90 per patient per 6 months. Costs to 
patients and family and those in other sectors (transportation) poorly accounted to the total costs 
(4.18% and 4.09%, respectively) (Table 4). 
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Table 4. Costs per patient during the 6-month period (n=114) (2015 US$) 
 Mean  cost % of total costs Median cost 
Health care sector costs 
HD 
HD   6632.68 71.64 7636.64 
Emergency HD 37.58 0.41 0.00 
Total 6670.27 72.05 7636.64 
Health care professionals 
Specialist physician 23.16 0.25 0.00 
Dietitian 0.00 0.00 0.00 
Psychologist 1.53 0.02 0.00 
Total 24.69 0.27 0.00 
Medications 
Calcium Carbonate 60.77 0.66 46.92 
Calcium Acetate 39.37 0.43 0.00 
Sevelamer 109.26 1.18 0.00 
Cinacalcet 0.00 0.00 0.00 
Active Vitamin D 15.54 0.17 0.00 
Vitamin D 4.82 0.05 0.00 
Vitamin B complex 21.78 0.24 12.80 
Iron IV 134.20 1.45 116.14 
Iron 8.32 0.09 0.00 
EPO 870.24 9.40 675.50 
Total 1264.31 13.67 1315.28 
Hospitalization 532.90 5.76 0.00 
Professional home care 0.43 0.005 0.00 
Total 8492.61 91.73 8439.30 
Costs to patient and family 
Informal care 196.52 2.12 0.00 
Productivity losses 190.64 2.06 0.00 
Total 387.16 4.18 131.00 
Costs in other sectors 
Travel 378.62 4.09 435.99 
Total 378.62 4.09 435.99 
Total societal costs 9258.39 100 9201.22 
SD: standard deviation, Min: minimum, Max: maximum, HD: hemodialysis, IV: intravenous, 
EPO: erythropoietin 
 
SENSITIVITY ANALYSES 
As detailed in Table 5, using minimal and maximal reported values for hemodialysis, 
hospitalization and specialist physician consultation resulted in societal costs close to those 
found in the base-case analysis. When compared with the base-case results, the biggest 
differences were caused by changes in hospitalization costs (differences in the mean costs per 
patient were +US$1443.90 and US$-469.39, for the maximal and minimal fees, respectively).  
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Using other sources for estimating resources use and costs resulted in almost similar results to 
those of the base-case analysis. Using the costs obtained from key informants, the societal costs 
were US$8964.03 per patient per 6 months (3.17% lower than the value obtained in the base-
case analysis). Using health care resources use obtained from the patients’ medical charts, and 
the costs obtained from key informants, the analysis resulted in societal costs of US$9273.56 
per patient per 6 months (0.16% higher than the value obtained in the base-case analysis). 
Table 5. Sensitivity analyses (Costs per patient during the 6-month period in 2015 US$) 
 Mean total 
costs 
Difference from the mean costs 
obtained in the base-case analysis 
2015 US$ 2015 US$ % 
Analysis 1 
Different costs 
Hemodialysis 
Minimum 9014.00 -244.38 -2.63% 
Maximum 9609.03 350.640 +3.78% 
Hospitalization 
Minimum 8789.00 -469.39 -5.06% 
Maximum 10702.30 1443.90 +15.59% 
Specialist physician consultation 
Minimum 8829.27 -429.11 -4.63% 
Maximum 9653.28 394.89 +4.26% 
Highest estimate 11097.62 1839.23 +19.86% 
Lowest estimate 8531.07 -727.31 -7.85% 
Analysis 2 
Costs from key informants 8964.03 -294.35 -3.17% 
Analysis 3 
Resources use from medical charts 
and costs from key informants 9273.56 15.170 +0.16% 
 
 
PREDICTORS OF SOCIETAL COSTS 
The best model retained HD time per week, gender, social status and hypertension comorbidity 
as predictors of the variability in societal costs. The model accounted for 56.2% of the 
variability in societal costs and for 54.2% when adjusted for the number of predictors. Female 
gender was significantly associated with greater societal costs (US$9798.80 vs. US$8820.91 
for males). Being widowed or divorced also predicted greater societal costs (US$11190.38 vs. 
US$9168.48 and US$8889.66 for single and married, respectively). Having hypertension as 
comorbidity also significantly contributed to greater societal costs (US$9835.49 vs. 
US$8104.20). Finally, greater weekly time on HD (necessitating more HD sessions per week) 
was significantly associated with greater societal costs (Table 6). 
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Table 6. Predictors of societal costs of hemodialysis 
Predictor Standardized 
Coefficients 
p 95.0% Confidence Interval 
Lower Bound Upper Bound 
HD time per week 0.65 <0.001 579.34 907.96 
Gender (female) 0.19 <0.001 269.43 1588.57 
Social status (widowed or divorced) 0.17 0.01 180.27 1645.61 
Hypertension comorbidity 0.14 0.04 8.26 1490.73 
HD: hemodialysis 
 
DISCUSSION 
To our knowledge, this is the first COI study on HD conducted in Lebanon. The 6-months 
societal cost per HD patient was estimated at US$9258.39 for the year 2015, with the largest 
part (91.73%) being attributed to health care costs, estimated at US$8,492.61. In comparison 
with the Gross Domestic Product (GDP) per capita of US$10,424.28 forecast for 2015 [34], the 
mean annual cost per HD patient ($US18,516.7) was 43.70% higher.  
The study sample was similar to the general HD population in Lebanon described by the NKR 
in 2012 [25] in many sociodemographic aspects, such as age (60.2±14.3 in our sample vs. 
59.4±16.2 in the general HD population), gender (males: 55.3% vs. 56.8%), educational level 
(illiteracy: 21.9% vs. 23.4%). Employment was slightly lower in our sample than in the general 
population (17.5% vs. 23.6%, respectively). As for the clinical characteristics, kidney diseases 
were the cause of end stage renal disease in both groups (37.7% vs. 42%). Both groups have 
hypertension and diabetes as comorbidity (66.7% vs. 57.8%; and 36% vs. 29.2%, for our sample 
and the general HD population, respectively). Nevertheless, HD vintage was shorter in our 
sample (47.82±49.38 vs. 58.6±61.3 months). Assuming that 3,300 patients are currently being 
treated by HD, the total annual cost for the Lebanese society would therefore be 
US$61,105,374, with an estimated total annual health care cost US$56,051,226. Accordingly, 
≈ 1.82% of the total health expenditure in Lebanon in 2012 (US$3,083,009,900.8) [35] would 
be spent on HD patients, who actually represent less than 0.1% of the total Lebanese population. 
All these factors pinpoint HD as a great economic burden to the health system in the country. 
These results are of utmost importance for health care payers in Lebanon, especially the MOPH, 
since it covers the cost of therapy for around 55% of HD patients in the country and for whom, 
about 8% of the Ministry’s budget is allocated [25].  
Interestingly, productivity losses only contributed to 2.06% of the total cost. Although this cost 
component has been rarely assessed in COI studies on HD, the proportion found in this study 
is greatly lower than what was reported from other countries [21,22,36,37]. Beside differences 
in measurement and valuation methods, this finding might be attributed to the fact that 82.5% 
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of the patients in our study were already unemployed or retired at the time of the analysis. 
Moreover, being prevalent patients, they already adapted their work schedules and daily life 
activities to their HD treatment, and the majority of them eventually managed to avoid losing 
additional hours of work or daily life activities due to their illness and its treatment. 
Furthermore, the resulting low number of lost work hours might be attributed to the fact that 
we only estimated productivity losses during the past 6-month and we did not directly collect 
information about whether the patients were unemployed due to their renal disease. The direct 
comparison of the cost of HD in Lebanon with the costs reported from neighboring countries is 
challenging, because of the differences in the costs included and the methodological disparities 
when measuring and valuing costs. Arefzadeh et al. [36] estimated the annual societal cost of 
HD in Iran to be US$13,201.81 per patient (uprated to 2015US$). However, the authors 
followed a different taxonomy for costs and did not clearly report the method used for valuing 
some of the included costs. Transportation and absence from work (28.9%), staffs (21.5%) and 
treatment instruments (21.1%) costs constituted the largest part of the total costs. In Jordan, 
published COI studies reported some different results. In Al-Shdaifat and Manaf [38], the 
annual societal cost per patient uprated to 2015US$ were US$10,843.91 (direct medical cost: 
41%; direct non-medical cost: 11% and indirect cost: 48%), whereas in Batieha et al. [20] the 
direct annual cost per patient cost rose to US$22,367.67. Despite using a different 
categorization of costs in the first study, data collection was conducted in a similar way to the 
one used in this analysis. However, costs related to premature death were included which might 
explain the differences found in the contribution of productivity losses between the study by 
Al-Shdaifat and Manaf [38] and our study. No ample information were provided in Batieha et 
al. [20] to enable investigation of the reasons behind the differences between this study and 
ours.  
On the other hand, our study might have underestimated the total HD costs incurred by the 
Lebanese society since the costs of drugs related to co-morbidities, such as insulin for the 
treatment of diabetes, or anti-hypertensive medications for the treatment of high blood pressure, 
were not measured and included in the analysis. 
The current study faced several challenges. Information regarding resource consumption and 
cost were not readily available. Rather, they were obtained from a variety of sources (patient 
recall, patients’ medical charts and key informants), with each having its own strengths and 
limitations. Reactivating the NKR, having cost databases and national cost estimates of HD is 
thus recommended to facilitate future COI and economic evaluation studies. Having a manual 
for cost analysis in health care research in Lebanon would also facilitate a more accurate and 
systematic way for conducting future COI studies in the country. On the other hand, this 
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analysis has several strengths. First, it was a multicentric study, thus enabling the 
generalizability of its findings to the HD population in Lebanon. Second, we used a societal 
perspective, thus providing a holistic view on the economic burden of HD to the Lebanese 
society. Third, we relied on a bottom-up approach for costing, which is considered preferable 
in terms of estimating costs for chronic patients [39]. Finally, our findings were robust to several 
sensitivity analyses. Our study is subject to several limitations as well. First, we used a self-
reported questionnaire to estimate health care consumption. This may cause recall bias, 
although available evidence indicate that questionnaire design and respondent motivation were 
more influential on recall bias than the period of recall [40]. Second, patients with limited 
cognitive skills may have troubles understanding the questions. In an attempt to overcome these 
two limitations, the resource utilization questionnaire used in this study was designed following 
good practices for improved accuracy in resource use estimation [41]. Third, we relied on 
information collected from patients to value the costs of resources. This was done because there 
is no manual for cost analysis in health care research in Lebanon. Finally, differences in funding 
of health care systems, in dialysis modality utilization, and other cost estimation techniques 
limit the accuracy of the comparison of our results with other countries.  
Reducing the economic burden of HD could be achieved by decreasing the number of patients 
requiring this treatment. Preventing the progression of renal disease is one suggested option. In 
Lebanon, the most frequent causes of renal failure are diabetes mellitus, hypertension and 
kidney diseases [25]. Early detection, correct referral to specialists and adequate medical and 
dietetic management of these diseases [42–44] are essential for slowing progression to renal 
failure, delaying or even eliminating the need for RRT. These programs are of critical 
importance, since it is assumed based on extrapolation from international data that there are 
between 41,000 and 82,000 stage 3 and 4 CKD patients in Lebanon, and most of them are 
unaware of their condition [25,45]. On the other hand, increasing the use of live or cadaveric 
donor kidney transplantation could be another option. These RRT are considered to be the most 
cost-effective treatments for renal failure, offering considerable improvement in the patients’ 
quality-of-life [46]. Efforts to foster the culture of organ donation through public education and 
awareness, increased support from religious leaders, and enhancement of government 
infrastructure and financial resources are recommended [47]. In the meantime, other cost-
effective forms of RRT, such as home HD could be suggested. This type of treatment has shown 
to be cost-effective and is associated with better health outcomes for patient survival and 
quality-of-life [48–50]. 
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CONCLUSION 
This study pioneers in assessing the costs of HD in Lebanon from a societal perspective, and is 
one of the very first COI studies in the country. The economic burden of HD is high in Lebanon. 
The largest part of this burden is attributable to the regular HD treatment. Further studies in 
larger populations would be necessary to assess potential differences between different 
subgroups of this population. This paper presents detailed cost figures that could be used in 
future cost-effectiveness analyses in the Lebanese HD population, where very few, if any, 
economic evaluations are available. It is also hoped that the information generated from this 
report will be used as a pertinent advocate to justify the implementation of public health 
interventions and programs targeting the prevention of HD. 
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Appendix 1: Resource utilization questionnaire 
1 What is your insurance/3rd party payer? 
□NSSF □ MOPH □ Army □COOP □Private □Other………………….. 
 
2 In the past 6 months, how often have you contacted a specialist physician (like a 
cardiologist &/or endocrinologist &/or surgeon &/or …….)?---------------------- 
How much did it cost per visit?------------------------ 
How much of it did you pay from your pocket?------------------------ 
 
3 In the past 6 months, how often have you contacted your dietitian?---------------------- 
How much did it cost per visit?------------------------ 
 
4 In the past 6 months, how often have you contacted a psychologist?---------------------- 
How much did it cost per visit?------------------------ 
 
5 In the past 6 months, how many nights have you spent in the hospital?---------- 
How much did it cost per day?------------------------------------------ 
How much of it did you pay from your own pocket? --------------------------------- 
 
6 In the past 6 months, how many times did you have to go for an extra emergency 
hemodialysis session?  -------------------------------------------------- 
 
7 List the number of medications that you are prescribed in the past 6 months  
 Calcium 
carbonate 
Calcium 
acetate 
Sevelamer Cinacalcet Vitamin D 
How many pills per day      
 Active 
Vitamin D 
Vitamin B 
complex 
Iron Pills IV iron  Erythro-
poietin 
How many pills per day      
For which one of them did you pay from your own pocket (were not reimbursed) in the 
past 6 months?  
 
 
 
8 In the past 6 months, how many hours per week on average did you need family/ friends to 
take care of you or help you due to your health situation?------------------------ 
How much did it cost per hour?------------------------ 
 
9 In the past 6 months, how many hours per week did you need home care professionals 
(paid help) like home nurses or home doctors….? 
How much did it cost you?------------------------ 
 
10 In the past 6 months, how many days were you unable to perform your daily activities due 
to your health (for example, days lost from work or school, days where you were unable to 
perform domestic work)?------------------------ 
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ABSTRACT  
Background: The Nutrition Education for Management of Osteodystrophy trial showed that stage-
based nutrition education by dedicated dietitians surpasses existing practices in Lebanon with respect 
to lowering serum phosphorus among general haemodialysis patients. The present study explores the 
effect of nutrition education specifically on hyperphosphataemic patients from this trial. 
Methodology: Hyperphosphataemic haemodialysis patients were allocated to a dedicated dietitian 
(DD), a trained hospital dietitian (THD) and existing practice (EP) protocols. From time-point (t)-0 
till t-1 (6 months) the DD group (n=47) received 15 min of biweekly nutrition education by dedicated 
dietitians trained on renal nutrition; the THD group (n=89) received the usual care from trained 
hospital dietitians; and the EP group (n=42) received the usual care from untrained hospital dietitians. 
Patients were followed-up from t-1 till t-2 (6 months). Analyses used two-way repeated measures 
analysis of variance and Cohen’s effect sizes (d). 
Results: At t-1, phosphataemia significantly decreased in all groups (DD:-0.27mmol L-1; EP:-
0.15mmol L-1; THD:-0.12mmol L-1; p<0.05); the DD protocol had the greatest effect relative to EP 
(d=-0.35) and THD (d=-0.50). Only the DD group showed more readiness to adhere to a low 
phosphorus diet at t-1; although at t-2, this regressed to baseline levels. The malnutrition 
inflammation score remained stable only in the DD group, whereas the EP and THD groups exhibited 
a significant increase (DD: 6.74, 6.97 and 7.91; EP: 5.82, 8.69 and 8.13; THD: 5.33, 7.92 and 9.42, 
at t-0, t-1 and t-2, respectively).  
Conclusion: The results of the present study suggest that the DD protocol decreases serum 
phosphorus compared to EP and THD, at the same as maintaining the nutritional status of 
hyperphosphataemic haemodialysis patients. Assessing the cost-effectiveness of the DD protocol is 
recommended. 
 
KEYWORDS 
Dietitians; haemodialysis; hyperphosphatemia; patient education. 
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INTRODUCTION 
Hyperphosphataemia is consistently and independently associated with increased cardiovascular and 
all-cause morbidity and mortality in haemodialysis patients [1–7]. To manage this, patients must 
adhere to haemodialysis sessions, complex medication regimens and dietary phosphorus restriction 
[8,9]. However, adherence to a low phosphorus diet is found to be the poorest among all dietary 
restrictions [10] and almost half of haemodialysis patients have a serum phosphorus level higher than 
the recommended level of 1.78 mmol L-1 [8,11]. Hyperphosphataemia is the most common mineral 
abnormality among haemodialysis patients in developed and developing countries. It is even present 
among patients receiving optimal medical care [12,13].  
Hyperphosphataemia management is a true challenge in modern nephrology, especially because 
phosphorus restriction often poses the risk of reducing protein intake, precipitating malnutrition, 
wasting and poor survival [14]. Consistent expert dietary education and regular follow-up are needed 
to help haemodialysis patients sustain a low phosphorus intake, subsequently normal phosphataemia, 
at the same time as maintaining a good nutritional status [8,9,15].  
Nutrition education, especially when utilizing cognitive or behavioural components improves 
phosphorus control among haemodialysis patients [16–19]. Nevertheless, stronger evidence is needed 
to better identify optimal frequency and approaches of dietetic education to ensure long-term dietary 
phosphorus management without compromising the nutritional status of patients [19,20]. 
The Nutrition Education for Management of Osteodystrophy (NEMO) trial [21] assessed the effect 
of a 2 hours per month stage-based nutrition education using the transtheoretical model of behavioural 
change on serum phosphorus control in the general haemodialysis population. NEMO reported 
statistically significant improved phosphataemia management, increased adherence to (and 
knowledge of) a low phosphorus diet, and decreased deterioration in patients’ quality of life and 
nutritional status [22,23]. However, the effect of this intervention specifically on patients with 
hyperphosphataemia was not explored. This subpopulation has higher risks of morbidity and 
mortality as a result of hyperphosphataemia, among whom achieving normal phosphataemia is 
recommended. In the present study, we aimed to assess, via a pre-specified analysis of the NEMO 
trial, the effectiveness of intensive stage-based nutrition education provided by dedicated dietitians 
on hyperphosphataemia management among hyperphosphataemic haemodialysis patients and to 
compare this with the existing practices in Lebanon. 
 
MATERIALS AND METHODS 
We used data from the NEMO trial, a multicentre randomised controlled trial conducted in 12 
hospital-based haemodialysis units in Lebanon [21].  
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PARTICIPANTS 
For the NEMO trial, eligible patients were those treated in recruited haemodialysis units, comprising 
Lebanese, adults (≥18 years), free of cancer, infection with the human immunodeficiency virus and 
hepatitis, not having undergone major surgery in the past 3 months, on haemodialysis for at least 6 
months, able to understand the procedure of the study, able to communicate verbally or through 
writing, and willing to participate in the study. Informed consent was obtained from all participants 
prior to the start of the study.  
For the current analysis, patients had to meet the above-mentioned criteria; moreover, they had to be 
hyperphosphataemic. Hyperphosphataemia was defined as a mean serum phosphorus for the 6 months 
prior to the beginning of the NEMO trial >1.78 mmol L-1 [Kidney Disease Outcomes Quality 
Initiative guidelines [8]]. Eligibility criteria were confirmed through a review of the patient medical 
charts.  
 
DESIGN 
A detailed description design is provided in Karavetian et al. [21]. In brief, participants were followed 
for 12 months, and measures were collected at 3 time-points (t): t-0 (beginning of month 1: July, 
2011), t-1 (end of month 6) and t-2 (end of month 12: June 2012). Twelve hospital-based 
haemodialysis units were randomly recruited to the NEMO trial from the official list of hospital-
based haemodialysis units in Lebanon. They were simple randomly assigned to cluster A (six units) 
and cluster B (six units) using EXCEL (Microsoft Corp., Redmond, WA, USA). Cluster A patients 
were then assigned according to their haemodialysis shifts into two protocols: Dedicated Dietitian 
(DD) and Existing Practice (EP). Cluster B patients were assigned to the Trained Hospital Dietitian 
(THD) protocol. 
From t-0 till t-1, the 3 groups received the following interventions: 
• DD group: dietitians in this group received a formal training on renal dietetics [24] and were 
dedicated only to haemodialysis units. They provided the patients with 15-min biweekly 
individualized educational sessions (seven sessions per month) considering the patient stage of 
behavioural change towards a low phosphorus diet, using a renal-oriented culturally-validated 
educational tool based on the transtheoretical model of behavioural change [21,22]. DD also provided 
the patients with a 1-monthly reinforcement session, where the phosphataemia result was discussed 
and a new target was set for the coming month using motivational interviewing. The stage-based 
nutrition education was conveyed during the haemodialysis sessions because this timing is optimal 
for educating haemodialysis patients [16]. In these units, the existing practice was not compromised 
and hospital dietitians continued providing their standard care. 
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• EP group: patients received the usual care by their hospital dietitians, who did not receive any 
additional training on renal dietetics. This group reflected the situation in Lebanon, where hospital 
dietitians have limited knowledge on renal dietetics and where care of haemodialysis patients 
constitutes a small proportion of their hospital responsibilities [25]. In this group, dietetic consults 
were performed only upon nephrologists' requests. 
• THD group: patients received usual care by their hospital dietitians who were educated on renal 
dietetics to an equal extent as the dietitians in the DD group, although they were not dedicated to 
haemodialysis patients. Accordingly, no minimal dietitian-patient time was set for this group and 
dietitians were left to continue providing their usual care. 
A follow-up period, with no intervention in all groups, followed from t-1 until t-2.  
Throughout the study, hyperphosphataemic patients in the three groups underwent the same 
interventions as their fellow normo-or hypophosphataemic patients. 
The NEMO trial obtained ethical approval from the institutional review boards of participating 
institutions. 
 
OUTCOME MEASURES AND ASSESSMENT TOOLS 
Consistent with the NEMO trial [21], outcome measures included serum phosphorus (mmol L-1), 
dietary phosphorus (mg day-1) and phosphorus-to-protein ratio (mg g day-1) intake, stage of 
behavioural change towards a low phosphorus diet and the malnutrition inflammation score. 
Serum phosphorus (mmol L-1) comprised the primary outcome. This was retrieved from the medical 
charts of patients. The 6-month mean values were calculated at the three time-points. 
Phosphorus (mg day-1) and phosphorus-to-protein ratio (mg g day-1) intakes were estimated by a 3-
monthly 24-h recalls, analysed using the USDA database [26]. The 6-month mean values were 
calculated at the three time-points. 
Stage of behavioural change towards a low phosphorus diet was assessed on a monthly basis via a 
decisional tree based on the transtheoretical model of behavioural change [27], with the components 
being modified to address phosphataemia and a low phosphorus diet. Patients were assigned to each 
stage according to their scores (1, Precontemplation; 2, Contemplation; 3, Preparation; 4, Action; 5, 
Maintenance). Higher scores indicated a greater readiness to adhere to a low phosphorus diet. The 6-
month mean values were calculated at the three time-points. 
The nutritional and inflammatory status was assessed via the malnutrition inflammation score. This 
is a renal-tailored tool, associated with measures of nutrition, atherosclerosis, inflammation, anaemia, 
quality of life, hospitalization and mortality among haemodialysis patients. It is the gold standard for 
examining other scoring systems for the malnutrition-inflammation complex syndrome [28–31]. The 
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malnutrition inflammation score has 10 components, with four levels of severity ranging from 0 
(normal) to 3 (severely abnormal). The total score ranges from 0 to 30, with a higher score reflecting 
more severe degrees of malnutrition and inflammation. The biochemical components of the score 
were collected from the medical charts of patients. The malnutrition inflammation score was 
calculated at the three time-points.  
Outcomes were collected by trained research dietitians using prepiloted standardized forms. 
 
STATISTICAL ANALYSIS 
Data from participants who failed to complete the study because they were transferred, received a 
transplant, died, or withdrew, were not included in the analysis. Analyses were conducted using the 
SPSS, version 21 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used for sample 
characteristics. Chi square and Fisher’s Exact tests were used to assess between-group baseline 
differences of categorical variables. One-way analysis of variance (ANOVA) and the Kruskal-Wallis 
test followed by a Mann-Whitney test and Bonferroni correction were used to assess between-group 
baseline differences of continuous variables. The effects of the three protocols (DD versus EP versus 
THD) on study outcomes and their interactions over time (t-0 versus t-1 versus t-2) were analysed 
using two-way repeated measures ANOVA, with protocol and time being the between- and within-
group factors, respectively. Accordingly, the effect of the intervention was assessed within each group 
at the three time-points, as well as between the three groups at each time-point. Where a statistically 
significant effect was found, post-hoc Bonferroni comparisons were undertaken. Cohen’s d effect 
size measures were calculated for serum phosphorus to examine the magnitude of the effect of each 
protocol at t-1 [32]. d<|0.2| reflected no effect, |0.2| was considered low, |0.5| medium, and |0.8| large 
[33]. A negative d represented improvement because phosphataemia is a negative-oriented outcome 
(higher values indicate deterioration) [34]. P<0.05 was considered statistically significant.  
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RESULTS 
Twelve hospital-based haemodialysis units were included in the present study. Of the 570 patients 
who met the inclusion criteria of the NEMO trial, 235 patients were also hyperphosphataemic (DD: 
65; EP: 57; THD: 113). Of these, 178 completed the study (DD: 47; EP: 42; THD: 89) and were 
included in the current analysis. Attrition was almost similar in the three groups (DD: 27.7%, EP: 
26.3%; THD: 21.2%) (Figure 1).  
 
 
Figure 1.  Flow Diagram of the Trial. 
 
 
 
Included in the trial (n=570) 
Excluded (n=335) 
● Not hyperphosphatemic (n=335) 
 
Analysed (n=46) 
● Lost to follow-up (n=3): death (n=3) 
● Discontinued intervention (n=0) 
Allocated to Dedicated Dietitian (n=65) 
● Received allocated intervention (n=55) 
● Did not receive allocated intervention 
(n=10): death (n=4), transfer (n=2), renal 
transplant (3), withdrawal (n=1) 
 
● Lost to follow-up (n=5): death (n=5) 
● Discontinued intervention (n=1): 
withdrawal (n=1) 
Allocated to Existing Practice (n=57) 
● Received allocated intervention (n=54) 
● Did not receive allocated intervention 
(n=3): death (n=2), renal transplant (n=1) 
Analysed (n=42) 
 
Allocation 
Time-point 0 
Randomized (n=235) 
Enrollment 
● Lost to follow-up (n=11): death (n=5), 
transplant (n=4), extended hospitalization 
(n=1), unknown (n=1) 
● Discontinued intervention (n=2): 
withdrawal (n=2) 
 
Allocated to Trained Hospital Dietitian 
(n=113) 
● Received allocated intervention (n=113) 
Analysed (n=89) 
 
● Lost to follow-up (n=6): death (n=4), 
transfer (n=1), extended hospitalization (n=1) 
● Discontinued intervention (n=0) 
● Lost to follow-up (n=6): death (n=4), 
transplant (n=1), unknown (n=1) 
● Discontinued intervention (n=0) 
Time-point 1 
● Lost to follow-up (n=8): death (n=2), 
transfer (n=2), transplant (n=1), extended 
hospitalization (n=3), 
● Discontinued intervention (n=3): 
withdrawal (n=3) 
Time-point 2 
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PARTICIPANTS' CHARACTERISTICS 
At baseline, DD, EP and THD patients were generally similar in terms of sociodemographic and 
clinical characteristics (Table 1). Participants were relatively young (mean age: 56.5 years), more 
than half were males (58.4%), and one-third reached high school (21.9%) and university (11.2%) 
education. Approximately one-third (35.4%) were employed and the majority (77.5%) were married. 
One-third (30.3%) had diabetes, two-thirds (64.0%) were hypertensive and 14.6% had concomitant 
cardiovascular diseases. The patients were on haemodialysis for 51.3 months, on average, with a 
mean of 10.4 h of treatment per week. Patients in the EP group spent less time on treatment than those 
in the DD and THD groups (9.1 h versus 10.7 and 10.8 h, respectively). Mean parathormone levels 
were normal (447.0 ng L-1). On average, calcium-phosphorus byproduct was higher than the 
recommended level (4.76 mmol2 L-2) (63). Mean body mass index was 25.3 kg m-2; patients in the 
DD group had a greater body mass index than those of the THD group (26.8 vs. 24.2 kg m-2).  
 
Table 1. Participants’ Characteristics [% or mean (SD)] (n=178) 
 Dedicated 
Dietitian (n=47) 
Existing 
Practice (n=42) 
Trained Hospital 
Dietitian (n=89) 
Male (%) 44.7 61.9 64.0 
Social Status (%) 
Single 23.4 9.5 18.0 
Married 68.1 85.7 78.7 
Other 8.5 4.8 3.4 
Employed (%) 34.0 26.2 40.4 
Educational Level (%) 
Illiterate 19.1 14.3 18.0 
Read & Write 17.0 14.3 14.6 
Elementary 36.2 23.8 38.2 
High school 21.3 31.0 18.0 
University 6.4 16.7 11.2 
Co-morbidities (%) 
Diabetes 43.2 26.2 27.0 
Hypertension 73.3 61.9 61.8 
Cardiovascular diseasesa 27.3 9.5 11.2 
Otherb 39.3 22.7 9.8 
Age (years) (mean (SD)) 54.36 (16.54) 57.71 (13.86) 57.03 (15.91) 
Vintage (months) (mean (SD)) 50.78 (46.92) 48.08 (46.50) 53.12 (53.27) 
Hemodialysis time (h week-1) (mean (SD)) 10.77 (2.71)c 9.10 (2.98)cd 10.89 (1.84)d 
Parathormone (ng L-1) (mean (SD)) 417.95 (445.18) 412.73 (348.21) 474.07 (399.75) 
Calcium-Phosphorus Byproduct (mmol2 
L-2) (mean (SD)) 
4.75 (0.93) 4.68 (0.70) 4.80 (0.83) 
Body Mass Index (kg m-2) (mean (SD)) 26.86 (5.53)c 26.16 (4.98) 24.24 (3.84)c 
ap<0.05 indicates a difference between-groups based on a chi-squared test, bp<0.05 indicates a 
difference between-groups based on Fisher’s exact Test, c,dp<0.05 indicates a difference between-
groups based on a Kruskal-Wallis test followed by a Mann-Whitney test and Bonferroni correction. 
Table 2 summarizes changes in study outcomes of patients who finished the 12-month trial.  
CHATPTER 4 
89 
Table 2. Study Outcomes per Protocol at the Three Time-Points [mean (SD)] (n=178) 
 Dedicated 
Dietitian (n=47) 
Existing Practice 
(n=42) 
Trained Hospital 
Dietitian (n=89) 
Serum Phosphorus 
(mmol L-1) 
t-0 2.20 (0.35)ab 2.18 (0.33)a 2.15 (0.30)a 
t-1 1.92 (0.41)a 2.02 (0.47)ab 2.03 (0.39)a 
t-2 1.96 (0.52)*,b 2.22 (0.58)*,b 2.03 (0.42) 
Malnutrition-
Inflammation Score 
t-0 6.74 (3.22) 5.82 (2.88)ab 5.33 (3.72)ab 
t-1 6.97 (3.59) 8.69 (3.85)a 7.92 (3.33)ac 
t-2 7.91 (3.86) 8.13 (3.41)b 9.42 (4.03)bc 
Stage of Behavioural 
Change 
t-0 2.72 (1.35)a 2.64 (1.17) 2.92 (1.25)a 
t-1 4.11 (0.53)*,**,a 2.67 (1.09)* 2.71 (1.12)**,b 
t-2 2.56 (1.04) 2.73 (0.93) 2.33 (1.19)ab 
Phosphorus Intake (mg 
day-1) 
t-0 814.98 (396.60)ab 985.80 (359.81)*,ab 762.04 (382.49)* 
t-1 667.70 (233.64)a 812.18 (310.76)ac 783.26 (276.78)a 
t-2 591.62 (254.74)b 548.29 (225.44)*,bc 701.16 (310.10)*,a 
Phosphorus-to-Protein 
Ratio (mg g day-1) 
t-0 15.60 (4.61) 16.73 (3.98) 14.81 (4.32)a 
t-1 15.78 (4.59) 15.18 (4.08) 15.46 (3.93) 
t-2 16.33 (2.58) 15.84 (1.51) 16.05 (2.15)a 
t: time-point. 
abc Differences across columns indicate significant differences (p<0.05) within each group at t-0 
versus t-1 versus t-2, *,** differences across in rows indicate significant differences (p<0.05) 
between the groups (dedicated dietitian versus existing practice versus trained hospital dietitian) at 
each of the three time-points, based on two-way repeated measures analysis of variance with post-
hoc comparisons using Bonferroni correction. 
 
SERUM PHOSPHORUS (MMOL L-1)  
At baseline (t-0), serum phosphorus was similar between the three groups. Following the intervention 
(t-1), phosphataemia significantly dropped in all groups, with no differences between them. The 
greatest decrease was noted among DD patients (0.27 mmol L-1 vs. 0.15 mmol L-1 and 0.12 mmol L-
1 in the EP and THD groups, respectively). DD protocol had a medium greater effect than THD 
protocol (d=-0.50) and low greater effect relative to EP protocol (d=-0.35). THD and EP protocols 
had no superiority over each other (d=-0.12). At 6-month post-intervention (t-2), serum phosphorus 
remained significantly lower than baseline levels only in the DD group, whereas it increased to 
baseline levels in the EP and THD groups. At t-2, patients in the DD group had a significantly lower 
phosphataemia than those in the EP group.  
 
MALNUTRITION INFLAMMATION SCORE 
At baseline, the malnutrition inflammation score was similar between the three groups. It remained 
stable only in the DD group throughout the study. By contrast, the other groups exhibited a significant 
increase in their mean score (EP: 5.82, 8.69 and 8.13; THD: 5.33, 7.92 and 9.42 at t-0, t-1 and t-2, 
respectively), indicating a worsened nutritional status over time.  
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STAGE OF BEHAVIOURAL CHANGE  
At t-0, patients were, on average, in the pre-action stage of behavioural change towards low 
phosphorus diet, without significant differences between the three groups. At t-1, only patients in the 
DD group progressed to the action stage and were significantly more ready to adhere to a low 
phosphorus diet than patients in the EP and THD groups who stagnated in the pre-action stage. At t-
2, DD patients regressed to baseline levels. Patients in the THD group exhibited a continuous 
significant regression in their readiness to adhere to a low phosphorus diet throughout study period. 
At the end of the intervention, all groups returned to the pre-action stage. 
 
PHOSPHORUS INTAKE (MG DAY-1)  
From t-0 till t-1, reported phosphorus intake significantly dropped in the DD and EP groups. Reported 
phosphorus intake further decreased in all groups at t-2.  
 
PHOSPHORUS-TO-PROTEIN RATIO (MG G-1 DAY-1) 
No changes between- or within-group were noted throughout the study, except in the THD group who 
showed a significant increase in dietary phosphorus-to-protein ratio between t-0 and t-1. 
 
DISCUSSION 
The present study explored the effect of nutrition education based on the transtheoretical model of 
behavioural change and provided by DD on the outcomes of hyperphosphataemic haemodialysis 
patients, who as a result of hyperphosphataemia, are at increased risks of morbidity and mortality; 
and for whom the intervention aiming to decrease serum phosphorus is appropriately targeted. The 
participants shared characteristics common to hyperphosphataemic haemodialysis patients [35–41]; 
they were relatively young, predominantly males and literate. 
Educating hyperphosphataemic haemodialysis patients based on the transtheoretical model of 
behavioural change by a dedicated competent dietitian for 30 min per week, during 6 months, 
significantly improved their readiness to adhere to a low phosphorus diet and decreased their 
phosphataemia without compromising their nutritional status. This was conducted without the need 
for additional resources, except ensuring adequate dietitian education and dietitian-patient time. The 
DD protocol was superior to the other protocols: EP representing the existing practice in Lebanon 
(i.e. no specialisation for dietitians in renal dietetics and no imposed dietitian-patient time), and THD 
representing a viable alternative, which is ensuring dietitian education without imposing a minimum 
dietitian-patient time.  
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The results of this analysis are in line with the findings of the NEMO trial [22,23]. Following the 
intervention, a significant drop in phosphataemia was noted among patients in the three groups. The 
greatest effect was noted in the DD group. The finding of this group might be explained by the effect 
of intensive dietitian-led education, resulting in the enhanced adherence of patients to a low 
phosphorus diet, as exhibited by their improved stage of behavioural change. Strong evidence 
supports the beneficial effect of dietitian involvement in haemodialysis care, especially in phosphorus 
management [19]. In the DD group, the dietitians monitored the progress of each patient and had 
adequate time to provide individualized evidence-based education. Implementing practice guidelines 
not only relies on their scientific validity, but also on their usability by clinicians [42], where 
insufficient time is a crucial barrier [43]. Even the most qualified and organized dietitian is unable to 
provide quality care when time allocation with patients is inadequate [44]. Insufficient time to provide 
care for haemodialysis patients was commonly noted among Lebanese hospital dietitians [25]. 
Besides time factor, DD intervention comprised aspects not widespread among Lebanese hospital 
dietitians [25]: the educational material was culturally-specific and the dietitians were extensively 
trained on renal dietetics. 
Possible factors might explain the significant drop in phosphataemia post-intervention in the other 
groups. As reported in Karavetian et al. [22], the mild improvement in the THD group, might be 
attributed to the fact that dietitians in this group upgraded their educational methods and increased 
the frequency of consultations after receiving the training. However, the intensity of the education 
remained suboptimal, resulting in a lower improvement in phosphataemia. This explanation is 
supported by our data (M. Karavetian) showing that dietitians in the THD group visited the patients 
at best once monthly. This was expected considering the schedule overload of these dietitians [25]. 
As for the EP group, contamination of information through patients and nurses took place [22]. 
Patients in this group were subject to passive education because educational posters and material were 
hung on the dialysis units’ walls during the intervention period and DD patients who changed their 
dialysis shifts might have shared the new knowledge with their peers who were in the EP group. 
Moreover, nurses transferred the educational material from the DD to the EP group. 
The decrease in serum phosphorus should not be regarded as sole outcome of this intervention and 
should be interpreted in the light of other findings, notably the nutritional status. While all patients 
had a higher malnutrition inflammation score at the end of the study (denoting a worsened nutritional 
status), this increase was significant only in the EP and THD groups and not in the DD group. This 
reinforces that only intensive, timely and individualized education by competent dietitians resulted in 
careful and effective care (decreased phosphataemia, without compromising the patients’ nutritional 
status) [8,9,15]. This is a key finding for clinical practice and policy makers because worsened 
nutritional status of haemodialysis patients is associated with increased morbidity and mortality and 
higher healthcare costs [14,45].  
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The intensive stage-based nutrition education created a momentum for improving patient adherence 
to a low phosphorus diet, through enhancing their self-management skills and collaborating 
involvement in their disease management. Nevertheless, this progress was lost when the intervention 
resolved. Relapse and regression are natural steps within the behavioural change cycle [46]. Evidence 
suggests that the effect of an intervention (if not provided continuously) might fade over time [22,47]. 
This might translate into an increase in phosphataemia over the long term and relapse towards 
baseline values.  
Discussing the results of dietary phosphorus and phosphorus-to-protein ratio is challenging. The 24-
h recall is often biased in haemodialysis patients since it relies on the patient’s ability to remember 
and accurately report consumed foods. The 24-h recall often underestimates actual intake, even when 
conducted by a trained interviewer, and can generate a great variability in the mean daily nutrient 
intake [48]. A lack of data pertaining to potential confounders is another limitation for the present 
study: hospitals did not routinely provide information on dialysis adequacy (Kt v-1, urea reduction 
ratio) and medication prescription (vitamin D, phosphate binders). However, random allocation of 
groups would most likely result in a similar distribution of hospitals based on quality of medical care. 
The positive results noted in the DD group might not be only due to the adherence to a low phosphorus 
diet but also greater adherence to phosphate binders because some of the educational sessions 
emphasized their importance. The design of the present study did not allow this issue to be assessed 
because the prescription of phosphate binders within Lebanese haemodialysis units is within the sole 
authority of nephrologists. This issue remains to be explored by future studies. The final major 
limitation to the present study is the contamination of information between the DD and EP groups, 
and the potential underestimation of the true effectiveness of the DD protocol. Opting for this design 
was informed by a study by Griva et al. [49] among haemodialysis patients, who argued that allocation 
of participants based on their shift would limit cross-contamination of information between groups. 
However, we encountered an opposite effect in our trial. This learning experience should inform the 
design of future studies among haemodialysis patients, by alerting researchers that the prevention of 
contamination through allocation of participants based on their dialysis shift is not always possible, 
and resorting to running the trial in different units might be a more suitable alternative in this patient-
population. Stage-based nutrition education provided by trained dietitians on the basis of 30 minutes 
per week is an effective approach for improving hyperphpsphataemic haemodialysis patients' 
adherence to low phosphorus diet and decreasing their serum phosphorus without compromising their 
nutritional status. This protocol is superior to the existing practice (EP) in Lebanon and to the other 
possible alternative (THD). The assessment of the cost-effectiveness of the DD protocol for 
reimbursement reasons is recommended as a next step, and its implementation in Lebanese 
haemodialysis units should be advocated, if it is shown to be cost-effective. This assessment is needed 
to better inform the integration of this model in routine practice, especially in the light of the high 
CHATPTER 4 
93 
cost and the nonconclusive evidence behind the cost-effectiveness of other phosphorus-lowering 
interventions in this population (i.e. non-calcium-based phosphate binders) [50].  
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ABSTRACT 
Objective: To assess the cost-effectiveness of nutrition education by dedicated dietitians (DD) for 
hyperphosphatemia management among hemodialysis patients. 
Design: Trial-based economic evaluation. 
Setting: 12 Lebanese hospital-based units. 
Subjects: 545 prevalent patients, allocated by cluster randomization to DD, trained hospital dietitian 
(THD) and existing practice (EP) groups. 
Intervention: Phase I (6 months): DD group (n=116) received intensive education by DD trained on 
renal nutrition; THD (n=299) received usual care from trained hospital dietitians; EP (n=130) 
received usual care from untrained hospital dietitians. Patients were followed-up during Phase II (6 
months).  
Main outcome measures: Resources use, societal costs, serum phosphorus, quality-adjusted life-
years (QALYs). 
Results: At baseline, EP had the lowest weekly hemodialysis time and DD had the highest mean 
serum phosphorus and malnutrition-inflammation score. The additional costs of the intervention were 
low compared with the societal costs (DD: $76.7, $21,007.7; EP $4.6, $18,675.4; THD: $17.4, 
$20,078.6, respectively). Between Phases I and II, DD showed the greatest decline in services use 
and the highest mean decrease in societal costs (DD: -$2,364.0; EP: -$1,727.7; THD: -$1,105.7). At 
endline, DD experienced the greatest mean decrease in adjusted serum phosphorus (DD: -0.32; EP: 
+0.16; THD: +0.04 mg/dL), no difference in QALY, and the highest societal costs. DD protocol had 
a cost-effectiveness ratio of $7,853.6 per 1 mg decrease in phosphorus, compared with EP; and was 
dominated by THD. Regarding QALY, DD was dominated by EP and THD. The results were 
sensitive to changes in key outcomes. 
Conclusion: DD protocol yielded the greatest effectiveness and decrease in costs, but did not affect 
QALY. Regarding serum phosphorus, it was likely to be cost-effective compared with EP but had a 
low probability of being cost-effective compared with THD. Regarding QALY, DD was not likely to 
be cost-effective. Assessing the long-term cost-effectiveness of DD protocol, on similar groups, is 
recommended. 
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INTRODUCTION 
Elevated serum phosphorus is a serious consequence of the chronic kidney disease. It is associated 
with increased patient morbidity [1], mortality [2–5], and high healthcare costs [6]. International 
clinical practice guidelines recommend “normalizing” serum phosphorus of hemodialysis patients 
through dialysis, phosphate-binding medications, and low phosphorus diet [7,8]. However, more than 
a decade after the first guidelines were issued, hyperphosphatemia remains a common condition 
among renal patients, especially those treated with hemodialysis, with nearly 1 in 2 patients being 
hyperphosphatemic [9,10].  
Economic evaluations are a useful tool to identify the economic value of an intervention and guide 
decision making. Up-till-now, in hyperphosphatemia management, efforts were focused on one 
intervention: phosphate binders [11] and despite the mounting evidence on the clinical effectiveness 
of dietary education [12], the cost-effectiveness of this intervention has not been addressed [11]. 
The most recent local evidence on the effectiveness of dietetic interventions for hyperphosphatemia 
management among prevalent hemodialysis patients emanate from the Nutrition Education for 
Management of Osteodystrophy (NEMO) trial [13]. Results from the NEMO trial showed that 
intensive education by DD was superior to the other protocols in reducing serum phosphorus, without 
compromising the nutritional status of the patients [14–16]. Assessing the value for money of DD 
would be very important for helping decision makers efficiently allocate scarce resources devoted to 
hemodialysis patients. 
The aim of this study was therefore to conduct an economic evaluation (including a cost-effectiveness 
analysis (CEA) and a cost-utility analysis (CUA)), from the societal perspective of DD vs. EP and 
THD interventions in hemodialysis patients in Lebanon. 
 
METHODS 
We used individual patient-level data from the NEMO trial to perform the CEA and CUA and 
followed international guidelines for the analysis and reporting of economic evaluations [17,18]. A 
societal perspective was used, with a time horizon of 1 year. 
 
TRIAL 
Design 
The design, methods and clinical results of the NEMO trial are detailed elsewhere [13–16]. The 
NEMO trial was conducted in Lebanon and compared three protocols of nutrition education for 
hyperphosphatemia management among hemodialysis patients. In brief, 12 hospital-based 
hemodialysis units (n=570) were randomly assigned to cluster A (6 units; n=271) and cluster B (6 
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units; n=299). Cluster A patients were then equally assigned according to their hemodialysis shifts 
into 2 protocols: DD (n=133) and EP (n=138); cluster B patients were assigned to THD protocol. 
Participants were followed for 12 months, and measures were collected at 3 time-points: t-0 
(beginning of month 1), t-1 (end of month 6) and t-2 (end of month 12). The NEMO trial received 
ethical approval from the ethical committees of participating hospital-based hemodialysis units, and 
was conducted according to the Declaration of Helsinki. 
Subjects 
Consenting patients, adult, receiving dialysis for at least 6 months, free of cancer, infection with 
human immunodeficiency virus and hepatitis C were considered. 
Interventions 
Phase I (t-0 till t-1: 6 months): DD group received intensive nutrition education during hemodialysis 
sessions by trained dietitians dedicated to hemodialysis units, on a basis of 2 hours per month. The 
existing practice was not compromised in these units, and hospital dietitians were left to provide their 
usual care; EP group received usual care by their hospital dietitians, where patients’ consults are upon 
the nephrologists' requests (this group represented the existing practice in Lebanon, where no 
dietitians are dedicated to hemodialysis patients); and THD group received usual care by their hospital 
dietitians who were equally trained on renal nutrition as the dedicated dietitians, but were not devoted 
to hemodialysis patients in particular (this group represented an alternative to having a dedicated 
dietitian; whereby hospital dietitian’s education is ensured, but dietitian-to-patient time is not set).  
Phase II (t-1 till t-2: 6 months) was a follow-up period. 
 
ECONOMIC EVALUATION 
Outcomes 
The outcome of the CEA was serum phosphorus, and that of the CUA was quality-adjusted life-year 
(QALY). QALY incorporates the quality of a health state (quality-of-life: QoL) with the duration of 
survival (life-years: LYs) using a multiplicative formula. It is the preferred and most common 
outcome in economic evaluation [19]. QoL was measured with the Short Form (SF)-36 questionnaire, 
assessing the 2 dimensions of physical and mental health over the past 30 days [20]. Patients 
completed the validated culturally-specific pilot-tested version of the SF-36 [13,21] at t-0, t-1 and t-
2. Serum phosphorus was retrieved from the patients' medical charts, and its 6-month mean values 
were calculated at the 3 time-points. 
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Costs 
Cost data were collected at t-1 and t-2, following the 3 steps of costs identification, measurements 
and valuation, as detailed in Rizk et al. [22]. Costs identification: included costs were categorized as 
(1) healthcare sector costs (cost of the dietetic intervention, costs associated with hemodialysis, 
emergency hemodialysis, healthcare professional consultation, hospitalization, medications, and 
integrated home care); (2) costs to patient and family (caregiver costs and productivity losses); and 
(3) costs in other sectors (travel costs) [17]. Costs measurement: using a pilot-tested resource 
utilization questionnaire (Appendix S1) adapted to Lebanese hemodialysis patients. Costs valuation: 
the costs were gathered and calculated in Lebanese pounds (LBP), converted to US$ (1 US$= 1,507.5 
L.L.; year of reference: 2011) [23] and uprated to 2015US$ using Consumer Price Indices (Index, 
2010=100) [24]. A macro-costing valuation was applied, whereby composite intermediate resources 
were identified and measured. The mean reported costs incurred by patients were used to value the 
costs of emergency hemodialysis, consultations with healthcare professionals, hospitalizations, and 
professional care. The costs of drugs were derived from the Lebanese National Drug Index [25]. 
Valuation of informal care was based on the proxy good method [26] and valuation of productivity 
losses was based on the human capital approach [27]. Costing of the intervention in each group is 
detailed in Appendix S2. The reported quantity/frequency of use of each service was multiplied by 
its respective mean cost to obtain the total costs. Discounting was not applied, as the analysis was 
limited to 1 year.  
Preparation of data  
Serum phosphorus was adjusted for baseline differences between the three groups, following a 
regression method controlling for baseline serum phosphorus, age, gender, weekly hemodialysis time 
and malnutrition-inflammation score (MIS), as detailed by van Mastrigt et al. [28]. For the base-case 
CEA, missing values of patients who withdrew during Phase I were replaced by their baseline value 
minus half of the difference in serum phosphorus between t-0 and t-1 of participants from the same 
unit and study group (peers), assuming that the patients attrited at mid-point of the phase and that 
evolution of serum phosphorus was linear. For Phase II, missing values were replaced by the patients’ 
values at t-1 minus the difference in serum phosphorus between t-1 and t-2 of their peers.  
For the CUA, SF-36 QoL data were converted to utility [29]. Mean utility between t-0 and t-1; and 
between t-1 and t-2 were retained for Phase I and Phase II, respectively. Missing QoL data were 
imputed by last observation carried forward, when available, or by the mean of the peers. Regarding 
LYs, for each phase survived, patients were allocated 0.5 LYs. Patients not surviving the phase due 
to mortality or extended hospitalization were allocated 0.25 LYs, assuming that they withdrew at the 
mid-point of the study phase. The LYs of those who were transferred, got a transplant, or withdrawal 
were imputed by the mean of their peers. QALYs was the product of utility and LYs. Total QALYs 
were obtained by summing QALYs at each phase. As for the costs, the missing values of patients 
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who survived the phase were imputed by the mean of their peers. For those who died or were 
extensively hospitalized, their values were imputed by half of the mean costs of their peers, for the 
same above-mentioned reasoning. Those who attrited for other reasons were attributed the mean costs 
of their peers in parallel to their LYs. 
Analyses 
Analyses were conducted using SPSS. Descriptive statistics were generated. Chi square and Student’s 
T test were used to determine baseline between-group differences for categorical and continuous data, 
respectively. One-way ANOVA followed by Bonferroni Post Hoc were used to assess the between-
group differences in costs at t-1 and t-2. p<0.05 was used for significance. To determine the cost-
effectiveness and cost-utility of DD, incremental cost-effectiveness and cost-utility ratios (ICERs, 
ICURs) were calculated. The ICER/ICUR is a ratio that compares the additional costs and effects of 
the assessed intervention with the control. The cost-effectiveness and cost-utility of DD vs. EP/THD 
were calculated as the difference in mean costs (C) divided by the difference in mean effects (E) 
(serum phosphorus and QALY, respectively) at t-2:  
DD vs. EP=(CDD - CEP)/(EDD - EEP); DD vs. THD=(CDD - CTHD)/(EDD - ETHD).  
Sensitivity analyses 
Three one-way sensitivity analyses were performed to test the robustness of the results of the base-
case. The first analysis assessed the effects of excluding maintenance hemodialysis and transportation 
costs, following the reasoning of Grima et al. [30]. The second analysis examined the impact of 
imputation; and accordingly included complete cases only. The third analysis was carried out only on 
hyperphosphatemic patients (phosphorus >5.5mg/dL) at baseline, as they are at higher risks for 
morbi-mortality and are reported to have higher costs than normophosphatemic patients. In the final 
analysis, we used for the CEA, the mean unadjusted serum phosphorus difference between t-2 and t-
0; and for the CUA, we used the adjusted QALYs (regression-based QALY adjustment), since QoL 
is associated with clinical outcomes among hemodialysis patients, including hospitalization and 
mortality [20,31].  
Non-parametric bootstraps were conducted to assess the stochastic uncertainty in the data using the 
bootstrapping technique in Excel, where the original sample was re-sampled, resulting in 5000 
simulated ICERs/ICURs per scenario. Cost-effectiveness/utility acceptability curves 
(CEACs/CUACs) were plotted using the probability estimates of DD’s cost-effectiveness (compared 
with each of the other interventions) over a range of willingness-to-pay (WTP) thresholds. The latter 
were defined as the amount of money the society is willing to pay to gain one unit of effect. In 
Lebanon, the value the society is willing to pay to gain one QALY is not defined. Accordingly, we 
used several thresholds ranging from 3 times the Gross Domestic Product in Lebanon ($31,272.84)- 
threshold suggested by the World Health Organization [32,33] to £30,000 ($43,612.49)- explicit 
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threshold adopted in the United Kingdom [34], and $50,000- implicit threshold adopted in the United 
States [35].  
 
RESULTS 
PATIENTS’ CHARACTERISTICS 
The flow diagram of the trial is detailed in Appendix S3. At baseline, the three groups were 
comparable with respect to sociodemographic characteristics, except for employment status. Weekly 
hemodialysis time was significantly lower in the EP group. DD group had the highest mean serum 
phosphorus, which was above the recommended range [7]. DD group had the highest mean MIS, 
denoting the worst malnutrition-inflammation status (Table 1).  
Table 1. Participants’ characteristics (n=545) 
 DD (n=116) EP (n=130) THD (n=299) 
Male (%) 66 (56.9) 72 (55.4) 182 (60.9) 
Social Status (%) 
Single 26 (22.4) 18 (13.8) 44 (14.7) 
Married 83 (71.6) 102 (78.5) 242 (80.9) 
Other 7 (6.0) 10 (7.7) 13 (4.3) 
Employed (%)* 38 (32.8) 24 (18.5) 99 (33.1) 
Educational Level (%) 
Illiterate 23 (19.8) 28 (21.5) 79 (26.4) 
Read & Write 17 (14.7) 22 (16.9) 33 (11.0) 
Elementary 38 (32.8) 36 (27.7) 108 (36.1) 
High school 24 (20.7) 24 (18.5) 43 (14.4) 
University 14 (12.1) 20 (15.4) 36 (12.0) 
Co-morbidities (%) 
Diabetes 39 (36.1) 50 (38.5) 99 (33.2) 
Hypertension 77 (69.4) 83 (63.8) 203 (68.1) 
Cardiovascular diseases 30 (27.8) 27 (20.8) 62 (20.9) 
Other* 29 (40.3) 22 (25.6) 17 (16.3) 
Age (years) (mean (SD)) 57.56 (15.18) 59.96 (15.22)  60.51 (14.94) 
Utility (mean (SD)) 0.56 (0.06) 0.56 (0.06) 0.55 (0.06) 
Vintage (months) (mean (SD)) 61.02 (64.39) 46.94 (48.62) 57.30 (53.06) 
HD time (hours/week) (mean (SD)) 10.64 (2.49)‡ 9.53 (2.77)‡§ 11.14 (1.45)§ 
Sodium† (mEq/L) (mean (SD)) 59.61 (2.41) 58.88 (4.71)‡ 59.88 (0.64)‡ 
Potassium† (mEq/L) (mean (SD)) 1.34 (0.22) 1.35 (0.22) 1.33 (0.20) 
Phosphorus† (mg/dL) (mean (SD)) 5.57 (1.52)‡ 5.39 (1.49) 5.16 (1.44)‡ 
Calcium† (mg/dL) (mean (SD)) 8.66 (0.80)‡ 8.62 (0.97) 9.11 (1.57)‡ 
CaP† (mg2/dL2) (mean (SD)) 48.37 (14.43) 46.65 (13.56) 47.11 (15.09) 
PTH† (pg/mL) (mean (SD)) 400.85 (457.61) 377.52 (360.64) 344.89 (338.50) 
Albumin† (g/L) (mean (SD)) 38.76 (3.77) 39.42 (4.28) 39.74 (4.36) 
MIS (mean (SD)) 7.30 (3.31)‡ 6.55 (3.17) 6.07 (3.90)‡ 
BMI (Kg/m2) (mean (SD)) 25.10 (5.69) 25.43 (5.20) 24.31 (4.96) 
†Pre-dialysis values; *p<0.05 indicates a difference between-groups based on Chi square Test, ‡,§p<0.05 
indicates a between-group difference based on Bonferroni Post Hoc. DD: dedicated dietitian, EP: existing 
practice; THD: trained hospital dietitian; SD: standard deviation; HD: hemodialysis; PTH: parathyroid 
hormone; CaP: calcium-phosphorus byproduct; MIS: malnutrition-inflammation score; BMI: body mass 
index.  
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SERVICES USE 
During Phase I, DD group consumed more services than other groups (especially emergency 
hemodialysis, specialist physician consults, several medications and hospitalization). THD group 
used more professional home care and lost more productivity hours. EP group used more informal 
care. During Phase II, DD group consumed a greater volume of emergency hemodialysis, specialist 
physician consults, sevelamer, and erythropoietin. THD group consumed more calcium carbonate, 
professional home care and lost more productivity hours (Table 2).  
Between Phase I and Phase II, DD group showed the greatest decline in the use of the most costly 
healthcare services. The volume of emergency hemodialysis decreased by 44% compared with 18.6% 
and 16.8% in the EP and THD groups, respectively. The consumption of sevelamer decreased by 
51.1%, relative to 32.2% in the EP group and to an increase of 29.8% in THD. Hospitalization days 
decreased by 48.4% in DD compared with 11.9% and 2% in EP and THD groups, respectively. DD 
group also exhibited the slowest increase in the use of patient and family-related services (+7.44% 
vs. +57.6% and +19.6% for DD, EP and THD, respectively). 
 
COSTS 
The cost distribution of the 3 groups is displayed in Appendix S4. As per Table 3, societal, healthcare, 
patient and family-related costs differed between-groups. The mean cost of the nutrition education 
was the highest in DD group; yet the cost of this intervention represented less than 1% of the societal 
costs of each of the three groups during both study phases.  
The mean total societal costs were the highest in the DD group. Similarly, the mean healthcare costs 
were higher in the DD group. THD group had higher mean costs to patients and family. While, during 
Phase I, social costs were the highest in DD group, THD had the highest costs during Phase II. 
Between Phase I and Phase II, DD group exhibited the highest mean decrease in costs (-$2,226.4) 
(EP: -$1,320.8; THD: -$654.6). This was remarkably noted for costs of emergency hemodialysis (-
$51 vs. -$11.5 vs. -$2.4), medications (-$419.9 vs. -$61.0 vs. -$58.5) and hospitalization (-$1,151.0 
vs. -$1,010 vs. -$310.6) costs.  
 
T
a
b
le
 2
. 
S
er
vi
ce
s 
u
se
 d
u
ri
n
g
 t
h
e 
1
2
-m
o
n
th
 p
er
io
d
 
 
D
D
 g
ro
u
p
 (
n
=
1
0
7
) 
E
P
 g
ro
u
p
 (
n
=
1
1
2
) 
T
H
D
 g
ro
u
p
 (
n
=
2
5
7
) 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
P
H
A
S
E
 I
 
H
ea
lt
h
ca
re
 s
ec
to
r 
co
st
s 
H
D
 
H
D
 (
se
ss
io
n
) 
1
0
7
 (
1
0
0
) 
7
2
.4
 
7
8
.0
 
1
1
2
 (
1
0
0
) 
6
7
.6
 
7
8
.0
 
2
5
7
 (
1
0
0
) 
7
5
.6
 
7
8
.0
 
E
m
er
g
en
cy
 H
D
 (
se
ss
io
n
) 
3
9
 (
3
6
.4
) 
1
.2
 
0
.0
 
2
1
 (
1
8
.6
) 
0
.4
 
0
.0
 
9
 (
3
.5
) 
0
.1
 
0
.0
 
H
ea
lt
h
ca
re
 p
ro
fe
ss
io
n
a
ls
 
S
p
ec
ia
li
st
 p
h
y
si
ci
an
 (
co
n
ta
ct
) 
2
8
 (
2
6
.2
) 
0
.7
 
0
.0
 
2
6
 (
2
3
.2
) 
0
.4
 
0
.0
 
6
2
 (
2
4
.1
) 
0
.4
 
0
.0
 
D
ie
ti
ti
an
 (
co
n
ta
ct
) 
1
 (
0
.9
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
2
1
 (
8
.2
) 
0
.1
 
0
.0
 
P
sy
ch
o
lo
g
is
t 
(c
o
n
ta
ct
) 
0
 (
0
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
M
ed
ic
a
ti
o
n
s 
C
al
ci
u
m
 C
ar
b
o
n
at
e 
(T
ab
le
t)
 
8
0
 (
7
4
.8
) 
5
6
3
.5
 
5
4
9
.0
 
8
9
 (
7
9
.5
) 
4
7
8
.5
 
3
6
6
.0
 
1
7
4
 (
6
7
.7
) 
4
0
2
.6
 
2
1
3
.5
 
C
al
ci
u
m
 A
ce
ta
te
 (
T
ab
le
t)
 
4
3
 (
4
0
.2
) 
2
8
8
.0
 
0
.0
 
3
9
 (
3
4
.8
) 
2
3
6
.0
 
0
.0
 
1
0
8
 (
4
2
.0
) 
2
9
9
.6
 
0
.0
 
S
ev
el
am
er
 (
T
ab
le
t)
 
3
2
 (
3
0
.0
) 
2
2
6
.6
 
0
.0
 
2
6
 (
2
3
.2
) 
7
4
.2
 
0
.0
 
5
5
 (
2
1
.4
) 
8
4
.5
 
0
.0
 
C
in
ac
al
ce
t 
(T
ab
le
t)
 
1
 (
0
.9
) 
1
5
.4
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
A
ct
iv
e 
V
it
am
in
 D
 (
C
ap
su
le
 1
0
0
 
m
L
) 
6
3
 (
5
8
.9
) 
4
.5
 
0
.4
 
6
4
 (
5
7
.1
) 
3
.0
 
0
.7
 
1
3
6
 (
5
2
.9
) 
4
.9
 
1
.4
 
V
it
am
in
 D
 (
T
ab
le
t)
 
3
3
 (
3
0
.8
) 
1
5
.4
 
0
.0
 
2
6
 (
2
3
.2
) 
9
.2
 
0
.0
 
5
5
 (
2
1
.4
) 
8
.7
 
0
.0
 
V
it
am
in
 B
 c
o
m
p
le
x
 (
In
je
ct
ab
le
 
S
o
lu
ti
o
n
) 
7
1
 (
6
6
.4
) 
4
7
.9
 
7
2
.0
 
6
0
 (
5
3
.6
) 
2
6
.1
 
1
5
.1
 
9
7
 (
3
7
.8
) 
1
9
.1
 
0
.0
 
Ir
o
n
 (
T
ab
le
t)
 
3
6
 (
3
3
.6
) 
5
1
.3
 
0
.0
 
3
6
 (
3
2
.1
) 
3
6
.4
 
0
.0
 
5
9
 (
2
3
.0
) 
4
0
.0
 
0
.0
 
In
tr
av
en
o
u
s 
Ir
o
n
 (
In
je
ct
ab
le
 
A
m
p
o
u
le
) 
7
2
 (
6
7
.2
) 
1
3
.6
 
1
2
.0
 
7
8
 (
6
9
.6
) 
1
3
.7
 
1
2
.0
 
1
4
6
 (
5
6
.8
) 
9
.2
 
6
.0
 
E
ry
th
ro
p
o
ie
ti
n
 (
V
ar
io
u
s)
 
8
5
 (
7
9
.4
) 
1
7
0
2
4
7
.5
 
1
9
2
0
0
0
.0
 
8
0
 (
7
1
.4
) 
1
3
8
9
0
0
.0
 
1
4
4
0
0
0
.0
 
1
9
8
 (
7
7
.0
) 
1
3
1
9
0
1
.4
 
9
6
0
0
0
.0
 
H
o
sp
it
a
li
za
ti
o
n
 (
D
a
y
) 
4
8
 (
4
4
.9
) 
4
.6
 
0
.0
 
3
9
 (
3
4
.8
) 
2
.8
 
0
.0
 
8
2
 (
3
1
.9
) 
2
.3
 
0
.0
 
P
ro
fe
ss
io
n
a
l 
h
o
m
e 
ca
re
 (
H
o
u
r)
 
3
 (
2
.8
) 
0
.1
 
0
.0
 
3
 (
2
.6
) 
0
.0
 
0
.0
 
5
 (
1
.9
) 
1
2
.4
 
0
.0
 
C
o
st
s 
to
 p
a
ti
en
t 
a
n
d
 f
a
m
il
y 
In
fo
rm
al
 c
ar
e 
(H
o
u
r)
 
5
1
 (
4
7
.7
) 
9
4
.4
 
0
.0
 
5
3
 (
4
7
.3
) 
1
1
5
.6
 
0
.0
 
1
1
3
 (
4
4
.0
) 
6
2
.1
 
0
.0
 
P
ro
d
u
ct
iv
it
y
 l
o
ss
es
 (
H
o
u
r)
 
7
0
 (
6
5
.4
) 
1
9
2
.2
 
5
6
.0
 
5
9
 (
5
2
.7
) 
9
9
.3
 
1
0
.0
 
1
6
7
 (
6
5
.0
) 
2
9
1
.7
 
4
8
.0
 
C
o
st
s 
in
 o
th
er
 s
ec
to
rs
 
T
ra
v
el
 (
T
ri
p
) 
1
0
7
 (
1
0
0
) 
1
4
4
.8
 
1
5
6
.0
 
1
1
2
 (
1
0
0
) 
1
3
5
.1
 
1
5
6
.0
 
2
5
7
 (
1
0
0
) 
1
5
1
.1
 
1
5
6
.0
 
 
 
CHAPTER 5 
107 
 
D
D
 g
ro
u
p
 (
n
=
9
3
) 
E
P
 g
ro
u
p
 (
n
=
9
3
) 
T
H
D
 g
ro
u
p
 (
n
=
2
1
7
) 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
U
se
rs
 
M
ea
n
 
M
ed
ia
n
 
P
H
A
S
E
 I
I 
H
ea
lt
h
ca
re
 s
ec
to
r 
co
st
s 
H
D
 
H
D
 (
se
ss
io
n
) 
9
3
 (
1
0
0
) 
7
2
.7
 
7
8
.0
 
9
3
 (
1
0
0
) 
6
7
.7
 
7
8
.0
 
2
1
7
 (
1
0
0
) 
7
5
.5
 
7
8
.0
 
E
m
er
g
en
cy
 H
D
 (
se
ss
io
n
) 
2
7
 (
2
9
.0
) 
0
.7
 
0
.0
 
1
7
 (
1
8
.3
) 
0
.3
 
0
.0
 
9
 (
4
.1
5
) 
0
.1
 
0
.0
 
H
ea
lt
h
ca
re
 p
ro
fe
ss
io
n
a
ls
 
S
p
ec
ia
li
st
 p
h
y
si
ci
an
 (
co
n
ta
ct
) 
3
5
 (
3
7
.6
) 
0
.8
 
0
.0
 
2
6
 (
2
8
.0
) 
0
.4
 
0
.0
 
6
0
 (
2
7
.6
) 
0
.5
 
0
.0
 
D
ie
ti
ti
an
 (
co
n
ta
ct
) 
0
 (
0
) 
0
.0
 
0
.0
 
1
 (
1
.1
) 
0
.0
 
0
.0
 
1
 (
0
.5
) 
0
.0
 
0
.0
 
P
sy
ch
o
lo
g
is
t 
(c
o
n
ta
ct
) 
0
 (
0
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
0
 (
0
) 
0
.0
 
0
.0
 
M
ed
ic
a
ti
o
n
s 
C
al
ci
u
m
 C
ar
b
o
n
at
e 
(T
ab
le
t)
 
5
8
 (
6
2
.4
) 
4
7
9
.0
 
3
6
6
.0
 
6
5
 (
6
9
.9
) 
4
9
1
.8
 
3
6
6
.0
 
1
0
2
 (
4
7
.0
) 
3
3
9
.0
 
0
.0
 
C
al
ci
u
m
 A
ce
ta
te
 (
T
ab
le
t)
 
2
1
 (
2
2
.6
) 
2
0
7
.9
 
0
.0
 
1
9
 (
2
0
.4
) 
1
4
6
.4
 
0
.0
 
8
1
 (
3
7
.3
) 
3
1
4
.6
 
0
.0
 
S
ev
el
am
er
 (
T
ab
le
t)
 
1
2
 (
1
2
.9
) 
1
1
0
.7
 
0
.0
 
6
 (
6
.5
) 
5
0
.3
 
0
.0
 
2
9
 (
1
3
.4
) 
1
0
9
.6
 
0
.0
 
C
in
ac
al
ce
t 
(T
ab
le
t)
 
0
 (
0
) 
0
.0
 
0
.0
 
2
 (
2
.2
) 
6
.9
 
0
.0
 
5
 (
2
.3
) 
1
4
.3
 
0
.0
 
A
ct
iv
e 
V
it
am
in
 D
 (
C
ap
su
le
 1
0
0
 
m
L
) 
4
6
 (
4
9
.4
) 
4
.5
 
0
.0
 
3
8
 (
4
0
.9
) 
3
.4
 
0
.0
 
9
9
 (
4
5
.6
) 
3
.8
 
0
.0
 
V
it
am
in
 D
 (
T
ab
le
t)
 
1
3
 (
1
4
.0
) 
1
6
.3
 
0
.0
 
1
6
 (
1
7
.2
) 
1
8
.3
 
0
.0
 
2
4
 (
1
1
.1
) 
7
.0
 
0
.0
 
V
it
am
in
 B
 c
o
m
p
le
x
 (
In
je
ct
ab
le
 
S
o
lu
ti
o
n
) 
5
4
 (
5
8
.1
) 
3
7
.8
 
1
4
.2
 
4
2
 (
4
5
.2
) 
3
0
.6
 
0
.0
 
7
5
 (
3
4
.6
) 
1
6
.9
 
0
.0
 
Ir
o
n
 (
T
ab
le
t)
 
2
2
 (
2
3
.7
) 
3
7
.8
 
0
.0
 
1
9
 (
2
0
.1
) 
2
4
.2
 
0
.0
 
3
8
 (
1
7
.5
) 
3
4
.4
 
0
.0
 
In
tr
av
en
o
u
s 
Ir
o
n
 (
In
je
ct
ab
le
 
A
m
p
o
u
le
) 
5
7
 (
6
1
.3
) 
1
3
.8
 
1
2
.0
 
5
8
 (
6
2
.4
) 
1
0
.6
 
1
2
.0
 
1
3
4
 (
6
1
.8
) 
1
0
.5
 
6
.0
 
E
ry
th
ro
p
o
ie
ti
n
 (
V
ar
io
u
s)
 
8
7
 (
9
3
.5
) 
1
6
8
2
5
8
.1
 
1
9
2
0
0
0
.0
 
8
1
 (
8
7
.1
) 
1
2
1
6
3
3
.5
 
9
6
0
0
0
.0
 
1
8
9
 (
8
7
.9
) 
1
4
5
1
0
0
6
.0
 
9
6
0
0
0
.0
 
H
o
sp
it
a
li
za
ti
o
n
 (
D
a
y
) 
3
8
 (
4
0
.8
) 
2
.4
 
0
.0
 
2
0
 (
2
1
.5
) 
2
.5
 
0
.0
 
5
8
 (
2
6
.7
) 
2
.2
 
0
.0
 
P
ro
fe
ss
io
n
a
l 
h
o
m
e 
ca
re
 (
H
o
u
r)
 
6
 (
6
.5
) 
3
.2
 
0
.0
 
2
 (
2
.2
) 
0
.0
 
0
.0
 
8
 (
3
.7
) 
1
2
.0
 
0
.0
 
C
o
st
s 
to
 p
a
ti
en
t 
a
n
d
 f
a
m
il
y 
In
fo
rm
al
 c
ar
e 
(H
o
u
r)
 
5
3
 (
5
5
.2
) 
3
2
2
.3
 
1
4
4
.0
 
4
9
 (
5
2
.7
) 
3
0
2
.2
 
3
0
.5
 
8
4
 (
3
8
.7
) 
1
8
6
.3
 
0
.0
 
P
ro
d
u
ct
iv
it
y
 l
o
ss
es
 (
H
o
u
r)
 
5
6
 (
6
0
.2
) 
2
0
6
.5
 
1
6
.0
 
5
5
 (
5
9
.1
) 
1
5
6
.4
 
1
2
.0
 
1
4
6
 (
6
7
.6
) 
3
4
9
.0
 
2
0
8
.0
 
C
o
st
s 
in
 o
th
er
 s
ec
to
rs
 
T
ra
v
el
 (
T
ri
p
) 
9
3
 (
1
0
0
) 
1
4
5
.4
 
1
5
6
.0
 
9
3
 (
1
0
0
) 
1
3
5
.3
 
1
5
6
.0
 
2
1
7
 (
1
0
0
) 
1
5
1
.0
 
1
5
6
.0
 
D
D
: 
d
ed
ic
at
ed
 d
ie
ti
ti
an
, 
E
P
: 
ex
is
ti
n
g
 p
ra
ct
ic
e;
 T
H
D
: 
tr
ai
n
ed
 h
o
sp
it
al
 d
ie
ti
ti
an
; 
H
D
: 
h
em
o
d
ia
ly
si
s.
 
      
COST-EFFECTIVENESS OF NUTRITION EDUCATION 
108 
CHAPTER 5 
109 
Table 3. Costs during the 12-month period (US$2015) 
 DD group (n=116) EP group (n=130) THD group (n=299) 
Mean  Median Mean  Median Mean  Median 
PHASE I 
Healthcare sector costs 
HD 7023.6* 7636.6 6512.8*† 7636.6 7182.7† 7636.6 
Maintenance HD 6911.0* 7636.6 6477.3*† 7636.6 7173.6† 7636.6 
Emergency HD 112.6*† 0.0 35.4* 0.0 9.2† 0.0 
Healthcare professionals 31.3 0.0 26.4 0.0 20.8 0.0 
Medications 1938.9*† 1898.5 1331.6* 1362.3 1339.7† 1279.5 
Hospitalization 1738.7* 0.0 1564.6^ 0.0 801.0*† 0.0 
Professional home care 2.0 0.0 0.6 0.0 210.1 0.0 
Total 10463.9*† 9899.3 8877.8* 8153.9 9014.8† 8740.8 
Costs to patient and family 
Informal care 155.0 20.2 195.0 20.2 118.1 40.3 
Productivity losses 364.3 122.3 194.0* 34.9 493.5* 134.4 
Total 510.3 307.1 388.9* 147.4 611.6* 285.0 
Costs in other sectors 
Travel 395.9 436.0 376.3* 436.0 421.5* 436.0 
Intervention costs 74.5*† 76.9 2.6*‡ 2.6 13.3†‡ 13.7 
Total societal costs 11724.2*† 10697.3 10203.8* 9544.8 10600.9† 10102.3 
PHASE II 
Healthcare sector costs 
HD 6015.9 7484.3 5718.2* 6385.6 6423.3* 7484.3 
Maintenance HD 5954.3 7484.3 5694.3* 6385.6 6416.5* 7484.3 
Emergency HD 61.6*† 0.0 23.9*  0.0 6.8† 0.0 
Healthcare professionals 53.7* 0.0 13.1* 0.0 24.9 0.0 
Medications 1519.0 1762.3 1270.6 1431.4 1281.2 1028.1 
Hospitalization 587.7 0.0 554.6 0.0 490.4 0.0 
Professional home care 61.2 0.0 0.5 0.0 140.4 0.0 
Total 8237.5 9220.6 7557.0 7382.7 8360.2 8571.7 
Costs to patient and family 
Informal care 429.7* 32.5 367.4 2.9 228.9* 0.0 
Productivity losses 352.2 38.5 216.6* 14.0 526.8* 119.8 
Total 781.9 328.2 584.0 135.8 755.7 237.0 
Costs in other sectors 
Travel 338.7 427.3 333.1* 364.6 375.1* 427.3 
Intervention costs 2.2* 2.6 2.1† 2.6 4.2*† 5.2 
Total societal costs 9360.2 10270.0 8475.2 8709.8 9495.2 9656.5 
TOTAL COSTS 
Healthcare sector costs 
HD 1309.5 15121.0 12231.0* 13911.9 13606.0* 15121.0 
Maintenance HD 12865.3 15121.0 12171.7* 13871.7 13590.0* 15121.0 
Emergency HD 174.2*† 67.0 59.3*‡ 0.0 16.0†‡ 0.0 
Healthcare professionals 85.1 20.5 39.5 16.6 45.8 14.7 
Medications 3457.9*† 3341.1 2602.3* 2555.5 2620.9† 2318.0 
Hospitalization 2326.3* 603.5 2119.2 445.8 1291.5* 199.4 
Professional home care 63.2 0.0 1.1 0.0 350.5 0.0 
Total 18972.0* 19070.3 16993.1* 17358.1 17914.7 17593.3 
Costs to patient and family 
Informal care 584.7* 251.5 552.3† 161.2 346.9*† 116.6 
Productivity losses 716.5* 415.1 410.6† 144.0 1020.3*† 581.4 
Total 1301.2 998.1 972.9* 526.8 1367.3* 783.4 
Costs in other sectors 
Travel 734.6* 863.3 709.3† 750.3 796.6*† 863.3 
Intervention costs 76.7*† 79.5 4.6*‡ 5.2 17.4†‡ 18.8 
Total societal costs 21007.7* 21548.0 18675.4* 18721.3 20078.6 19826.6 
*,†,‡p<0.05 indicates a between-group difference based on Bonferroni Post Hoc.  
DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; HD: hemodialysis. 
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STUDY OUTCOMES 
During Phase I, mean adjusted serum phosphorus decreased in the DD (-0.58 mg/dL) and EP (-0.09 
mg/dL) groups; and remained unchanged in THD. During Phase II, mean serum phosphorus increased 
in all groups. This increase was most accentuated in the DD and EP (+0.26 and +0.25 mg/L, 
respectively) than the THD group (+0.04 mg/dL). At the end of the study, EP group had the highest 
mean serum phosphorus. Moreover, mean serum phosphorus in the EP and THD groups was higher 
than baseline values, in contract to DD group. At each study phase, EP group had the highest mean 
QALY; and by the end of the study, it gained the most QALYs (Table 4). 
 
Table 4. Study outcomes (mean (SD)) 
 DD (n=116) EP (n=130) THD (n=299) 
PHASE I 
Phosphorus†‡ (mg/dL)  4.99 (0.98)* 5.30 (1.17)* 5.16 (0.89) 
QALY† 0.2781 (0.0436) 0.2809 (0.0419) 0.2759 (0.0441) 
PHASE II 
Phosphorus†‡ (mg/dL)  5.25 (1.39) 5.55 (1.75)* 5.20 (0.97)* 
QALY† 0.2570 (0.0877) 0.2620 (0.0844) 0.2609 (0.0797) 
Total 
QALY† 0.5352 (0.1233) 0.5429 (0.1207) 0.5368 (0.1185) 
†Imputed values; ‡Regression-based adjusted values; *p<0.05 indicates a between-group difference based on 
Bonferroni Post Hoc.  
DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; SD: standard deviation. 
 
COST-EFFECTIVENESS AND COST-UTILITY ANALYSES 
In the base-case CEA (Table 5), in comparison with EP protocol, the ICER of DD for total societal 
costs per 1 mg decrease in serum phosphorus was $7,853.6. On the other hand, THD protocol 
dominated DD (i.e. DD group had higher serum phosphorus and higher societal costs). THD protocol 
was likely to be the most cost-effective. In the CUA, DD protocol was dominated by EP and THD 
protocols. Even for the highest WTP threshold, the probability that DD protocol being cost-effective 
is almost null. EP protocol had the highest probability of being cost-effective (Figure 1).  
 
Table 5. Incremental cost-effectiveness and utility-ratios 
 DD vs. EP  DD vs. THD  
 Incremental 
effects 
Incremental 
costs 
ICER Incremental 
effects 
Incremental 
costs 
ICER 
Serum phosphorus (mg/dL) 
Base-Case* -0.31 +2404.5 7853.6† +0.05 +988.4 Dominated 
Complete cases* -0.41 +2555.2 6248.5† -0.02 +1049.8 59425.9† 
HD costs* excluded -0.31 +1685.6 5505.5† +0.05 +1775.2 Dominated 
P>5.5 mg/dL* -0.73 +4295.6 5887.4† -0.004 +1175.2 265243.2† 
Decrease in P (Detla 
adjustment) 
-0.40 +2404.5 5935.9† -0.11 +988.4 9212.8† 
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 DD vs. EP  DD vs. THD  
 Incremental 
effects 
Incremental 
costs 
ICER Incremental 
effects 
Incremental 
costs 
ICER 
QALY 
Base-Case -0.01 +2404.5 Dominated -0.002 +988.42 Dominated 
Complete cases -0.01 +2555.2 Dominated +0.002 +1049.8 449603.7 
HD costs excluded -0.01 +1685.6 Dominated -0.002 +1775.2 Dominated 
P>5.5 mg/dL +0.02 +4295.6 192938.1 -0.01 +1175.2 Dominated 
Adjusted QALY* -0.01 +2404.5 Dominated -0.003 +988.4 Dominated 
*Regression-based adjusted values; †Absolute values are presented, given that the beneficial outcome is the 
decrease in serum phosphorus, resulting in a negative ICER.  
DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; ICER: incremental cost-
effectiveness ratio; HD: hemodialysis; P: serum phosphorus; QALY: quality-adjusted life-year. 
 
 
Figure 1a. Cost-effectiveness acceptability curve presenting the probability of the protocol is cost-
effective (y-axis) with respect to serum phosphorus, given various ceiling ratios for willingness-to-
pay (x-axis).  
The ICER was represented in absolute values, given that the beneficial outcome is the decrease in serum phosphorus, 
resulting in a negative ICER. DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; ICER: 
incremental cost-effectiveness ratio. 
 
Figure 1b. Cost-utility acceptability curve presenting the probability the protocol is cost-effective (y-
axis) with respect to quality-adjusted life-year gain, given various ceiling ratios for willingness-to-
pay (x-axis).  
DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; ICUR: incremental cost-utility ratio. 
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SENSITIVITY ANALYSES 
The results of the cost-effectiveness and cost-utility of three protocols were inconclusive (Table 5). 
Regarding serum phosphorus, for all scenarios, the ICER of DD vs. EP was lower than the base-case 
result, thus more cost-effective. When compared with THD, the ICER of DD ranged between 
$9,212.8 for the delta adjustment, and $265,243.2 for hyperphosphatemic cases. THD protocol had 
the highest probability of being cost-effective for hyperphosphatemic patients and when hemodialysis 
and transportation costs were excluded. For the delta adjustment, and for complete cases, the 
probability of DD and THD being cost-effective tied at $8,000 and $60,000, respectively; above these 
values, DD was the most cost-effective protocol (Appendix S5).  
Regarding QALY, DD protocol was dominated by EP for all scenarios, expect for hyperphosphatemic 
cases, and by THD for all scenarios, except for complete cases. Even for the highest suggested WTP 
threshold, the probability of DD protocol being cost-effective was low. EP was the most cost-effective 
protocol (Appendix S6).  
 
DISSCUSSION 
In this study, we explored the cost-effectiveness of intensive nutrition education provided by trained 
dedicated dietitians (DD), compared with the existing practice (EP) in Lebanon- where dietitians have 
limited knowledge about renal nutrition and no dietitian-to-patient contact time is set, and to another 
protocol (THD) where dietitian education is ensured, yet contact time with patients is not established.  
The results showed that the direct costs of the nutrition education are extremely low compared with 
the costs of other interventions incurred as part of the management of hemodialysis patients. At the 
end of the study, in comparison with EP and THD groups, DD group exhibited the greatest decrease 
in serum phosphorus, no difference in QALY, and the highest societal costs.  
Regarding serum phosphorus management, DD protocol was likely to be cost-effective compared 
with EP. However, it is very difficult to draw a firm conclusion of this analysis, since we lack a 
societal WTP threshold for decrease in serum phosphorus. The results were inconclusive in 
comparison with THD. Regarding QALY, DD protocol was dominated by both of the other protocols, 
in most of the cases. When DD was not dominated (the case of hyperphosphatemic patients in 
comparison with EP, and complete cases in comparison with THD), it was associated with a cost per 
QALY gained higher than what is considered to be an efficient use of finite healthcare resources 
[32,34,35]. The probability of DD being cost-effective was low for the base-case and sensitivity 
analyses.  
Several factors might explain these results. At baseline, DD group had the highest MIS and serum 
phosphorus. High MIS predicts increased mortality, days and frequency of hospitalization, as well as 
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lower QoL [36–39]. High serum phosphorus is associated with the same deleterious consequences 
[2–5,40]. This suggests higher baseline costs of DD compared with the other groups. This might also 
explain the greater decline in resources use and costs (notably for hospitalization and medications, 
especially costly phosphate binders) after the implementation of the intervention (Phase II). Within 
this scope, it is worthy to note that despite achieving a greater serum phosphorus decrease in 
comparison with THD (-0.32 vs. +0.04 mg/dL), mean serum phosphorus of the DD group remained 
higher, causing it to be dominated in the base-case analysis. The contradictory results between this 
analysis and the one using the delta adjustment illustrate this observation. Moreover, patients in the 
DD group might have been more critically ill than those in the other groups, as exhibited by the high 
mortality rate even before enrollment in the study. In addition, as mentioned in Karavetian et al. [14] 
the effectiveness of the DD protocol might have been partially “masked” by the improvement noted 
in the EP group, where contamination of information through patients and nurses and passive 
education through posters and distribution of educational material took place; and in THD group 
where the intervention was sustained during Phase II, in contrast to the DD group, where the 
intervention was stopped. 
The sensitivity analysis demonstrated uncertainty in the cost-effectiveness of the DD protocol. In 
particular, we were not able identify whether the nutrition education is an economically attractive 
intervention among hyperphosphatemic patients and contradictory results were obtained regarding 
serum phosphorus and QALY. This finding is not in line with results from a previous economic 
evaluation of phosphate binders [41] which revealed better cost-effectiveness with increasing serum 
phosphorus- taken the accentuated morbi-mortality risk with hyperphosphatemia. The limited time 
horizon in our study (1 year vs. lifetime in Brennan et al. [41]) might explain this contradictory 
finding, as it did not allow us to explore future decrease in mortality and morbidity with better 
phosphorus control due to the nutrition education. 
Our analysis depended on numerous assumptions and have several limitations. First, although we 
resorted to adjustments for baseline differences in key parameters of the economic evaluation (serum 
phosphorus and utility), we were not able to adjust our analysis for all baseline differences between 
the three groups, notably the malnutrition-inflammation status. Second, we did not collect cost data 
at baseline, assuming that the cluster randomization would results in similar groups; however, this 
was not the case and groups ended having different baseline key variables, and potentially different 
resource consumption characteristics. Exploring baseline costs might have explained the higher costs 
in the DD group. Third, the most important assumptions in our analysis related to attrited cases. We 
used patient-specific values when available from a previous time-point, and followed the imputation 
by the mean using the most detailed values, where data from a previous time-point were unavailable. 
We assumed that is the most feasible method in light of the limited number of patients in each group 
in each unit, although it might not be the most robust one. The results were sensitive to this parameter 
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and ICERs/ICURs varied between the base-case analysis and when only complete cases were 
included. Potentially, attrited patients had different resource-consuming characteristics than the ones 
who finished the trial. A post-hoc analysis addressing this issue might provide an answer to this 
question. In addition, we assumed that death or hospitalization took place at the mid-point of each 
phase, that costs and serum phosphorus followed a linear evolution throughout time, that patients 
maintained their QoL at withdrawal, and applied our analyses accordingly. We adopted these method 
because costs, serum phosphorus and QoL values were not available at time of attrition; and due to 
the lack of studies describing the evolution of costs, serum phosphorus and QoL mainly before death, 
transfer and transplant… in hemodialysis patients. Fourth, as discussed in Rizk et al. [22] the 
estimation of resources consumption used a self-reported questionnaire- rather than documented 
sources (patient or facility records). This potentially leads to recall bias or poor understanding of the 
questions among patients with limited cognitive skills. Valuation of some resources costs also relied 
on information collected from patients, due to the lack of a manual for cost analysis in healthcare 
research in Lebanon. In an attempt to overcome these two limitations, the resource utilization 
questionnaire used in this study was designed following good practices for improved accuracy [42]. 
Fifth, economic evaluations of interventions targeting hyperphosphatemia management in 
hemodialysis patients usually adopt a time horizon longer than the one adopted in this study, in order 
to capture the long-term effect of reducing serum phosphorus [11]. In fact, the time horizon should 
be long enough to include all relevant costs and outcomes of the intervention [43]. This was not the 
case of our analysis, and exploring this issue through a model-based analysis adopting a lifetime 
horizon is needed, especially that DD protocol was associated with the best clinical outcomes and 
greatest decrease in societal costs in post-implementation. Additionally, it is worthy to note that the 
cost of the intervention is expected to further decrease on the long run, taken that the initial training 
of the dietitians (≈10% of the cost of DD intervention) is a one-time intervention. Finally, differences 
in healthcare systems funding, costs of healthcare and other resources, and societal WTP for health 
interventions, among other factors, limit our ability to directly generalize our results to other 
countries.  
The primary strength of this analysis is that it used patient-level data from a randomized controlled 
trial; and tried to compare a novel intervention with the existing practice, and to another alternative, 
that could be considered as a first step towards implementing evidence-based care for hemodialysis 
patients in Lebanon. In addition, NEMO was conducted following a practical fashion, increasing the 
likelihood of the generalizability of its results to real-world practice; and its economic evaluation was 
performed from the preferred (societal) perspective. 
According to the National Kidney Registry, nearly 3,300 patients receive hemodialysis in Lebanon 
[44]. The monthly budget implications of making dedicated dietitians available for all patients would 
be substantial (≈$40,000). Yet, a closer look at the cost savings of this intervention are also likely to 
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be quite substantial, making this intervention worthy of an exhaustive evaluation and possibly of its 
consideration as part of the management of hemodialysis patients. For instance, the difference in the 
mean decrease in societal costs between DD and EP ($636.3) and between DD and THD ($1,258.3) 
in post-implementation, would offset more than 8 and 16 times the cost of the 6-month nutrition 
education, respectively.  
Finally, this CEA assessed dedicated dietitians providing education targeting serum phosphorus. This 
is one aspect of the medical nutrition therapy of renal patients; and exploring other outcomes of the 
dietetic management is recommended, especially that previous evidence suggest substantial costs 
savings of nutrition interventions among renal patients through malnutrition prevention and 
management [45] and improved QoL [46,47]. Future clinical studies should investigate the impact of 
nutrition education on relevant clinical endpoints (i.e. morbidity and mortality), and CEA should 
assess equitable groups at baseline using an extended time horizon, to have a more realistic evaluation 
of the economic attractiveness of this intervention. While healthcare funding decisions must be made 
using the best currently available data, it is possible that future estimates of the cost-effectiveness of 
the nutrition education may differ. 
 
PRACTICAL IMPLICATIONS 
The additional costs of the nutrition education were low as compared with the total societal costs of 
hemodialysis patients. Regarding serum phosphorus, DD protocol is likely to be cost-effective 
compared with EP, and the probability of DD being cost-effective compared with THD protocol was 
low. No effect of DD was noted on QALY, and the intervention was therefore dominated in terms of 
cost per QALY gained. 
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Appendix S1: Resource utilization questionnaire 
 
1 What is your insurance/3rd party payer? 
□NSSF □ MOPH □ Army □COOP □Private □Other………………….. 
 
2 In the past 6 months, how often have you contacted a specialist physician (like a cardiologist 
&/or endocrinologist &/or surgeon &/or …….)?---------------------- 
How much did it cost per visit?------------------------ 
How much of it did you pay from your pocket?------------------------ 
3 In the past 6 months, how often have you contacted your dietitian?---------------------- 
How much did it cost per visit?------------------------ 
4 In the past 6 months, how often have you contacted a psychologist?---------------------- 
How much did it cost per visit?------------------------ 
5 In the past 6 months, how many nights have you spent in the hospital?---------- 
How much did it cost per day?------------------------------------------ 
How much of it did you pay from your own pocket? --------------------------------- 
6 In the past 6 months, how many times did you have to go for an extra emergency 
hemodialysis session?  -------------------------------------------------- 
7 List the number of medications that you are prescribed in the past 6 months  
 Calcium 
carbonate 
Calcium 
acetate 
Sevelamer Cinacalcet Vitamin D 
How many pills per day      
 Active 
Vitamin D 
Vitamin B 
complex 
Iron Pills IV iron  Erythro-
poietin 
How many pills per day      
For which one of them did you pay from your own pocket (were not reimbursed) in the past 
6 months?  
 
 
8 In the past 6 months, how many hours per week on average did you need family/ friends to 
take care of you or help you due to your health situation?------------------------ 
How much did it cost per hour?------------------------ 
9 In the past 6 months, how many hours per week did you need home care professionals (paid 
help) like home nurses or home doctors….? 
How much did it cost you?------------------------ 
10 In the past 6 months, how many days were you unable to perform your daily activities due 
to your health (for example, days lost from work or school, days where you were unable to 
perform domestic work)?------------------------ 
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Appendix S2: Costing of the nutrition education 
 
Table 1. Cost components and mean costs per patient of the three protocols (LBP) 
  # Unit Cost Unit Phase I Phase II 
Dedicated Dietitian protocol 
1) Dietitian traininga  12055.34 0 
2) Educational materialb 78 papers 50.00 LBP/paper 3900.00 0 
3) Nutrition education 12 
hours (2hours/ 
month/6months) 7526.88 LBP/hour 90322.58 0c 
4) Standard dietetic care 0.5 hour (1 hour/ year)c 7527.88 LBP/hour 3763.94 3763.94 
Total 110041.87 3763.94 
Existing Practice protocol 
Standard dietetic care 0.5 hour (1 hour/ year)d 7527.88 LBP/hour 3763.94 3763.94 
Trained Hospital Dietitian protocol 
1) Dietitian traininga  12055.34 0 
2) Nutrition education 1 hour (2 hours/ year)e 7526.88 LBP/hour 7526.88 7526.88 
Total 19582.23 7526.88 
aIncluding training cost and cost of dietitian time for attending the training. Rational and conduct of 
the training was described in Karavetian & Rizk (2016). Training cost per dietitian, obtained from 
its provider (MK who is a co-author of this article), was multiplied by the number of dietitians 
needed to provide the nutrition education and divided by the number of patients. Dietitian cost per 
hour was obtained from the Syndicate of Dietitians in Lebanon (personal communication) and from 
a national survey among Lebanese hospital dietitians (Karavetian et al., 2013) 
bObtained from the provider of the training (MK who is a co-author of this article) 
cIntervention was stopped during Phase II 
dMean number of hours as per the standard care in Lebanon (Karavetian et al., 2013) 
eMean number of hours allocated to patients in the group (unpublished data). 
 
The costs gathered and calculated in LBP were converted to US$ (1 US$= 1507.5 L.L.; year of 
reference: 2011) (BDL, 2016) and uprated to 2015US$ using Consumer Price Indices (Index, 
2010=100) (OECD, 2016). The costs of the dietetic interventions for the DD, EP and THD groups 
for Phase I and Phase II were as follows: $74.5, $2.2; $2.6, $2.1; and $13.3, $4.2, respectively. 
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Appendix S3: Flow diagram of the trial 
 
A total of 720 patients participated in the study. 570 of those met the inclusion criteria. 
 
 
 
Figure 1. Flow diagram of the trial. 
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Appendix S4: Cost distribution of the study groups 
 
 
 
 
Figure 2. Cost distribution of the study groups.  
 
aDD (dedicated dietitian): 2.5th percentile: $19,799.49; 
97.5th percentile: $22,377.03 
bEP (existing practice): 2.5th percentile: $17,556.73; 
97.5th percentile: $19,843.65 
cTHD (trained hospital dietitian): 2.5th percentile: 
$19,325.09; 97.5th percentile: $20,871.02. 
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Appendix S5: Cost-effectiveness acceptability curves for sensitivity analyses 
 
Complete cases                                                                  Hemodialysis costs excluded 
 
Hyperphosphatemia at baseline                                       Difference in serum phosphorus 
 
Figure 3. Cost-effectiveness acceptability curve presenting the probability the protocol is cost-
effective (y-axis), with respect to serum phosphorus, given various ceiling ratios for willingness-to-
pay (x-axis).  
Sensitivity analyses performed for complete cases, hemodialysis and transportation costs excluded, hyperphosphatemia 
at baseline and difference in serum phosphorus as outcome. The ICER was represented in absolute values, given that 
the beneficial outcome is the decrease in serum phosphorus, resulting in a negative ICER. DD: dedicated dietitian, EP: 
existing practice; THD: trained hospital dietitian; P: serum phosphorus; HD: hemodialysis; ICER: incremental cost-
effectiveness ratio. 
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Appendix S6: Cost-utility acceptability curves for sensitivity analyses 
 
Complete cases                                                                  Hemodialysis costs excluded 
 
 Hyperphosphatemia at baseline                                       Adjusted QALY 
 
Figure 4. Cost-utility acceptability curves presenting the probability the protocol is cost-effective 
(y-axis), with respect to QALY gain, given various ceiling ratios for willingness-to-pay (x-axis). 
Sensitivity analyses performed for complete cases, hemodialysis and transportation costs excluded, hyperphosphatemia 
at baseline and adjusted QALY. DD: dedicated dietitian, EP: existing practice; THD: trained hospital dietitian; P: serum 
phosphorus; HD: hemodialysis; QALY; quality-adjusted life-year; ICUR: incremental cost-utility ratio. 
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In Lebanon, as in many developing and developed countries alike, managing hyperphosphatemia 
among hemodialysis patients remains challenging [1,2]. Given that elevated serum phosphorus is a 
strong and independent predictor of patient morbidity and mortality, of use of healthcare services and 
of costs, and given that healthcare resources are limited, this thesis aims to enhance our understanding 
of the health technology assessment (HTA) of hyperphosphatemia management among hemodialysis 
patients within the Lebanese setting. We open this chapter with a presentation of the main findings 
of the thesis and then discuss some of the methodological considerations. We conclude with 
recommendations for clinical practice, and for further research in support of public health policy 
making (in Lebanon). 
 
MAIN FINDINGS OF THE THESIS  
Box 1: Main findings 
• Research is limited on the cost-effectiveness of phosphorus-lowering interventions 
among hemodialysis patients 
• Calcium acetate seems to be the most cost-effective phosphate binder in first- and 
second-line use in hemodialysis patients  
• Hemodialysis is a resource-intensive therapy in Lebanon, posing a heavy burden on the 
national healthcare system and on Lebanese society 
• Intensive nutrition education for hyperphosphatemia management is clinically effective 
in decreasing serum phosphorus without compromising the nutritional status of 
hyperphosphatemia hemodialysis patients 
• Intensive nutrition education is an inexpensive intervention within hemodialysis patient 
management, and is associated with a decrease in resource use and in societal costs 
• Intensive nutrition education does not have any incremental effect on quality-adjusted 
life-years among hemodialysis patients in the short term 
 
ECONOMIC EVIDENCE SYNTHESIS 
First, in Chapter 2, we systematically reviewed full economic evaluations of phosphorus-lowering 
interventions among adult hemodialysis patients, published between 2004 and 2015. Twelve studies 
were identified, all of which reported on the comparative cost-effectiveness of phosphate binders. 
The majority of high-quality studies favored first- and second-line use of calcium acetate over 
calcium-free binders in prevalent patients. Only one high-quality study, funded by the industry, 
reported better cost-effectiveness of second-line lanthanum carbonate over calcium-based binders, in 
incident patients. We found limited evidence regarding the cost-effectiveness of calcium-free binders, 
and it was therefore impossible to draw firm conclusions, due to the suboptimal quality and 
heterogeneity of the included studies, as well as the lack of studies addressing some clinical scenarios. 
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Our work adds evidence regarding the limited number of cost-effectiveness studies of phosphorus-
lowering interventions in hemodialysis patients and the suboptimal quality of published economic 
evaluations [3,4], and accordingly the need for further high-quality economic evaluations. 
 
COST-OF-ILLNESS OF HEMODIALYSIS AND THE BURDEN OF HYPERPHOSPHATEMIA 
In Chapter 3, we conducted a retrospective, bottom-up, prevalence-based cost-of-illness (COI) 
estimate, using data from the Nutrition Education for Management of Osteodystrophy (NEMO) trial. 
The mean 6-month societal costs of hemodialysis were estimated at $9,258, of which 91.7% were 
attributable to healthcare costs, 4.2% to patient and family costs, and 4.1% to costs in other sectors. 
The annual costs of hemodialysis in Lebanon were estimated at $61 million and healthcare costs were 
estimated at $56 million. The latter represented around 1.82% of the total healthcare expenditures in 
Lebanon (estimated $3 billion in 2012). This study highlighted the debilitating financial burden of 
hemodialysis on Lebanese society and third party payers (the annual cost per patient: $18,517, being 
43.7% higher than the national gross domestic product per capita). The study also provided a typical 
illustration of the high cost of hyperphosphatemia management through phosphate binders, especially 
calcium-free agents. Phosphate binders accounted for 2.3% of annual societal costs and 16.7% of 
annual costs for medications. Moreover, despite being used by only 23.7% of the study population, 
the average cost of sevelamer outweighed the combined costs of calcium carbonate and calcium 
acetate, which were used by 78.9% and 35.1% of the study population, respectively. We argue that 
the current financial burden of managing phosphatemia through phosphate binders is higher than it 
was in 2012, when the Nutrition Education for management of Osteodystrophy (NEMO) trial was 
conducted. In recent years, sevelamer and lanthanum carbonate largely penetrated the Lebanese 
market and are being prescribed increasingly by nephrologists in Lebanon (Personal communication 
with the Department of Nephrology, Ministry of Public Health, Lebanon, 2016). 
 
CLINICAL EFFECTIVENESS OF INTENSIVE NUTRITION EDUCATION 
In Chapter 4, we used the data from the NEMO trial to assess the impact of intensive nutrition 
education on the hyperphosphatemic subset of hemodialysis patients. The intervention resulted in an 
immediate significant decline in serum phosphorus in all study groups. It was the greatest among 
Dedicated Dietitian (DD) patients, who also solely progressed in their readiness to adhere to a low-
phosphorus diet. At 6 months post-implementation, serum phosphorus remained stable in the DD and 
Trained Hospital Dietitian (THD) groups, yet, it increased significantly in the Existing Practice (EP) 
group, to levels higher than at baseline. Also, DD patients relapsed in their adherence to the low-
phosphorus diet. Most importantly, throughout the trial, the malnutrition inflammation score (MIS) 
remained stable only in the DD group, in contrast to the other groups, who exhibited a significant 
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increase, denoting a worsened nutritional status and predicting severely deleterious outcomes, such 
as poorer quality-of-life, increased risk of hospitalization and greater risk of death [5]. The 
improvement in the EP group was not expected, and the potential reasons behind it are detailed in the 
section for methodological considerations. Conversely, the mild improvement in the THD group was 
expected and may be a result of the upgraded and intensified visits of dietitians to the hemodialysis 
unit in comparison with their usual practice. Karavetian & Ghaddar [6] and Morey et al. [7] reported 
that the presence of a dietitian as an “authoritative figure”, and simple yet frequent interactions 
between the dietitian and the patients can improve serum phosphorus outcomes. Accordingly, we 
suggest that intensive and sustained behavioral nutrition education results in the greatest patient-
driven decline in serum phosphorus. While these findings are in line with previous reviews of the 
literature conducted by Matteson & Russel [8], Caldeira et al. [9] and Karavetian et al. [10], our 
results fill in a gap within evidence-based practice guidelines [11], and provide evidence that irregular 
and distant follow-ups for patients participating in phosphorus-lowering dietary interventions 
adversely impacts their nutritional status. Maintaining good or stable nutritional status during dietary 
phosphate restriction requires sufficient time for careful instruction, regular counseling and close 
monitoring by a competent dietitian.  
 
COST-EFFECTIVENESS OF INTENSIVE NUTRITION EDUCATION 
In Chapter 5, we assessed the cost-effectiveness and cost-utility of intensive nutrition education (DD 
protocol) for hyperphosphatemia management among hemodialysis patients, in comparison with the 
existing practice (EP protocol) in Lebanon and another proposed alternative (THD protocol). The 
additional costs of the nutritional intervention were greatly higher in the DD group than in THD and 
EP. Yet, it was, in all groups at both study phases, very low in comparison with the societal costs 
(<0.64%), and with the costs of other resources used. For instance, the cost of phosphate binders was 
more than 6 times higher than that of the intensive nutrition education (sub-analysis on complete 
cases from the DD group). With regard to outcomes, the DD group witnessed the greatest decline in 
serum phosphorus, yet no differences in utility nor in quality-adjusted life years (QALY) were noted 
between the groups. Regarding the use of services and consequent costs, the DD group used the most 
services and generated the greatest total societal costs. At 6 months post-implementation of the 
intervention, the DD group showed a sharp decline in use of services and in societal costs; this decline 
was the greatest among the 3 groups. This was especially noted with regard to costly services, such 
as calcium-free phosphate binders, hospitalization, and emergency hemodialysis sessions. In the base-
case analysis, the DD protocol was likely to be cost-effective in comparison with EP. Yet, it was 
dominated by THD. As for the cost-utility analysis, the DD protocol was dominated by both EP and 
THD. The sensitivity analyses yielded varying and inconclusive results, suggesting uncertainty in the 
study results.  
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METHODOLOGICAL CONSIDERATIONS 
Box 2: Methodological considerations 
• Conducting a systematic review of health economic evaluations and interpreting its 
results are challenging 
• A direct comparison of the results of the cost-of-illness study with other countries is 
challenging due to methodological issues, as well as to differences in clinical and health 
systems, among other factors 
• We lack essential elements for research in health technology assessment in Lebanon 
• National guidelines for conducting and reporting health economic studies (cost-of-
illness and economic evaluations) do not currently exist in Lebanon 
 
Various methods were used in this dissertation, including a systematic review (Chapter 2), a COI 
study (Chapter 3), a randomized controlled trial (RCT) (Chapter 4) and a trial-based economic 
evaluation (Chapter 5). This section addresses the methodological challenges, strengths and 
limitations of these methods. 
 
SYSTEMATIC REVIEW 
Over the past decades, the understanding and management of serum phosphorus in hemodialysis 
patients have been transformed. Tight control of serum phosphorus was recommended by evidence-
based practice guidelines [12], and the use of pharmaceutical agents, especially expensive calcium-
free binders, has proliferated, on the basis of little or no additional clinical benefit [13–17]. It is thus 
becoming incumbent on us to conclusively demonstrate the cost-effectiveness of these agents [18], 
and to assess the economic value of other interventions. Systematic reviews addressing clinical 
questions are essential in health care. They are regarded as the highest level of evidence, are often 
looked upon as a starting point for developing practice guidelines and are widely recognized as critical 
in guiding decision makers towards implementing best health care policy and practice [19–22]. In 
parallel, since 1990, publishing has seen a steady flow of systematic reviews of economic analyses 
[23]. These reviews integrate information from multiple studies [24] and are therefore useful for 
synthesizing economic evidence about health interventions [25] and providing key information for 
policy making and HTA processes [24–26].  
While we followed available recommendations for conducting and reporting on systematic reviews 
of economic evaluations in health care [21,27], and for appraising the quality of included studies [28], 
the conduct of the review faced many challenges and our results were subject to several limitations 
which are common to economic reviews [24,29]. These challenges are on one hand methodological, 
and on the other hand relate to the transferability of our results, to aid decision making across different 
settings. The first set of limitations could be summarized by the lack of a standard methodology for 
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preparing systematic reviews of health economic evaluations (identification, appraisal, and synthesis 
of evidence), and for reporting on the results in a way most useful to end users [23,29]. These 
challenges were recently addressed in a series of reviews on the development of systematic reviews 
of economic evaluations [25,30,31]. This series also highlighted some of the limitations that we faced 
while conducting this review, such as the lack of standard techniques for reaching consensus between 
reviewers when there are disagreements regarding the inclusion of studies, on evidence synthesis and 
on assessing quality, as to date  resolution of these disagreements relies solely on discussion between 
authors. Another limitation is the lack of validated tools for assessing the quality of both model-based 
and trial-based economic evaluations. In addition, some economic evaluations lacked adherence to 
methodological and reporting guidelines. This hindered evidence synthesis, the overall quality of the 
evidence of the review, and the explanation of potential differences between study findings. Our 
results are also limited by the multitude of factors surrounding the transferability of economic 
evaluations between countries, such the epidemiology and clinical management of 
hyperphosphatemia, availability and prices of health services, and different decision contexts and 
budget constraints [26,32]. Delineating tools to identify potential transferability, such as a score or 
index defining minimal methodological and structural requirements to enable health economic 
evaluation to be transferable to various decision making contexts could be regarded as a feasible 
approach [33].  
The use of systematic reviews of economic evaluations in decision making seems to be hindered by 
behavioral and political factors, which could affect the usefulness of reviews for making decisions 
[34]. Potentially, interaction between researchers and policy makers to better highlight information 
that is relevant for decision making, involving policy makers in the production of reviews, and making 
the synthesized evidence available in user-friendly “front ends” are warranted to facilitate better 
understanding and greater use of the results of economic reviews [24,29,35]. Finally, it is worth noting 
that, while synthesis of health-economic evidence could inform policy makers, it cannot entirely 
overshadow the importance of context-specific cost-effectiveness information and the need for 
adapting synthesized evidence to local economic guidelines [32].  
 
COST-OF-ILLNESS STUDY 
COI studies are being conducted increasingly with the aim of highlighting the burden of the disease, 
over and above the usual epidemiological estimates of morbidity and mortality, helping to determine 
medical research priorities and providing a baseline against which new interventions can be assessed 
[36,37].  
The findings of our COI study are in line with previous regional and international publications, 
highlighting the high financial burden of hemodialysis [38,39]. The annual COI of hemodialysis in 
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Lebanon found in our study ($18,517) was below the costs reported from high-income countries [38], 
and fell in the middle of the range of costs reported from other upper middle-income countries [39] 
(i.e. $7,608 in South Africa to $30,467 in Turkey; uprated to the year 2015). The direct comparison 
of our results with those of other studies is challenging. In fact, the wide variability in the annual cost 
estimates of hemodialysis between countries and between authors within the same country was 
reported in a systematic review of COI studies by Mushi et al. [39], although all of the studies 
reviewed followed the same Sum_Diagnosis Specific estimation method [40]. These differences can 
obviously be explained by the varying methodologies used, i.e. study design and costing approach, 
perspective adopted, type of costs and which cost items were included in the analysis. This is 
illustrated by the staggering difference COI of hemodialysis in South Africa (ranging between $7,608 
and $25,682) [39] and in Jordan ($10,844 [41] and $22,368 [42]), for example. Yet, there are further 
underlying factors when benchmarking against other studies, such as the characteristics of the sample, 
practice guidelines and the clinical management of patients, methodological considerations (sources 
of information, costs of the services used, and differences in applying costing approaches), as well as 
country- and health system-specific issues, i.e. availability and validity of information and 
reimbursement mechanisms, among others. This issue is clearly illustrated when comparing our study 
with that of Abreu et al. [43], in Brazil. 
The heterogeneity in the conduct of COI studies and lack of transparent reporting are common for 
dialysis [38,39,44], as well as for other diseases [37,45–48]. These factors make it challenging to 
compare results across studies and over time [37,45,46]. Also, the wide variation of cost estimates 
raises serious questions regarding the accuracy and validity of COI studies, consequently hindering 
their use in healthcare decision making [47,48]. For COI studies to be more robust and useful, closer 
agreement among researchers and strict adherence to available recommendations around “best 
practices” is a worthy first step [37,49–53] while waiting for guidelines on the methodology and 
reporting of COI studies to be published [54]. These awaited guidelines, coupled with improvement 
in data availability and quality, may enhance the credibility and validity of COI studies and increase 
their use by policy makers [48,54].  
It is essential, however, to acknowledge the limitations of using COI studies in public health policy 
making [53]. While these studies can present a useful opportunity for communicating with the public 
and policy makers on the relative importance of an illness, and can foster policy debate and stimulate 
research and policy initiatives aiming at more cost-effective treatment and prevention of illness, 
without other information they cannot guide decisions on the allocation of scarce health resources 
[36]. Rather, for this aim, cost-effectiveness studies of health technologies should be undertaken [36]. 
Finally, to date there is little information on the applications and outcomes of the use of COI in real-
life policy making, and the value of pertinent research on this is uncertain [48,52,55]. More discussion 
is needed among all stakeholders to define the most useful metrics for public and private health care 
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decision makers, legislators, employers, insurers and providers, to identify opportunities for COI to 
be a good economic tool within decision making [48]. 
 
RANDOMIZED CONTROLLED TRIAL 
When evaluating the effectiveness of an intervention, the RCT design is generally regarded as 
providing the most reliable evidence in health care. This is because this design minimizes the risk of 
confounding factors influencing the results, and permits elucidation of the impact of a health 
intervention. Accordingly, the findings of RCTs are probably closer to the true effects of a particular 
intervention than the findings generated by other research methods in health care [56]. 
Our effectiveness study was conducted using data from the NEMO trial [1], and holds the same 
strengths, limitations and methodological considerations. First, NEMO was implemented within the 
national health care setting, rather than operating in the idealized experimental environment, 
consequently generating “real life” useful and practical data [57]. Second, few specific exclusion 
criteria were applied, and the participants shared characteristics common to hyperphosphatemic 
hemodialysis patients reported from other areas of the world [7,58–63]. These factors suggest that the 
results of this study are likely to be generalizable to this patient population. The final major strength 
pertains to the use of the MIS to assess the nutritional status of the patients. This tool is regarded as 
the gold standard for assessing the nutritional status of hemodialysis patients, and is predictive of 
short and long-term mortality, morbidity, hospitalization and quality of life (QOL) outcomes [5,64–
66]. The most important limitation of the NEMO trial pertains to the recruitment of the intervention 
and control groups from the same hemodialysis units, and their assignment to different protocols 
based on their dialysis shifts. The cluster-based randomization was obviously chosen for compelling 
feasibility reasons, and was used in previous research on an educational intervention among 
hemodialysis patients [67]. However, in our study, this design resulted in a contamination of 
information between DD and EP groups, which might explain the improvement in serum phosphorus 
in the latter group, where serum phosphorus was mimicking changes seen in the DD group, but to a 
lower extent. Accordingly, the cluster randomization of patients based on dialysis shifts seems not to 
be an effective allocation method for this patient population, given the frequent possible interaction 
among patients, and between them and healthcare providers, and the potential exposure of control 
subjects to educational material [68]. Care must be taken in future trials employing a cluster-based 
randomization in order to maintain the practical implementation of the trial without compromising its 
internal validity. Next, the second phase of the study was intended to be a follow-up phase, where the 
impact of removing the intervention would be assessed. However, we could not evaluate this issue in 
the THD group, where the trained hospital dietitians continued to provide their “upgraded” care, and 
it was unethical to ask them to go back to their pre-training care or to reduce the frequency of 
hemodialysis patients consults. Third, we tried to explain the mechanism by which the intervention 
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was effective in reducing serum phosphorus by exploring the evolution in dietary phosphorus intake 
and phosphorus-to-protein ratio, but this was a challenge. The tool that we used (24-hour dietary 
recall) for this aim has numerous limitations in hemodialysis patients. The 24-hour recall relies on 
the patient’s ability to remember and accurately report foods consumed, and may underestimate actual 
intake even when conducted by a trained interviewer, and can generate great variability in the mean 
daily nutrient intake [69]. This limitation should fuel the search for practical and valid tools in this 
regard. Fourth, we did not collect information regarding adherence to phosphate binders, which was 
targeted in some of the educational sessions. Previous similar studies suggested that nutrition 
education could contribute to an increase in the efficacy of phosphate binders by reducing the dosage 
needed and ameliorating compliance and tolerability [58]. This issue remains to be explored by future 
studies.  
 
TRIAL-BASED ECONOMIC EVALUATION  
Given the scarcity of healthcare resources, economic evaluations which compare the costs and 
outcomes of an innovative intervention with a control intervention (usually existing care) are 
explicitly being used to inform decision makers on the efficient use of available resources for 
maximizing health benefits. Economic studies conducted alongside randomized controlled trials, i.e. 
trial-based economic evaluations, are a primary source of data on the cost-effectiveness of health 
technologies [70,71] and their use is partial basis for health service decision making in many settings 
[71].  
Interpreting the results of our trial-based economic evaluation was challenging. Given the striking 
baseline differences in key parameters, it was impossible to draw a firm conclusion about the cost-
effectiveness of the DD protocol. At baseline, the DD group had the highest MIS and serum 
phosphorus, which reportedly predict increased mortality, days and frequency of hospitalization, as 
well as lower QOL [5,64–66,72–75]. These factors made it practically impossible for intensive 
nutrition education to be cost-effective. For instance, although the DD group achieved a greater serum 
phosphorus decrease in comparison with the THD group (-0.32 vs. +0.04 mg/dL), the mean serum 
phosphorus of the DD group remained higher, causing it to be dominated in the base-case analysis. 
Although we resorted to adjustments in serum phosphorus and utility, we were not able to adjust our 
analysis for all baseline differences between the three groups, notably the malnutrition-inflammation 
status. Feasible statistical means are needed to allow simultaneous multiple adjustments and the 
generation of patient-level data (for bootstrapping and for the construction of cost-effectiveness 
acceptability curves). Furthermore, as these baseline differences suggest higher baseline use of 
resources and costs in the DD group, it would have been wise to collect costs data at baseline, and 
complement our analysis with a regression-based adjustment of patient-level cost data [76]. Although 
it is not common to report baseline costs in trial-based economic evaluations, van Asselt et al. [76] 
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argued that costs at baseline would influence costs during the trial and presented the case for reporting 
these costs and investigating their influence, in order to be able to attribute the difference that is found 
afterwards to the intervention. Regarding QALY, we could not detect any incremental effect of the 
intervention. This might be related to the short time horizon of the study, the improvement of serum 
phosphorus in all study groups and its potential impact on QOL, or to the simple fact that decreasing 
serum phosphorus among hemodialysis patients is not associated with improvement in QOL or 
survival, which has not been conclusively proven. Although our results did not confirm the cost-
effectiveness of intensive nutrition education, a closer look at the low cost of nutrition education, 
coupled with the greater decrease in use of services and in post-implementation costs would probably 
reveal the true added economic value of the DD protocol. The cost savings of this intervention are 
likely to be quite substantial, making it worthy of a thorough evaluation and possibly of considering 
it as part of the management of hemodialysis patients. 
Finally, the performance of this economic evaluation was subject to many challenges, specifically the 
lack of essential elements in HTA research in Lebanon, which forced us to adopt alternative methods 
to circumvent these limitations. While neighboring countries have formally integrated HTA in 
decision making (e.g. reimbursement of drugs) and implemented some basic pertinent requirements 
[77,78], HTA research and applications in Lebanon are quasi-nonexistent, as the country lacks 
national methodological and reporting guidelines for economic evaluation and costing studies, 
standardized resource-use measures, country-specific utility weights, and a societal willingness-to-
pay threshold. We detail these issues and discuss pertinent research and public policy implications in 
the following section. 
 
IMPLICATIONS  
Box 3: Implications 
• Health technology assessment in Lebanon is necessary as part of the current reform of 
the Lebanese health sector 
• A concerted effort from all stakeholders is needed to build capacities for national health 
technology assessment, build evidence and bridge current gaps  
• It is necessary to search for cost-effective means to reduce the economic and clinical 
burden of hemodialysis and establish a framework linking scientific evidence to efficient 
national public health interventions and routine clinical practice 
• High-quality research addressing the impact of hyperphosphatemia management among 
hemodialysis patients on hard end-points is needed 
• High-quality research for cost-effective phosphate-lowering interventions in 
hemodialysis patients is needed 
 
CHAPTER 6 
137 
 
The findings of this dissertation present numerous implications for clinical practice, public health 
decision making, and research (especially for future local HTA). We detail these implications below. 
 
CLINICAL PRACTICE IMPLICATIONS 
Our results provide further high-quality evidence for clinicians regarding the effectiveness and 
“safety” of intensive behavioral nutrition education in enhancing adherence to a low-phosphorus diet 
and in lowering serum phosphorus levels, without compromising the nutritional status of 
hemodialysis patients. This approach was superior over marginal nutrition advice (existing practice 
in Lebanon). These findings reinforce the value of dietitians as an integral part of the nephrology care 
team, and shed light on their unique skills which enable them to actively and positively contribute to 
hyperphosphatemia management among hemodialysis patients, without the need for increased 
resources, other than ensuring adequate dietitian skills and sustained dietitian-to-patient time. 
 
PUBLIC HEALTH DECISION MAKING IMPLICATIONS 
Hemodialysis has been identified as a resource-intensive therapy and a major public health problem 
in Lebanon. With the rapidly increasing prevalence of hemodialysis in the country, the direct and 
indirect costs of this treatment are expected to rise. Accordingly, the search for measures optimizing 
hemodialysis management is crucial. By exposing the financial burden of hemodialysis and its main 
drivers, and by exploring the cost-effectiveness of two health technologies in this patient population 
i.e. phosphate binders and nutrition education, the current study provided decision makers with 
information for health services planning and potential cost containment initiatives. The review of the 
literature suggested that calcium acetate may be the most cost-effective binder and that the systematic 
use of calcium-free binders may not be a rational use of health resources. Rather, these agents might 
provide good value for money spent as second-line therapy in selected patients. The trial-based 
economic evaluation showed that the intensive nutrition education had a low direct cost, yet a low 
probability of being cost-effective. We argue that this intervention might be cost-saving, and we 
recommend further investigation into its cost-effectiveness. The only loss in the proposed technology 
is the initial training of the dietitians and their financial compensation, which is extremely inexpensive 
within hemodialysis patient management. We speculate that a significant reduction in the global 
clinical and economic burden of the disease can be achieved when this intervention is implemented 
in Lebanon.  
Concrete implications for health technology assessment implementation in Lebanon 
The Lebanese healthcare system is pluralistic and unregulated, with highly fragmented financing. The 
overwhelming majority of health care services and delivery units are privately owned and operated, 
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whereby the country, especially the capital Beirut, enjoys some of the most advanced medical 
facilities and services in the region, and exhibits a rapid and extensive diffusion and up-take of state-
of-the-art medical technologies. Over the last 20 years, the country has invested heavily in medical 
technologies and services, and it is a constant strategic challenge to moderate technology diffusion to 
the most efficient interventions. To date, major system deficiencies still limit the ability to ensure 
gross equity and efficiency. These include (but are not limited to) the lack of a clear policy and 
strategy for health care on the part of the government, the overwhelming preponderance of an 
unregulated private sector in the financing and provision of health care, the minimal pooling of 
resources with high out-of-pocket expenditures, the lack of systematic health data collection, and the 
unavailability of such data to the stakeholders and to the public [79].  
HTA has emerged globally as a powerful tool for institutionalizing the use of evidence in health care 
decision making, and for promoting health equity. Accordingly, the integration of HTA within 
national decision making has been advocated as part of the restructuring of the present healthcare 
system [79,80]. The creation of a national non-executive HTA agency which will guide the HTA 
process (identification, priority setting, assessment, appraisal, reporting, dissemination, and 
implementation in policy and practice) [81] of health care technologies is suggested. The agency 
would establish the effectiveness of technologies and mechanisms for prioritizing them for 
affordability and plausible public/collective responsibility. We propose this approach, as Lebanon's 
experience with autonomous public bodies is not encouraging, and the concept of having an agency 
overseeing the Ministry of Public Health is not compatible with the administrative and legal 
environment and would undoubtedly be politically rejected. However, it is common and feasible that 
a non-executive and preferably self-financing body fills the space between formal and self-regulation 
in the health care sector; hence the value of creating an HTA agency [80]. The HTA agency would 
not only be a viable option, but is also a necessity within the current reform of the Lebanese health 
sector. Its feasibility is assured by the support of the government, legislature, and relevant 
stakeholders, both nationally and regionally. 
The increasing demand for transparency and credibility in healthcare decision making in Lebanon, 
coupled with the growing culture of value-based care within the political and scientific communities 
present a unique opportunity that Lebanon should grasp for implementing national HTA [80,82]. A 
proposed initial step would be to map the national level of institutionalization and the current levels 
and trends in the HTA process, in terms of political buy-in, as well as stakeholder, human and 
financial capabilities. National-level mapping will provide information for assessing the feasibility of 
developing HTA. It is expected to provide insights regarding the ability to overcome many of the 
barriers associated with the initial development of a national HTA program, to help inform strategies, 
and to justify expenditure for HTA. Moreover, it will serve as a baseline measurement for future 
monitoring and evaluation [83,84]. 
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The establishment of a successful and sustainable HTA infrastructure requires several conditions [84–
89], some of which are already available in Lebanon [79,80,82]. These key conditions include a 
coherent and effective health policy structure, general awareness of HTA and its acceptance as a new 
and integrated tool for the routine evaluation of health technologies (and not a finite project or one-
off exercise), an interest and strong commitment from policy makers, an ability and willingness to 
commit public money to HTA, support from and involvement of key stakeholders (national-level 
policy makers, academicians, industry experts, care providers, mass media, civil societies, and 
patients, among others) throughout the HTA process, adequate governance through the establishment 
of implementation, monitoring and evaluation mechanisms as part of a transparency and 
accountability framework, in addition to working toward the independent status of an HTA agency 
and establishing management procedures including a protocol for dealing with conflicts of interest, 
as well as developing scientific capability and establishing an HTA training program, and 
collaborating with regional and international networks, entities and organizations to benefit from their 
experience in building the national HTA program. 
In particular, in a country like Lebanon, there might be stiff resistance to the introduction of HTA. 
Transparency, communication, clarity and openness, and the involvement of core stakeholders and 
professional bodies in the HTA process are essential for overcoming lack of trust and increasing 
credibility [84]. The latter factor is a crucial issue in establishing, sustaining, and using national HTA 
in policy making. However, international and regional experiences show that involving stakeholders 
cannot take place instantaneously. In fact, various stakeholders hold different interests, 
responsibilities, infrastructures, and barriers, all of which need to be considered, addressed and met 
for an HTA program to succeed. It is therefore essential to create a framework in which the ideas, 
needs and expectations of stakeholders are taken into account, and communication and interaction 
with them is assured [87,90–94].  
One additional major concern in developing countries is that the results of HTA reports are not used 
efficiently, and incorporating their evidence into policy faces manifold barriers at both professional 
and public levels [85,95]. HTA information tends to be used sporadically, rather than applied in a 
proactive, systematic manner [91], and the use of health technologies continues to be based on their 
efficiency and successful performance in developed countries, without establishing their costs and 
efficiency at the local level, as well as their cultural, social, and infrastructural adequacy [86]. If 
Lebanon is set to engage in HTA, a framework for linking HTA results to policy making and 
implementation is needed, and a systematic approach which involves policymakers, funding bodies, 
and healthcare providers, improving infrastructures, and boosting supervision of performance is 
recommended. Delineating a clear plan at the macro level of the health system for using HTA reports, 
raising awareness and promoting HTA-related knowledge for all audience groups should pave the 
way for an effective use of the results of these projects [91,95–97].  
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RESEARCH IMPLICATIONS 
First, the search for cost-effective means for reducing the economic and clinical burden of 
hemodialysis in Lebanon should be fostered. Furthermore, a framework linking scientific evidence 
to efficient national public health interventions and routine clinical practice should be established. 
The search should focus on means for preventing chronic kidney disease, and on means for preventing 
or slowing its progression, such as screening and early detection of chronic kidney disease, correct 
and timely referral to specialists and adequate medical and dietetic management of common local 
causes of kidney failure (including diabetes and hypertension) [98–100], as well as on approaches to 
increase the use of kidney transplantation [101], and other cost-effective forms of dialysis, such as 
home hemodialysis, where clinically indicated [102,103]. 
Second, research addressing hyperphosphatemia management among hemodialysis patients has 
seldom explored the impact of reducing serum phosphorus on hard end-points, such as mortality 
[18,104]. To date, the recommendation to lower serum phosphorus to a certain “target range” is based 
largely on cross-sectional or retrospective data [11,12], as it is unethical to randomize patients to 
different phosphate levels because of the observational data. Developing feasible methodologies to 
assess this issue in an ethical manner should be at the top of research agendas in nephrology care. 
Meanwhile, high-quality research on cost-effective phosphate-lowering interventions in hemodialysis 
patients, encompassing phosphate binders, nutrition education, various modalities of dialysis therapy, 
and extending other interventions, such as physical activity during dialysis, is needed. In addition, we 
recommend specific further research on the impact of the nutrition education on hard endpoints, such 
as the hospitalization, morbidity and mortality of hemodialysis patients, and on its long-term cost-
effectiveness. We also suggest mapping the current nutritional status (including phosphorus control 
and malnutrition-inflammation status) of hemodialysis patients, as well as their use of services and 
associated costs, to serve as a solid basis for future monitoring and evaluation studies. 
Third, the economic evaluation conducted as part of this dissertation exposed the “virgin” territory of 
health economic studies and the lack of infrastructure related to HTA research in Lebanon. Having 
local data, local technical expertise and local institutions are core requisites for establishing national 
HTA research [105]. Accordingly, we recommend the following: 1) delineating an explicit set of 
guidelines for conducting and reporting health economic studies (including economic evaluations); 
2) delineating costing guidelines; 3) developing standardized resource-use measures; 4) adapting 
generic QOL instruments to Lebanese society; 5) generating utility weights, and 6) estimating a 
societal threshold for willingness-to-pay. These recommendations require a concerted effort from all 
stakeholders to build capacities, make investments, and bridge research gaps in national HTA 
evidence [92,97]. As has been done successfully in other developing countries implementing HTA 
research, Lebanon needs to build a core interdisciplinary team with skills in HTA, clinical medicine, 
health economics, clinical epidemiology, information technology, and evidence synthesis [88]. Other 
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concrete steps include equalizing the criteria for performing HTA among Lebanese researchers, 
further training local expertise, establishing educational programs (MS degree) and fostering PhD 
research in this field, and facilitating network-building with international experts alongside scientific 
competence [89,106]. 
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The present thesis explored the health technology assessment (HTA) of hyperphosphatemia 
management among hemodialysis patients, with a focus on the Lebanese setting. It reviewed the 
evidence behind the cost-effectiveness of phosphorus-lowering interventions in this patient 
population; explored the cost of hemodialysis in Lebanon and its drivers; assessed the clinical 
effectiveness of dedicated dietitians providing nutrition education; and evaluated its cost-
effectiveness in comparison with the existing practices in Lebanon.  
This thesis is directed towards clinicians, policy makers and researchers, and contributes to the efforts 
tackling the burden of hyperphosphatemia, and aiming to offer optimal care to hemodialysis patients. 
This research informs decision makers about the high financial burden of hemodialysis and 
hyperphosphatemia management among hemodialysis patients in Lebanon, and about the 
effectiveness of intensive nutrition education as a phosphorus-lowering intervention. In light of the 
insufficient evidence about the cost-effectiveness of interventions targeting hyperphosphatemia 
management, this dissertation suggests the intensive nutrition education as a cost-saving solution. 
Finally, this thesis informs researchers about numerous gaps related to the HTA of interventions 
targeting hyperphosphatemia in this patient population on the international level, and about the gaps 
related to HTA evidence-building, specifically in Lebanon.  
This research could further be considered as an initial model of incorporating clinical and economic 
evidence in the assessment of health technologies in Lebanon, and a first step towards adopting a 
transparent value-based model of care within the national healthcare system.  
Although this thesis has several clinical, economic, societal, public policy and research implications 
discussed below, it is worthy to acknowledge its limitations (discussed in Chapter 6) and the need 
for further studies in order to fully understand the value of the proposed technology. 
 
PROPOSED TECHNOLOGY AND IMPLEMENTATION ROADMAP 
As insightfully declared by Pronovost et al. [1] “one of the greatest opportunities to improve patient 
outcomes will probably come not from discovering new treatments, but from more effective delivery 
of existing therapies”. The effective delivery of intensive nutrition education requires several key 
elements to be ensured: 1) expertise factor, i.e. adequate education and skills related to renal dietetics 
and nutrition education, requiring the translation of nutrition recommendations into core professional 
education programs to facilitate adoption, 2) time factor, i.e. adequate dietitian-to-patient ratio and 
sufficient dietitian-to-patient time, and 3) collaborative relationship with relevant organizations to 
support practicing dietitians in implementing renal nutrition guidelines, reduce practice variations 
and develop performance measures to assess compliance with the guidelines, all of which must be 
performed within a scientific and public policy supportive environment [2]. 
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We propose to allocate dedicated dietitians to hemodialysis units, as a first step towards implementing 
renal nutrition evidence-based practice guidelines, improving patient outcomes, and possibly 
decreasing pertaining societal costs. We propose this health technology as an innovative and feasible 
model of renal nutrition care in Lebanon and other developing countries with similar healthcare 
systems. As recommended by evidence-based practice guidelines, renal dietitians, playing a pivotal 
role in the unit, should determine the nutrition diagnosis and intervention for hemodialysis patients. 
Within the proposed technology, every hemodialysis patient will have access to a qualified dietitian 
and receive intensive nutrition counseling and dietary management based on an individualized plan 
of care developed before or at the time of commencement of hemodialysis therapy, and modified as 
indicated.  
Implementing this technology within hemodialysis units in Lebanon requires numerous 
considerations, extending from public health policy makers (system and organization), to third party 
payers, and to the renal nutrition and health care providers in Lebanon. We propose below a practical 
implementation roadmap entailing specific, concrete and actionable steps. 
 
Governance considerations 
• Health systems arrangements 
There is no specific description of the required dietetic care for hemodialysis patients in the Lebanese 
Healthcare Organizations Accreditation Law. Clinical duties of the hospital dietitian are limited to 
provision of evidence that the dietitian responds to requests to assess patients, in addition to a 
documented review on a standardized form in patients’ medical records, with no specifications for 
hemodialysis patients. The renal dialysis chapter of the accreditation law only requires evidence of 
regular consultation and coordination with other health professionals (e.g. dietitians), without further 
specifications of the dietitian-to-patient ratio or time. The roles and responsibilities of dietitians are 
thus not set nor organized by law. Accordingly, almost all hemodialysis patients in Lebanon receive 
only one yearly routine dietetic consultation; in addition to dietetic counseling delivered following 
nephrologists’ consult requests. 
 Proposed action 
Including an article in the Lebanese Healthcare Organizations Accreditation Law, specifying a 
minimal dietitian-to-hemodialysis patient ratio and time, as elaborated below. The article is also 
expected to clarify the roles and responsibilities of the dedicated dietitian. The latter could initially 
follow Academy of Nutrition and Dietetics (AND) and National Kidney Foundation (NKF)'s 
Standards of Practice (SOP) and Standards of Professional Performance (SOPP) for dietitians in 
nephrology nutrition [3], until country-specific standards are established (further details are provided 
below). 
VALORIZATION 
 
154 
Organizational considerations 
• Institutional arrangement 
Currently, hospital dietitians lack institutional support, including time allocation, to deliver effective 
care to hemodialysis patients. 85% of Lebanese hospital dietitians spend less than ten hours at the 
hemodialysis unit. They can only find limited time for hemodialysis patients’ consults within their 
other clinical, administrative and food service duties [4,5]. This limited time greatly falls below what 
is recommended by international guidelines [3,6–8]. 
 Proposed action 
Organizations must ensure adequate dietitian caseload (dietitian-to-patient time and ratio). This could 
be done through recruiting dietitians solely dedicated to hemodialysis patients, or establishing specific 
measurements within the hospitals' dietetic department to ensure the delivery of dietetic services 
compatible with the below-specified caseload. As initial implementation steps, we propose a dietitian-
to-patient ratio of approximately 1:100 hemodialysis patients (not exceeding 1:150) [3]. In dialysis 
facilities where the dietitian will have broader responsibilities (e.g. quality improvement, 
development and monitoring of protocols for patient care, research), the caseload ratio should be 
adjusted downward. The proposed dietitian-to-patient contact time includes an initial consultation of 
60-90 minutes, a follow-up within 1 month of 30-45 minutes, and regular nutritional updates of 45-
60 minutes, as needed [8]. We propose this initial dietitian staffing, until the optimal dietitian-to-
patient ratio of 1:70 [9] and dietitian-to-patient contact time of approximately 2 hours per month [6] 
could be achieved. 
• Financial arrangement 
The presence of a dedicated dietitian incurs additional costs to dialysis providers in Lebanon 
(hospitals); resistance of the latter bodies towards implementing this technology is expected. 
 Proposed action 
On average, the cost of the intensive nutrition education is around $1 per patient per session, assuming 
an optimal dietitian-to-patient ratio of 1:70. This cost is expected to further decrease on the long-run, 
due to the omission of the cost of the initial training of the dietitians, representing approximately 10% 
of the cost of the intervention. The monthly budget implications of making a dedicated dietitian 
available for the patient would be on average $12.5 (approximately $40,000 for the 3,300 patients 
currently treated by hemodialysis in Lebanon). As found in our economic evaluation, the monthly 
difference in the decrease in healthcare costs between the proposed intervention and the existing 
practice during the post-implementation phase was $151 per patient. This amount would offset more 
than 10 times the cost of the nutrition intervention. As the third party payers are expected to benefit 
from the cost savings resulting from the implementation of this technology, the cost of the intensive 
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nutrition education could be added to the bundled payment to the hospitals by third party payers. The 
latter will be in charge of reimbursing the dietitians. This reimbursement system would be similar to 
the mechanism adopted in the USA [10]. 
 
Provider considerations 
• Delivery arrangement 1: 
Lebanese hospital dietitians' knowledge of renal nutrition guidelines is poor, and specialized 
education, training or certification in renal dietetics do not exist in Lebanon [4,11]. 
 Proposed action: 
Dietitians must be provided with sufficient specialized education enabling them to deliver effective, 
comprehensive and individualized care using cognitive/behavioral strategies and culturally specific 
educational tools, along with easy-to-apply skills [12–14]. A possible roadmap to developing renal 
dietetic specialization in Lebanon consists of 1) integrating an intensive evidence-based renal 
dietetics course within the nutrition bachelor program or post-baccalaureate dietetic internship, 2) 
establishing a health practice accreditation system that periodically audits the knowledge and practice 
of dietitians working with renal patients, and 3) establishing a system of obligatory continuing 
education to maintain license to practice in this field [11]. Until renal dietetic specialization is ensured 
within the didactic or internship programs in Lebanon, providing intensive trainings to practicing 
dietitians intended to be allocated to hemodialysis units could be proposed, similarly to what was 
successfully done in the Nutrition Education for Management of Osteodystrophy (NEMO) trial [15]. 
Dietitians allocated to hemodialysis units would refer to international tools to assess their current skill 
levels and to identify areas for additional professional development in this practice area, such as the 
Academy of Nutrition and Dietetics (AND) and the National Kidney Foundation (NKF)'s SOP and 
SOPP [3], until country/regional-specific tools are elaborated. 
• Delivery arrangement 2: 
Country-specific practice-guidelines for renal dietetics do not exist in Lebanon. 
 Proposed action 
International evidence-based practice-guidelines on renal nutrition [6,7,16,17] would be applied, until 
country/regional-specific standards and guidelines are established. 
• Multidisciplinary care arrangement 
Disparity in the nutrition-related perceptions and recommendations between members of nephrology 
care team do exist [18]. Other members of the nephrology team were shown to have limited 
knowledge and skills related to some aspects of the nutritional management of hemodialysis patients 
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[19], and overlap in patient delivered messages might be a potential source of confusion for the patient 
[20].  
 Proposed action 
Dietitians are uniquely qualified to provide effective, tailored, and safe nutrition care to renal patients 
[21,22]. Recognizing the role of the dietitians at the hemodialysis unit, involving them in the 
multidisciplinary patient care, standardizing practices amongst renal care professionals, actively 
discouraging and correcting alienation between staff members, promoting  teamwork, respect for 
work product among staff members, and effective communication and coordination of care between 
all healthcare providers [9,20,23] are best practices in the hemodialysis units, that should be 
implemented for optimal patient outcomes. Until shortages in qualified dedicated dietitians are 
bridged, task shifting, i.e. delegation of some nutrition-related tasks, where appropriate, to less 
specialized health workers in nutrition (e.g. nurses) could be adopted as a temporary solution. 
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Hyperphosphatemia is a common condition among hemodialysis patients, and is associated with 
increased risks of morbidity and mortality and higher health care costs. Hyperphosphatemia is 
typically managed through a combination of hemodialysis treatment, phosphate binding medications 
and dietary phosphorus restriction; this approach is supported by clinical evidence. Given budgetary 
constraints, information about the value for money spent on health interventions is being used 
increasingly by decision makers to guide the efficient allocation of available health care resources. 
Health technology assessment (HTA), a form of policy research that systematically examines both 
the direct and indirect consequences of a health technology, provides relevant input to decision 
making in policy and practice. Specifically, economic evaluations, a part of HTA, compares health 
technologies in terms of costs and outcomes to assess their value for money.  
As in many countries, hemodialysis is a major public health problem in Lebanon, and 
hyperphosphatemia management in this patient population remains an ongoing challenge. Moreover, 
as part of the public rehabilitation strategy for the health sector, the integration of HTA into the 
decision making process for national public health care has been advocated. However, to date, no 
concrete action was taken in this regard. Therefore, we aim in this dissertation to provide insights into 
the HTA of hyperphosphatemia management among hemodialysis patients and explore economic 
considerations in this regard, with a focus of the Lebanese setting. 
The escalating clinical and economic burden of hyperphosphatemia, coupled with the high cost of its 
management on one hand, and limited healthcare resources on the other, provide the rationale for 
fostering the search for cost-effective interventions for managing hyperphosphatemia among 
hemodialysis patients. In particular, we first provided an overview of the cost-effectiveness of 
phosphorus-lowering interventions in this patient population. We then explored the financial burden 
of hemodialysis and hyperphosphatemia management through phosphate binders in Lebanon. Finally, 
we assessed the clinical and economic value of intensive nutrition education as a phosphorus-
lowering intervention among Lebanese hemodialysis patients. 
In Chapter 2, we conducted a systematic review of published economic evaluations of interventions 
aiming to manage hyperphosphatemia among hemodialysis patients; we provided a descriptive 
analysis and critically appraised these studies. All records included in our review addressed the 
comparative cost-effectiveness of phosphate binders, and we could not identify any study on different 
hemodialysis modalities, a low-phosphorus diet, or other types of interventions. We found limited 
evidence on the cost-effectiveness of non-calcium based binders in prevalent and incident patients, 
in first-line and sequential use. We could not generate firm conclusions due to the sub-optimal quality 
and heterogeneity of the included studies; moreover, there was a lack of studies addressing some 
clinical scenarios. In Chapter 3, we explored the societal cost-of-illness of hemodialysis and its 
drivers in Lebanon. We also provided insights into the financial burden of managing 
hyperphosphatemia through phosphate binders in this patient population in Lebanon. Our estimates 
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revealed a 6-month societal cost of hemodialysis of $9,258, with 91.7% of this cost attributable to 
healthcare costs, 4.2% to patient and family costs, and 4.1% to costs in other sectors (transportation), 
highlighting the high financial burden of hemodialysis on Lebanese society and the Lebanese 
healthcare system. We also observed the high cost of managing serum phosphorus through phosphate 
binders, especially calcium-free agents. In Chapter 4, we evaluated the clinical effect of intensive 
nutrition education on hemodialysis patients suffering from hyperphosphatemia. We found that this 
intervention is superior to the existing practice in Lebanon and to another proposed alternative, in 
terms of increasing patients’ adherence to a low-phosphorus diet and managing their 
hyperphosphatemia without compromising their nutritional status. Finally, in Chapter 5, we explored 
the economic value of this nutrition education in Lebanon, using several scenarios. We found that the 
cost of the intensive nutrition education was very low in comparison with the societal cost of 
hemodialysis and the costs of other health interventions in this patient population. We also noted that 
this intervention yielded the greatest decrease in use of resources and societal costs in comparison 
with the existing practice and the other alternative. However, we could not find any effect on quality-
adjusted life-years, and the intervention was dominated by its comparators. In light of the significance 
between group differences in baseline key parameters (serum phosphorus and malnutrition 
inflammation status), interpreting our findings was challenging. We suggest further long-term 
evaluation of intensive nutrition education on equitable groups at baseline, using a modeling study. 
The findings of this dissertation present several implications for clinical practice, for decision making 
in the sphere of public health, and for research, notably in local HTA. First, we provide additional 
high-quality evidence about the beneficial clinical effect of intensive nutrition education as a 
phosphorus-lowering intervention among hyperphosphatemic hemodialysis patients. Second, the 
results of this study provide insights for public health policy makers about the debilitating financial 
burden of hemodialysis in Lebanon and about the need for a rational allocation of resources for 
hyperphosphatemia management in this patient population. We also provide some concrete 
implications for the implementation of national HTA. Finally, this dissertation generates several 
directions for future research in the field of hyperphosphatemia management among hemodialysis 
patients, and in the field of HTA, specifically economic evaluations, in Lebanon. 
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